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Abstract
Ribosomally synthesized and post-translationally modified peptides (RiPPs) are a
burgeoning family of natural products with desirable bioactivities. The cyanobactin
class of RiPPs have demonstrated anticancer, anti-microbial activities and more, and
have therefore attracted research attentions. Cyanobactins are synthesised as a precursor
peptide (PatE homologues) containing recognition sequences and core peptides (sequences
that become the final products), the latter of which undergo various modifications
including heterocyclization, prenylation, oxidation and macrocyclization. The post-
translational modification enzymes (PTMEs) utilised to modify the cyanobactin precursor
have demonstrated magnificent versatilities that are potentially exploitable for the creation
of libraries of natural and unnatural compounds. The structure and function of each
of these enzymes are reviewed in Chapter 1, along with the current application of the
cyanobactin biosynthetic pathway.
Chapter 2 describes my work on creating and characterising modified heterocyclases.
The leader peptide was appended to heterocyclases that produce both thiazolines and
(methyl)oxazolines. The modified catalysts are not only capable of utilising leaderless
peptides, but also have higher yields than the native enzyme.
The next chapter investigates the reaction order of heterocyclase enzymes. The leader
peptide was found to be partially responsible for the reaction order. In Chapter 4 the same
investigation was applied to the oxidase, which aromatises and stabilises the heterocycles.
The oxidase reaction was determined to be independent of the leader.
Chapter 5 delves into the phosphate chemistry of the heterocyclase, which uses
ATP/Mg2+ via a kinase mechanism, but subsequently catalyses additional reactions that
yield AMP and PP
i
.
Finally, Chapter 6 describes the structural characterisation of Psychrobacter arcticus
ATP phosphoribosyltransferase (ATPPRT), which is the first dedicated enzyme in
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1.1 Peptide Natural Products
Bioactive peptides produced by organisms such as bacteria and fungi provide a plethora
of substances from which numerous drug leads have been, and continue to be identified
[1–3]. The majority of them yet unexplored, this vast family of compounds have
already yielded widely used drugs, including vancomycin and insulin. More recently,
novel antibiotics teixobactin [4] and malacidins [5] were discovered, both of which are
peptide-based natural products. With modern medicine being threatened by the rise
of antibiotic resistance and drug tolerance, it is imperative that we inquire into the
solutions nature has to o↵er, notably, the rich repertoire of peptide-derived secondary
metabolites. Bioactivity of peptide natural products comes from their diverse structures
and lush reserve of non-proteinogenic moieties, which in turn originate from the way they
are biosynthesised. In general, these peptides can be divided into two categories based
upon their biosynthesis: nonribosomal peptides (NRPs), like teixobactin and malacidins,
and ribosomally synthesized and post-translationally modified peptides (RiPPs). Due
to the structural and chemical complexity of both NRPs and RiPPs, total- and semi-
synthesis of these face major challenges, and their biosynthetic mechanisms have been
under extensive investigation as a result.
1.1.1 Nonribosomal Peptides
Secondary metabolites of this class include the antibiotic vancomycin, the anticancer
agent bleomycin and the immunosuppressant cyclosporin. Nonribosomal peptides are
synthesised by multimodular nonribosomal peptide synthetases (NRPS), which work
independently of mRNAs and the ribosomal machinery, but instead use bespoke building























PP M1 M2 M3
Figure 1.1: Overview of NRP and RiPP biosyntheses. (A) schematic showing the general
assembly line of nonribosmal peptide synthetases. Round shapes labelled ‘A’, ‘T’, ‘C’
and ‘TE’ represent the adenylation, thiolation, condensation and thioesterase domains,
respectively. (B) schematic of RiPP synthesis. PP, precursor peptide; M1, M2 and M3,
modifying enzymes; MP, mature peptide.
proteinogenic amino acids and other substrates before they are assembled by NRPS into
a polypeptide chain, which can then be further modified and decorated [7]. NRPS are
closely related to polyketide synthetases (PKS) and the two are often hybridised [9],
further increasing product diversity. Characterisation of NRPS mainly focused on bacterial
and fungal synthetases, but these synthetases have also been found in higher organisms
like drosophila [10] and nematodes [11]. The overall architecture of NRPS is that of
an assembly line (Figure 1.1A) [7], with an initiation module, one or more elongation
module(s), and a termination module, each of which in turn consists of multiple domains.
The initiation modules contains an adenylation domain (A), which selects and activates
amino acids using ATP, turning them into a high-energy aminoacyl-AMP species, and
a thiolation domain (T), also known as a peptidyl carrier protein domain (PCP), which
subsequently takes up the aminoacyl group with its -SH moiety. Following the T domain is
the condensation domain (C) of the first elongation module, which is succeeded by its own
set of A and T domains. Catalysed by the C domain, an amide bond is formed between
the first and the second amino acid, displacing the thioester bond that tethers the first
amino acid to its carrier protein. The same process occurs between the first and the second
elongation module, and so forth. After the last transfer, an thioesterase domain (TE) from
the termination module releases the full-length polypeptide, and in some cases cyclises it
[6]. Additional domains may be present in each module, for modifications of the nascent
peptide such as epimerisation [12], methylation [13] and oxidation [14]; alternatively, trans-
acting enzymes may be recruited for post-NRPS decorations [7]. As a general rule, each
building block requires its own adenylation and thiolation proteins, and a condensation
domain (or a variant) is required between every two modules. NRPSs are typically very
large as a result of this, exemplified by the 1.4 MDa cyclosporin synthetase [15].
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1.1.2 Ribosomally Synthesised and Post-Translationally Modified
Peptides
Ribosomally synthesized and post-translationally modified peptides [16] represent another
expanding class of natural products that have exhibited various bioactivities such as anti-
viral and anti-fungal [17, 18]. RiPP synthesis (Figure 1.1B) starts with a precursor
peptide made by the ribosome using the 20 common amino acids, which comprises a
leader peptide, further recognition sequences and a core sequence (the part that yields the
final product). The precursor is modified by a series of post-translational modification
enzymes (PTMEs) during maturation. These modifications enrich the peptides with
chemical groups and intramolecular structures, giving them complexities that rival NRPs.
Substantial work, led by the van der Donk group, has been carried out to characterise
lanthipeptides, compounds that comprises the lanthionine moiety (Figure 1.2A) [19],
whilst linear azol(in)e-containing peptides (LAPs, Figure 1.2B), cyanobactins (Figure
1.3) and thiopeptides (Figure 1.2C) are among the other families of best studied RiPPs
[16, 20–22]. Unlike NRP synthesis, RiPP synthesis circumvented the need for elaborate
multidomain synthetases, which can be burdensome for microorganisms and also di cult
to reconstitute and engineer in-vitro [23–25]. This however also meant their biosynthetic
gene clusters (BGCs) are less conspicuous than NRPS genes, which has to encode, in
multiplicity, essential modules of the assembly line (Figure 1.1A). It was the development
of genome mining tools that drastically expanded the number of RiPPs, and prompted
scientists to unify their classification and nomenclature [16, 26], even though sporadic
discoveries of the RiPP biosynthetic clusters date back to the 20th century [27]. To
date, tens of subfamilies of RiPPs have been characterised including the above mentioned
families, as well as bottromycins, lasso peptides and proteusins [16, 28]. RiPP biosynthesis
and the function of various PTMEs have been of great interest in recent years, largely due
to the fact that recognition between the precursor and the PTMEs are usually mediated
by conserved elements outside the core peptide, whereas the core itself is hypervariable
[16]. The uncoupling of recognition-catalysis not only enabled these enzymes to process
multiple natural substrates and those from closely related pathways, but also opened up
horizons for hybridisation, splicing and engineering, where the recognition elements on
substrates can be altered to lead them to (multiple) destined enzymes [29, 30]. Moreover,
core sequences can also be readily edited by means of molecular biology, exponentially
increasing substrate varieties. Together, the promiscuity of PTMEs and the alterability
of precursor sequences make the RiPP machinery a promising tool for the biosynthesis of
diverse peptide derivatives.
3
Figure 1.2: Examples of RiPPs. (A) Nisin A, an antibiotic lanthipeptide (lantibiotic)
commonly used as a food preservative. Dashed circle denotes the lanthionine moiety that
gives the name lantipeptides. (B) Microcin B17, an antibiotic LAP. (C) Thiostrepton A,
a thiopeptide containing four thiazoles and a thiazoline. Figures taken and adapted from
[16].
1.1.3 The Cyanobactin Family of RiPPs
Among the best characterised RiPPs are cyanobactins, such as patellamides, trunkamides
and ulicyclamides. Drug-like properties, including cytotoxicity, anti-tumour and anti-
malarial activities have been reported for this class of natural products [31–35], making
them interesting subjects of biomedical studies. First isolated from the marine ascidian
Lissoclinum patella in the 1980s [36], cyanobactins were later attributed to L. patella’s
cyanobacterial symbiont Prochloron didemni [37, 38]. Discoveries of cyanobactins from
other species were made throughout the 1990s and 2000s; in addition, compounds have
been identified after predictions made by means of metagenomic mining, resulting in a
great expansion of the size and diversity of the cyanobactin family [20, 21, 39, 40]. The
archetypical cyanobactin is an azol(in)e-containing head-to-tail macrocycle that is 6-11
amino acids in length [21], but members of the group also include homodetic macrocycles
that can be over 20 amino acids in length, as well as short, linear peptides featuring
extensive post-translational modifications such as N -prenylation and O-methylation [40].
An example of each type of cyanobactins is shown in Figure 1.3. Macrocyclic cyanobactins
have been of particular interest to researchers due to their rigid conformation that
facilitates binding to specific targets and increases resistance to degradation [41]. Chemical
synthesis of macrocycles usually involves complicated multiple-step processes (Figure 1.4)
[42] that are not readily applicable to a wide range of derivatives [42, 43], making the























































Figure 1.3: Examples of Cyanobactins. Patellamide A, a heterocycle-containing
macrocycle; Viridisamide A, a short, linear cyanobactin peptide; Anacyclamide A10, a
homodetic macrocyclic compound.
Figure 1.4: Total synthesis of Patellamide A as reported by Garcia-Reynaga and colleagues
[42]. Figure adapted from [42].
5
1.2 Overview of Cyanobactin Biosynthesis
The biosynthetic machinery of cyanobactins contains multiple PTMEs encoded in a single
gene cluster, along with the precursor peptide. Patellamides are the first of cyanobacterial
peptides to have the whole biosynthetic pathway reconstituted and characterised [37, 38],
and will be used as the model system here. The pat gene cluster encodes seven genes,
patA-patG, corresponding to the precursor peptide (PatE) and its PTMEs (Figure 1.5A).
The canonical PatE is composed of 71 amino acids: an N-terminal 37-residue leader
sequence, followed by two 8-residue core peptide cassettes each flanked by a protease
recognition sequence G(L/V)E(A/P)S on the N-terminus and a macrocycliztion signature
AYD on the C-terminus (Figure 1.5B). The cassettes shown in Figure 1.5B, VTACITFC
and ITVCISVC, encode patellamide C (Figure 1.5C) and patellamide A (Figure 1.3),
respectively. The proteins encoded with it are: PatA, a protease plus a domain of unknown
function (DUF); PatB and PatC, proteins of unknown function; PatD, a heterocyclase
(cyclodehydratase); PatF, a putative prenylase and PatG, a tripartite protein with an
oxidase domain, a protease (macrocyclase) domain and a DUF. With the exception of
PatB and PatC, which although conserved are non-essential to patellamide biosynthesis
[20, 21], the structures and functions of each of these PTMEs are reviewed in details in the
following sections. Figure 1.5C gives a chemist’s view of patellamide C with annotations
showing sites of modifications by each enzyme.
1.3 Heterocyclase
Heterocyclization (cyclodehydration) of serines, threonines and cysteines by PatD is
considered to be the first step in Patellamide biosynthesis [16, 44, 45]. In addition
to patellamides, azol(in)e-containing cyanobactins included macrocyclic ones such as
trunkamides [46, 47] and microcyclamides [35, 48, 49], as well as linear ones like
viridisamide A [40]. Phylogenetic studies [40, 50, 51] showed that clusters capable of
biosynthesizing cyanobactins that bear heterocycles encode a YcaO domain-containing
heterocyclase (cyclodehydratase), and optionally, an FMN-dependent oxidase (discussed
later in section 1.5). These genes are missing from biosynthetic clusters with products
that do not contain heterocycles. This section explains the roles of heterocycles in natural
products, reviews investigations of the cyanobactin heterocyclase and related enzymes,
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•   Heterocyclization/cyclodehydration (PatD)
•   Oxidation/dehydrogenation (PatGox)
•   N-terminal proteolysis (PatApro)
•   Head-to-tail macrocyclization (PatGmac)
•   Cα epimerisation (unknown)
Figure 1.5: The Cyanobactin biosynthetic pathway. (A) layout of the Patellamide
biosynthetic gene cluster. Pro, protease; DUF, domain of unknown function; Oxi, oxidase;
Mac, macrocyclase. (B) Annotated sequence of the precursor peptide PatE containing two
cassettes - VTACITFC (patellamide C) and ITVCISVC (patellamide A). (C) A chemist’s











































1.3.1 Azol(in)es in Natural Products
The heterocycles found in cyanobactins are five-membered thiazolines, oxazolines and
methyloxazolines (Figure 1.6), and their oxidised versions thiazoles and (methyl)oxazoles
[40, 50, 51]. The reduced forms thiazolidines and (methyl)oxazolidines (Figure 1.6) also
exist in natural products [52, 53], although not in cyanobactins. Azolines usually arise
in a dipeptide context, where the side chain of serine, threonine or cysteins cyclises
onto its preceding carbonyl group [52], but non-peptidyl moieties such as hydroxyphenyl
groups have been seen to precede oxazolines in compounds such as bacterial siderophores
[54–56]. Tandem arrays of heterocycles are not uncommon [52], and they may undergo
further modifications such as halogenation [57] and methylation [58]. Heterocycles reduce
polarity, add chemical diversity and conformational rigidity to peptides, as well as provide
recognition elements that interacts with specific targets [52, 59]. They are shown to
chelate iron in the siderophores mycobactin [54], vibriobactin [56] and yersiniabactin [53],
and Zinc/Magnesium in the antibiotic bacitracin [60], to act as DNA intercalators in
the anticancer agent bleomycin A2 [61], and there is evidence suggesting that they form
sequence-dependent contacts with RNAs and proteins [62, 63]. Among RiPPs azol(in)es
are prevalent in LAPs, thiopeptides and cyanobactins, compounds with varied bioactivities
such as cytotoxicity [16], to which heterocyclization may have contributed in di↵erent ways.
1.3.2 Chemistry of Heterocyclization
The heterocyclization reaction in cyanobactin biosynthesis is both ATP and magnesium
dependent [64, 65], as are other reactions catalysed by YcaO domain-containing enzymes
such as the thiazole/oxazole-modified microcin (TOMM) heterocyclase BalhD from
Bacillus sp. Al Hakam [66–69]. Formation of heterocycles in RiPPs starts with the
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hydroxyl or sulfhydryl group from a serine, threonine or cysteine side chain attacking the
amide bond N-terminal to it [70], leading to the formation of a tetrahedral intermediate
called hemiorthoamide (Figure 1.7A showing cysteine residue thiol as a nucleophile).
ATP hydrolysis was proposed to power motions in the enzyme, which functions as
a molecular machine of some sort [52, 66], but stoichiometric analysis pointed to a
mechanism where ATP is directly involved in the chemical reaction of heterocyclization
[71]. According to this mechanism, the activated tetrahedral oxygen attacks ATP on one of
the phosphorus atoms, forming a phosphorylated or pyrophosphorylated intermediate and
releases ADP/AMP; the adduct is subsequently eliminated to give thiazoline/oxazoline
[71]. An unambiguous mechanism for this step is yet to be established, with various
experimental evidence supporting both possibilities [45]. ADP and inorganic phosphate
(P
i
) were observed as the product of ATP hydrolysis during microcin B17 biosynthesis
and in the BalhC/D systems, pointing to the enzyme being a kinase (Figure 1.7A) [70,
71]. Structural analyses of ATP-bound E. coli YcaO and LynD supported this, showing
the  -phosphate exposed to attack and the  -phosphate shielded by the protein [64, 71].
However, AMP and pyrophosphate (PP
i
) have been detected during catalysis by TruD
and LynD [64, 65], contradicting the kinase mechanism. Furthermore, E. coli YcaO, the
function of which is unknown, hydrolyses ATP to AMP and PP
i
[72].
During non-ribosomal peptide synthesis, on the other hand, ATP/Mg2+-independent
heterocyclization is carried out by the Cy domain, a variant of the canonical condensation
domain [73]. Structurally the Cy domain resembles the C domain, although the highly
conserved active site HHxxxDG motif in C is replaced with a DxxxxD motif [74–76].
Nevertheless, Cy still performs condensation reactions (as well as cyclodehydration), and
the DxxxxD motif is believed to play a structural rather than a catalytic role in these
proteins [73–75]. Mutational analyses of the bacillamide synthetase Cy domain (BmdB
Cy2) showed that residues D1226 and T1196 are essential for heterocyclization, but not
condensation [74]. These residues are 2.9 Å apart in the BmdB Cy2 structure [74], and
conserved (2.7 Å apart) in the epothilone synthetase Cy domain (EpoB Cy) [75], making
them plausible candidates for catalytic residues. Figure 1.7B shows the mechanism of
heterocyclization proposed for BmdB Cy2, which occurs after the condensation of cysteine
and its preceding residue [74].
1.3.3 Structure of the Cyanobactin Heterocyclase
Structures of the heterocyclases TruD (P. didemni) and LynD (Lyngbya spp.) were
solved by X-ray crystallography [64, 65]. TruD and LynD share 79% sequence identity
with each other and are almost identical structurally (r.m.d.s of 1.30 over 779 residues).
Figure 1.8 shows the structure of LynD in complex with PatE (partially visible) and the















































































Figure 1.7: Heterocyclization mechanisms proposed for RiPPs and NRPS. (A) Kinase
model of heterocyclization by YcaO-domain heterocyclases. (B) Proposed mechanism of





















Figure 1.8: Crystal structure of LynD in complex with substrates. (A) Overview of the
LynD dimer. The two chains are in green and cyan; PatE (leader) sequences are shown
in yellow and magenta; AMP-PNP is shown as sticks. The peptide clamp, nucleotide-
binding site and the region ordered by leader binding are highlighted by dashed boxes.
(B) Close-up of the interface between LynD and PatE leader. Colour schemes are as in
(A). Residues from the leader and key residues from LynD are presented by sticks; dashed
lines signify hydrogen bonds; residues from the green chain is marked with a single prime;
residues from the cyan chain are marked with a double prime. (C) Key residues that di↵er
between LynD and heterocyclases whose products contain oxazolines.
molecule is oriented in such a way that the C-terminal domain (CTD) is on the top and
the N-terminal domains (NTDs) sit at the bottom. Domain 1 and 2 (NTDs) of TruD/LynD
(residues 1-315 of LynD) share limited sequence homology with the adenylating enzyme
MccB (an E1 ubiquitin-activating enzyme), with two conserved cysteines in a ‘CXXC’
motif coordinating a Zinc ion; However, residues of the nucleotide binding sites in the
MccB domain are not well conserved in LynD or TruD, making an MccB-like adenylating
mechanism unlikely. The function of the MccB domain in LynD is proposed to instead
lie in the ‘peptide clamp’ motif (Figure 1.8), consisting of three alpha helices and three
beta sheets, otherwise known as a winged helix-turn helix (HTH) motif. The active site of
the heterocyclase locates in the C-terminal, YcaO-like domain (residues 316-775), which
is shown to bind AMP, ADP + P
i
and AMP-PNP in structures of LynD complexed with
these nucleotides [64]. However, attempts to obtain density for the the core sequence of
PatE, which is modified by LynD, has been unsuccessful. Unlike the conversed leader
peptide which makes specific contacts with LynD, the core region is hypervariable and
probably has a higher level of a flexibility inside the active site.
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1.3.4 Substrate Recognition by the Heterocyclase
PatD-like enzymes have demonstrated very limited selectivity towards residues flanking
the transformed residue within core region, but their recognition of substrates depends
a conserved sequence within the N-terminal leader peptide [64, 65, 77]. This strategy,
also employed by a wide range of other PTMEs [16, 78], allows them to synthesise highly
variable products with the same catalyst. Despite the lack of sequence similarities between
the leader peptides of di↵erent classes of RiPPs and their cognate PTMEs, there is a shared
structural motif (the 3-helices, 3-sheets peptide clamp, as described in the last paragraph)
involved in protein-peptide recognition, which was discovered by a bioinformatics study
[79] and designated RiPP precursor peptide recognition element (RRE) - this designation
is used interchangeably with ‘HTH motif, ‘peptide clamp’ and ’RiPP domain’ in this
thesis. For instance, LynD and the lantibiotic nisin dehydratase NisB recognise residues
within and surrounding the consensus sequences ‘LAELSEEAL’ (PatE residues 26 to 34)
and ‘FNDL’ (NisA numberings -18 to -15), respectively [64, 80], but both enzymes utilise
structurally similar recognition domains (Figure 1.9). In both cases, the leader forms
a range of specific contacts with the HTH motif, including hydrophobic interactions,
hydrogen bonds and salt bridges, and adds a fourth beta sheet to it [64, 80]. In LynD,
leader binding also regularises a flexible region (residues 371-415) of the YcaO domain
(Figure 1.8), which was disordered in the apo structure of TruD, and turns it into part
of the active site [64, 65]. These interactions activate the enzyme and likely also orient
the rest of the peptide in such a way that the core sequence reaches the active site.
Unfortunately, the core peptide was seen in neither the LynD [64] nor the NisB structure
[80], making it di cult to elaborate on the role of leader in orienting the peptides.
In contrast, how the leader activates the cyanobactin heterocyclase is much better
characterised. Activation happens both when the leader is in cis with the core, like in the
native substrate, and when the leader and the core are added in trans [64, 77]. Cognate
leader peptides added in trans have also been shown to enhance the activities of other
PTMEs, such as the lacticin 481 synthetase LctM and the nisin synthetases NisB and
NisC [81, 82]. In addition, there are a number of cases where constitutively active versions
of PTMEs were created by fusing their cognate leader peptides to them [29, 64, 83].
The observation of trans-activation suggests that these enzymes have a nity for the core
peptides themselves, as in these cases binding of leader does not bring the core peptides
into spatial proximity with the enzymes. This native a nity for the core peptide can
however be enhanced by leader binding, as is the case between the lantibiotic synthetase
HalM2 and its cognate peptide [29]. It should be pointed out that the aforementioned
trans-activated and fused enzymes vary in their e cacy to process their substrates fully;
in other words, having the leader peptides in cis brings additional benefits. Leader binding




Figure 1.9: Structural resemblance of leader peptide binding in LynD and NisB. LynD and
NisB protein chains are shown in green and cyan, except for the peptide clamp domain
which is coloured grey; the leader peptide is shown in yellow; AMP-PNP in LynD and
active site residues in NisB are shown by stick presentation. The leader peptide adds a
beta-strand to the peptide clamp motif.
1.3.5 Specificity and Directionality of the Heterocyclase
Three amino acids, cysteine, threonine and serine, are substrates of the heterocyclase.
Depending on the enzyme, however, not all heterocyclizable residues are converted into
azolines. There are mainly two groups of enzymes, one of which, like PatD, catalyses
both cysteines and threonines/serines [67], whereas the other group, exemplified by
TruD, only produces thiazolines [65]. No enzyme has been reported to make oxazolines
exclusively, likely due to the higher nucleophilicity of the thiolate anion (Cys S ) compared
to the alkoxide (Ser O ) (pKa 8 vs 13). In addition, location of the residue within
the core peptide may also determine whether it is heterocyclization, for example, the
cyanobactin Comoramide A contains two threonines in the same cassette, of which only
one is heterocyclized [86]. It is not clear what causes the chemo- and regio-selectivity of
these enzymes. PatD shares 88% sequence identity with the cysteine-only catalyst TruD,
but is only 73% and 77% identical, respectively, with the enzymes MicD (Microcystis
aeruginosa) and TenD (Nostoc spongiaeforme var. tenue), which have been shown to
make oxazol(in)es [87]. A closer look however reveals that the numbers are skewed by
the almost identical (99% of sequence) N-terminal domains of PatD and TruD, and when
YcaO domains (residues 328-781 as of TruD) alone are compared, PatD were shown to be
more closely related with MicD and TenD than it is with TruD (Figure 1.10, Figure 1.11).
The sequences are still very similar globally (Figure 1.10), and only a few segments that
were common in PatD, TenD and MicD are not shared by the enzymes with thiazol(in)e-
only products (TruD, LynD, OscD): an ‘AE/QGSxAAYR’ sequence that corresponds to
residues 479-484 in TruD (472-479 in LynD), a ‘TV’ motif (TruD K620-A621, LynD K613-
T614), an ‘SK’ motif (TruD A667-T668, LynD A660-D662), a glutamate (TruD A677,
LynD A670), a proline (TruD A686, LynD T679) and a asparagine (TruD P778, LynD
P772). Equivalent residues in the LynD structure (Figure 1.8C) are found mostly on
the the solvent-accessible surface of the protein. Residues 472-479 are located in a loop,
13
                                                            TruD
300       310       320       330       340       350         
TruD  N     LK H L  R QCP CGD       GFEP KL SR K FT DGGHR  TPEQT F T LE    R    T   LQRR    L  E          A      VQ T A P S P RET P H S M
PatD  N     LK H L  R QCP CGD       GFEP KL SR K FT DGGHR  TPEQT F T LE    R    T   ILQRR    L  E          A      VQ T A P S P QE P H S T
MicD  N     LK H L  R QCP CGD       GFEP KL SR K FT DGGHR  TPEQT F T ID    R    S   IL R     V            A      VH V S V V S RQ H Q V R H H F
TenD  N     LK H L  R QCP CGD       GFEP KL SR K FT DGGHR  TPEQT F T LD    K    T   IMQRR    L  E          A      LQ I S L I P PE R R H T
OscD  N     LK H L  R QCP CGD       GFEP KL SR K FT DGGHR  TPEQT F T LD    K    T   ILQRR    L  E          A      LQ I S I I P PK R Q H A
LynD  N     LK H L  R QCP CGD       GFEP KL SR K FT DGGHR  TPEQT  S LD    K    T   ILQHR    L  E               VL H I S I I S PK P Q S GT
β13 α11 α12 
                                                            TruD
360       370       380       390        400       410        
TruD QKYQHL  P TGVVTELVR  DPANPLVHTY AGH FGS    LRGLR  L  KSSGKGK      I  I         IS          R   S   TS     N  R        G A. V H
PatD QKYQHL  P TGVVTELVR  DPANPLVHTY AGH FGS    LRGLR  L  KSSGKGK      I  I         IS          R   S   S     NT R        G SAG Y
MicD QKYQHL  P TGVVTELVR  DPANPLVHTY AGH FGS    LRGLR  L  KSSGKGK      V  I         LT          K      TT     NT K        S A A. Y
TenD QKYQHL  P TGVVTELVR  DPANPLVHTY AGH FGS    LRGLR  L  KSSGKGK      I  V         IT          R   S   TS     NT R        G A. H
OscD QKYQHL  P TGVVTELVR  DPANPLVHTY AGH FGS    LRGLR  L  KSSGKGK      I  V         IS          R   S   TS     T R        G S. H H
LynD QKYQHL  P TGVVTELVR  DPANPLVHTY AGH FGS    LRGLR  L  KSSGKGK      I  V         IT          R   S   TS     NT K        S A. H
η4 
                                                            TruD
420       430       440       450       460       470        
TruD TD QS ASG CEA ERYS IF GDEPRK AT AEL DLA HP   L FS  QY NR   N  S  R   L   I    G  Q      R  L   G   I  EQC   D     E  H R D SS
PatD TD QS ASG CEA ERYS IF GDEPRK AT AEL DLA HP   L FS  QY NR   N  S  R   L   I    G        R  L   G   I  EQC   D     D L L H R D A
MicD TD QS ASG CEA ERYS IF GDEPRK AT AEL DLA HP   L FS  QY NR   N    R   L   I    G  Q      R  L   G   L  ES        E L I L Y NT A E
TenD TD QS ASG CEA ERYS IF GDEPRK AT AEL DLA HP   L FS  QY NR   N  S  R      V    G  Q      R        I  QC   D     E L F F A A H E T A
OscD TD QS ASG CEA ERYS IF GDEPRK AT AEL DLA HP   L FS  QY NR   N  S  R   L   V      Q        L   G   I  EQC   E     D L A W C A A M
LynD TD QS ASG CEA ERYS IF GDEPRK AT AEL DLA HP   L FS  QY NR   N  S  K   L   V    G  Q      R  L   G   I  EQC   D     E L C G A T
α13 β14 α14 η5 α15 α16 α17 
                                                            TruD
 780                                                        
TruD    PF                                                       T M  P
PatD    PF                                                       T I  N
MicD    PF                                                       T I  N
TenD    PF                                                       I  MN
OscD    PF                                                       T M  P
LynD    PF                                                       T M  P
       TT       TT                                         TTruD
480        490       500       510       520       530       
TruD          WIP RF  S A  WTP WSLTEQ HKY P   CYY Y  P    F   DSNV      A  D   V         L TAL    P  R CR    ER.AT THD Q D K H T R F PEH S
PatD          WIP RF  S A  WTP WSLTEQ HKY P   CYY Y  P    F   DSNS AA      A Q ID   L         V TAI     R CK    AEG A YR H A K N LL PAD A
MicD          WIP RF  S A  WTP WSLTEQ HKY P   CYY Y  P    F   DSNS AA      V Q ID   V         V TA     P  R CK    AQG A YR N D K F G L EEQ A
TenD          WIP RF  S A  WTP WSLTEQ HKY P   CYY Y  P    F   DSNT AA      A Q ID   V         L T L    P  R CK    AQG E YR H D R G H M EAN A
OscD          WIP RF  S A  WTP WSLTEQ HKY P   CYY Y  P    F   DSNT VA       Q ID   M         V AM    P  H CR    ERA . HD Q VP T I H S PNH N
LynD          WIP RF  S A  WTP WSLTEQ HKY P   CYY Y  P    F   DSNT VA      A Q IE   V         L TAL    P  R R    EQA . HD Q D T H L PEH A G
β15 β16 α18 
T                                       TT                  TruD
540       550       560       570       580       590       
TruD GNAAGN LEEAILQGF ELVERD    WWYNR  RP V L  F EPYF  LQQFY    R      T         M      SV L     V    D S     LQ     Q  C S A S D QT N
PatD GNAAGN LEEAILQGF ELVERD    WWYNR  RP V L  F EPYF  LQQFY    R      S         M      SVAL     L    E S     LQ     Q  R E S E RS N
MicD GNAAGN LEEAILQGF ELVERD    WWYNR  RP V L  F EPYF  LQQFY    R      T         L      SIAM     I    D T     V      Q  R A S D D QQ N
TenD GNAAGN LEEAILQGF ELVERD    WWYNR  RP V L  F EPYF  LQQFY    R      T         M      SVAL     L    D S     VQ     Q  S G T N RE N
OscD GNAAGN LEEAILQGF ELVERD    WWYNR  RP V L  F EPYF  LQQFY    R      T         L      SVAL     L    D S     VQ     S  S A C N QE D
LynD GNAAGN LEEAILQGF ELVERD    WWYNR  RP V L  F EPYF  LQQFY    R      T         M      VAL     L    D S     VQ     N  G R A G N RE D
β17 α19 α20 
         TT                                                 TruD
600       610       620       630       640       650       
TruD  LWVLD TAD GIPAF G S R  G SER   GFGAHLDP   ILR  TEV Q G ELDKD     L   L     V V   S   I L        TVA   AL   N I L    N KA I
PatD  LWVLD TAD GIPAF G S R  G SER   GFGAHLDP   ILR  TEV Q G ELDKE     L   L     A L   S   V I        IA   AL   S V L    R TV S K
MicD  LWVLD TAD GIPAF G S R  G SER   GFGAHLDP   ILR  TEV Q G ELDKE     V   L     A    T   I I        TIA   AL   S V L    F R TV S
TenD  LWVLD TAD GIPAF G S R  G SER   GFGAHLDP   ILR  TEV Q G ELDKE     L        V V   T   I V        TI    L   S I L    F Y TV I G T
OscD  LWVLD TAD GIPAF G S R  G SER   GFGAHLDP   ILR  TEV Q G ELDKD     L   L     V V   S   L L        SIA   AL   N I     N KS V W
LynD  LWVLD TAD GIPAF G S R  G SER   GFGAHLDP   ILR  TEV Q G ELDKD     L   L     A V   S   L L        TIA   AV   N I L    N KT I
β18 β19 β20 α21 
                   TT       TT                              TruD
660       670       680       690       700       710       
TruD   D  L      W         P L  D     KTA DYP  W DDI T VM CV  A  V  E  D D LV ATL   V  SQPL      RR S   Y D  T  I S S KN AT N AAS Y A A K E KQ
PatD   D  L      W         P L  D     KTA DYP  W DDI T VM CV  A  VP E  E D ML VTL H  AP SQP    N   KR S   Y D    M K DG SK E ET C P R A E KV
MicD   D  L      W         P L  D     KTA DYP  W DDI T VM CV  A  IP D  E D ML VTV H  AP S PM   S   KR S    D  N   K DG SK N EN W P V H KT QT
TenD   D  L      W         P L  D     KTA DYP  W DDI T VM CV  A  IP E  E D LL VT H  VP SQPL   N   KR S   Y D  T  I Q KD SK G RES C P K QG
OscD   D  L      W         P L  D     KTA DYP  W DDI T VM CV  A  VP E  E  LL ATL H  VP TQ L   Q   K     Y E  T  I N KG ATN T AD Y S A L G K QE
LynD   D  L      W         P L  D     KTA DYP  W DDI T VM CV  A  VP E  D D LI L H  LP TQPL   Q   KR S   Y D  T  I N KS AT TEK AD Y T N QQ
α22 η6 η7 α23 
                        TT    TT                            TruD
720       730       740        750       760       770      
TruD  GLE  V DQTRPDIGLNVVKV  PG R  W R G GRLYD PV LGW   PL E   N A   TL L              IV  M F S F      V  K     A A M P. S REQ Q
PatD  GLE  V DQTRPDIGLNVVKV  PG R  W R G GRLYD PV LGW   PL E   N A   TL L              MI  M F S Y      V       A A M PT P Q LKE E
MicD  GLE  V DQTRPDIGLNVVKV  PG R  W R G GRLYD PV LGW   PL E   N A   M L              II  M F T F      I  K     A L V T Q LDA EE Q
TenD  GLE  V DQTRPDIGLNVVKV  PG R  W R G GRLYD PV LGW   PL E   N I   TL L              II    S F      V  K     V A M PT GL P RTV E
OscD  GLE  V DQTRPDIGLNVVKV  PG R  W R G GRLYD PV LGW   PL E   N A   TL V              IV  M F S F      V  K     A A M PH S RDE Q
LynD  GLE  V DQTRPDIGLNVVKV  PG R  W R G GRLYD PV LGW   PL E   N A   TL I              V  M F S F      V  K      A M PT H E LDE T Q
β21 β22 α24 η8 
Figure 1.10: Partial sequence alignment of the YcaO domains of heterocyclases TruD,
PatD, TenD, MicD, OscD (Oscillatoria nigro-viridis PCC 7112 ) and LynD. Blue boxes
show conserved regions; white texts on red backgrounds highlight residues that are
identical in all homologues and red texts represent other highly conserved residues.
Sequences were aligned with Clustal Omega [84] then plotted and annotated with
secondary structures from TruD structure (PDB: 4BS9, chain A) using the ESPript server
[85]. 14





















Figure 1.11: Phylogenetic trees of the Cyanobactin Heterocyclases TruD, PatD, TenD,
MicD, OscD and LynD. (A) Analysis based on full sequences of the proteins. (B) Analysis
based on C-terminal YcaO domains. X axis shows distances from last common ancester.
Trees were generated by Clustal Omega and plotted using the Phylogenetic Tree app in
Matlab.
which lines the passage that leads the peptide to the nucleotide binding site. A660,
T661 and P772 also form part of this entrance. Conformational di↵erences caused by
mutation of these residues in the oxazoline-producing homologues may underline their
broader substrate scope. Molecule structures of one or more of such enzymes will be
required to elucidate the changes.
Directionality is another interesting aspect of the TOMM heterocyclase mechanism.
Unlike NRPSs (Figure 1.1A) which operate in a modular fashion, RiPP PTMEs are
presented with precursor peptides that may contain multiple modifiable residues. Studies
of the heterocyclases BalhD and TruD showed a preferred order of catalysis, where the
enzyme starts from the C-terminus and works its way towards the N-terminus [65, 68]. The
lantibiotic synthetases LctM and HalM2, on the contrary, exhibit preference for an N-to-C
order of reaction (dehydration) [88, 89]. For LctM, it is thought that spatial positioning of
the substrate mediated by the leader peptide is combined with decreasing binding a nity
for each subsequent intermediate in securing the order of reaction [88]. The reason for these
enzymes to maintain an order of reaction might be to prevent the formation of incorrect
products during biosynthesis. For example, if an upstream modification enzyme converts
the substrate ABC into A*B*C*, and the its downstream enzyme recognises compounds
with C* as substrates, an N-to-C order in the first enzyme would preclude the second from
encountering the intermediates ABC*, A*BC* or AB*C, which cannot be turned into the
correct final product.
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1.4 Proteases PatA and PatG
Proteolysis of the N-terminal leader of PatE by heterocyclization, carried out by
the protease domain of the enzyme PatA [90], is a pre-requisite for the subsequent
macrocyclization reaction. The protease/macrocyclase domain of PatG further cleaves the
peptide to remove the C-terminal recognition sequence, as well as cyclising the remaining
octapeptide in an head-to-tail fashion [91] .
1.4.1 Structures and Mechanisms of PatA and PatG
The proteins PatA [90] and PatG [91] both harbour a subtilisin-like serine protease domain,
with a catalytic triad composed of serine, aspartate and histidine. PatApro cleaves after
the ’G(L/V)E(A/P)S’ recognition motif (Figure 1.5B), freeing the N-terminus of the core
peptide for macrocyclization [90], whereas PatGmac cleaves between the core peptide
and the ’AYD’ recognition site (Figure 1.5B), and joins the rest of the peptide in a N
to C manner [91]. The two enzymes share sequential, structural and and mechanistic
similarities (Figure 1.12). The first step in both PatApro and PatGmac reactions are
proposed to be the formation of a acyl-enzyme intermediate, as in other serine proteases
(Figure 1.12B). In PatA, this will be hydrolysed, resulting in the break of the amide bond.
An additional domain in PatG, designated the ’macrocyclization insertion’ (Figure 1.12A),
is thought to prevent hydrolysis of the first acyl-enzyme intermediate [91]; instead, the
deprotonated N-terminus of the core peptide attacks and a second tetrahedral intermediate
is formed, which leads to N-C macrocyclization. Unfortunately, the crystal structure for
PatGmac lacks electron density for the N-terminal amine of the core peptide sequence
[91], which precludes conclusions as to how substrate positioning a↵ects catalysis. It
is however hypothesized that the e↵ect is minor, as PatG and its homologues showed
notable substrate promiscuity. Peptides containing from 6 to 22 amino acids in the core
region and a combination of natural and unnatural amino acids have been successfully
macrocyclized, as long as they possess the signature sequence (proline/heterocycle)-AYD
[92–94]. In addition, peptide substrates containing up to three triazole groups and sugars
were shown to be macrocyclized [95, 96], further expanding the substrate scope of the
macrocyclase enzyme to include non-peptidic sca↵olds.
1.4.2 Reaction Rates of PatA and PatG
Both enzymes exhibited low turn over rates on various substrates in vitro.The hydrolysis
reaction catalyzed by PatA is several orders of magnitude slower than observed for other
proteases [99] and turnover numbers in the vicinity of 1 day?1 for the macrocyclase




























































































Figure 1.12: Structure and Mechanism of Macrocyclase. (A) The structures of PatG
macrocyclase domain (PDB: 4AKT), magenta, in complex with the substrate mimic
VPAPIPFPAYDG is overlaid with the apo structure of PatA (PDB: 4H6V), cyan. The
pink box hights the helix-loop-helix motif designated the ‘macrocyclization insertion’ [91].
The blue box shows the active site of PatGmac H618A, in which the site chain for the
catalytic histidine (H618) was added; and the three initial residues (VPA) from the core
sequence, labeled P6, P7, and P8 were added according to a structure prediction carried
out using PEPFOLD [97, 98]. (B) macrocyclization mechanism proposed for PatGmac.
The N-terminal amine of the peptide, instead of water, acts as a nucleophile in the
formation of the second tetrahedral intermediate. Figure adapted from [45].
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was sensitive to reducing agents, commonly used in in vitro assays to keep cysteine
residues available for heterocyclization [101]. This inhibition could be important in
delaying protease cleavage of the leader, which is needed for heterocyclization, and
therefore ensuring peptides are heterocyclized before they are cleaved. The authors
argued that in cyanobacteria, the native producers of cyanobactins, this process could
be regulated by their natural redox cycles [101]. The reason underlying PatGmac’s poor
catalytic e ciency could lie on the fact that the macrocyclase enzyme seems to trade-o↵
e ciency for a very simple recognition motif. Much faster macrocyclases such as the plant
enzymes Butelase 1 (Clitoria ternatea), PCY1 (Saponaria vaccaria) and the mushroom
enzyme GmPOPB (Saccharomyces cerevisiae) [102–105] have exhibited higher substrate
specificities. Alternatively the macrocyclase enzyme may have evolved to be bottleneck
of the process to allow other reactions required to make biologically active compounds to
take place [90, 92].
1.5 Azoline Oxidation
Following heterocyclization, thiazolines and oxazolines are in many cases oxidized by a
flavin mononucleotide (FMN)-dependent dehydrogenase to yield thiazoles and oxazoles
[70]. The oxidase (McbC) was first discovered as part of the thiazole/oxazole synthetase
McbBCD involved microcin B17 biosynthesis [70]. In cyanobactin biosynthetic pathways,
the oxidase is either a standalone enzyme or a part of the G protein [20]. Like the
heterocyclase, the oxidase is absent in pathways that do not require its function, such
the trunkamide (Tru) pathway, where the final products contains unoxidised thiazolines
[106]. Thiazolines arise more frequently than oxazolines among cyanobactins, and also
more commonly oxidised [21].
Oxidation of azolines aromatises and flattens the rings, reducing their reactivity
[107]. For example, azolines within peptides have been shown to hydrolyse in 10%
formic acid, whereas azoles in the same environment stayed intact [68]. Thiazolines
and oxazolines are also susceptible to methylation when reacted with methyl sulphate
or methyl bromide [108]. Oxidation of thiazolines to thiazoles increase aromaticity more
than that of oxazolines to oxazoles [107], and the higher prevalence of thiazoles compared
to (methyl)oxazole in cyanobactins [106] could be a reflection of that.
1.5.1 Mechanism of Oxidase Reactions
Oxidation occurs throughout biological systems and serves a variety of functions.
Numerous strategies to carry out oxidation reactions enzymatically have evolved in
response. Bioluminescence from fireflies is produced when a thiazoline ring in the molecule
18
....                                                        ThcOx
                  270       280        290       300        
ThcOx                               S                             I R  IR Y ITL LG L V....LATTD..........MTLTEA ET R E SD.QP AQ EF YRCAR KAVY
ArtGox                               S                             I R  IR Y ITI LG L I....IRQRD..........KTLTTA EK A E DENHP EQ EL YRTAR KEIY
McbC                               S                              V S LP I....FENKE..........VLFRPGFS... INISSSHNF RER SG NFCDKNKLSI
SagB                               S                             I R  R F M L L L V.....TKIS..........TALSTC IK R H Q SDR.Q P QD SNI YYACG SSQA
BcerB                               S                             L  L TL IG L V....VPTIP..........LS.... EIPL S..NSSTTP DE HY WYSFG TQLC
EpoB                               S                             R  VR F I G L VLRRDLDGKPVVDLTGLVPREAGLDVYAR R T LEA.P PFVEF RF SCLSS ....
BlmIII                               S                             L R  H F VTL L L VIRHEFDATDGVALSGPD.....DHH TA R H R DPG.P PD AAL GALRR ....
                TT            TT                            ThcOx
310                  320       330       340           350   
ThcOx                                G  Y                         R YPSG L L IY VH L G Y YTLPED...........PMQVGESTT P A E E PL QC....GD AA L H
ArtGox                                G  Y                         RR YP G M L IYL VR V G Y YTHDAEQAELLKAQFGEDFDWGELS P C A E E A RC....AG KP L H
McbC                                G  Y                         RR YPSG L PI VFL A Y YR...TIEKLLVNAFSS..PDPGSV P A E CRLSENTENWQ GTNV H
SagB                                G  Y                         R SG L PI L AR L G Y YSIR.............DGASDKITL NCA G H VFY NI....SK ID F E
BcerB                                G  Y                         RR PSG L P LYI LK G Y YQLN...............SERNVL SI A NE Y ID.....DYPD I H
EpoB                                G  Y                         K YPS   PV YA AK V G Y Y................EPDGAALP FR A ST QT Y SGRI..EG DE F Y
BlmIII                                G  Y                         K YPS   PV YL VH L G................RGP.GGEP YA A SS QT L PGKV..TG PG SHYV
                        ..                                  ThcOx
    360       370         380       390       400       410 
ThcOx       L                                             Y       PL H  V DA VLI F RL K YQ S T HP ADWTPEVESLVY ..WRATGQQSIPQI ITAR G FW HDIA SL
ArtGox       L                                             Y       PL H  I DA LLM F RL K YD N Q AQ DAADADIQALLK ..HQSSGEQGMPQV ITAR G FR RSLA AL
McbC       L                                             Y       PL  V L ALV F KA K YL SQA EP ATCNTQ..SLYRS .SGGDSERLGKPHF YCII E LF RYRG RM
EpoB       L                                             Y       P H  D III Y K K L YQ A RCYRHSSEE...NVR F.AEYGAINAENCNI YVYH M NTR GNQATAY
BcerB            L                                             Y       A H  L DA AA F K K YDA H R IL REGNFD..SYLA ..LGNRCNIHDCFG FVSTM W NFF NNFS RL
EpoB       L                                             Y       P H  V A LL I  H FE R LK SDHG.I....ERG HVPQNFDVFDEAAFG FVGRIDA ESL GSLSREF
BlmIII       L                                             Y       PA  I DA L I  WH RNR VS DPTATL....PA HAEINRAAYGEAAFS YLIAAIDA TPL GDLS DF
                                  .                         ThcOx
      420       430       440        450       460       470
ThcOx      G                                  L                   L  L QT A L IG IA  LGI KHV V Y FYLV TAMQ APSA AGNTTKF.CQ G NPDEEASVGEFS AAKPQ
ArtGox      G                                  L                   L  L QNL A L LG A  LGV KHV V Y YLV TNMG APCA AGDSDRF.AQ TG DYVVESSVGEFM SL...
McbC      G                                  L                   L E  M QNA A L V M  GA M T S Y VLV DQIG KNRVWA.GYTDSY AKT N DQRTVAPLIVQFF DVNDD
EpoB      G                                  L                   E  I QNI A IG L LL  VGAFI S E A QLT TALTYGSID .GYNKEY QE D DGLGEHVIHMTL TKESQ
BcerB      G                                  L                   D  L QL L LL  LQGL S V IG LECTKQFGYTNGVYF.QFLDRA NH G SEGEESVYAVIP STEPET
EpoB      G                                  L                   L E  M Q L A I VG V VL  LGC L A Y A L MEQ PSCN GVCP .QFDFEQ RP D RH..SDVYVHGM GRVDP
BlmIII      G                                  L                   V E  M Q L A I VG L A  LGT F A A T L MRT VGTG GLCP .TMDPAP RR FA TD..RHRFVHAL GRPRT
α9 α10 β15 
β16 β17 β18 
β19 α11 β20 η2 
α12 β21 α13 β22 
Figure 1.13: Sequence Alignment of RiPP and NRPS oxidases. Cyanobactin oxidases
ThcOx (Cyanothece sp. PCC 7425) and ArtGox (Arthrospira platensis) were aligned with
TOMM oxidases McbC (E. coli), SagB (Streptococcus pyogenes), BcerB (Bacillus cereus)
and NRPS oxidases EpoB (Sorangium cellulosum) and BlmIII (Streptomyces verticillus)
using Clustal Omega [84]. The alignment file was plotted and annotated with secondary
structures from ThcOx structure (PDB: 4LQ5) using the ESPript server [85].
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luciferin is oxidised in a ATP/Mg2+-dependent manner, via a dioxetanone intermediate,
catalysed by the enzyme luciferase [109]. Rather commonly, iron sulphur clusters or co-
factors such as NAD+, FAD, FMN and quinones are employed in cellular redox processes
[110]. Succinate dehydrogenase, a crucial enzyme in aerobic respiration that links the
citric acid cycle to the electron transport chain, employ FAD, ubiquinone, as well as
several iron sulphur clusters to carry out a series of redox reactions [111]. Azoline oxidases
are believed to utilise FMN for redox function. Primary sequence alignments with FMN-
bound dehydrogenases from RiPPs and non-ribosomal peptide synthetases show a limited
level of sequence homology (Figure 1.13). Most conserved residues are thought to involve
in FMN binding [45]. In addition, a lysine-tyrosine motif (KY-motif) is conserved in all
the RiPP oxidases (ThcOx, ArtGox, McbB, SagB and BcerB), but is replaced with a ‘LY’
sequence in the NRP oxidases. Mutagenic analysis of the TOMM oxidases McbC (E. coli)
and BalhB (Bacillus sp. Al Hakam) showed the KY motif to be essential for product
oxidation [112]. Analogously, in the related enzyme from Sulfolobus acidocaldarius DSM
639, SaciB, mutation of either lysine or tyrosine resulted in complete loss of activity [113].
BcerB from Bacillus cereus 172560W showed reduced activity when K185A mutant was
tested, whereas both Y186A and the double mutant K185A/Y186A were inactive [113],
echoing with the fact that the lysine is not conserved in NRPS oxidases (Figure 1.13).
A mechanism for oxidation [114] has been proposed for EpoB (Sorangium cellulosum)
and BlmIII (Streptomyces verticillus), NRPs enzymes catalyzing thiazole formation in
epothilone and bleomycin biosynthesis, respectively. In this mechanism (Figure 1.14), the
co-factor FMN is reduced twice as the thiazoline is oxidised, becoming FMNH
2
; molecular
oxygen then reoxidises FMNH
2









using a coupled assay following reactions by EpoB and BlmIII, in agreement with
their hypothesis [114]. However, molecular details are not available with regard to catalytic
residues and substrate placement.
It is not clear if oxidation occurs before or after cleavage of leader peptide during
cyanobactin biosynthesis. Crystals of ThcOx were only obtained when a part of the
leader peptide (NILPQQGQPVIR) was added in the co-crystallisation bu↵er, although
that peptide was not seen in the structure [106]. Interestingly, oxidation of heterocycles
have been observed on both macrocycles and linear, leaderless peptides, suggesting that
the leader peptide is not required for oxidation [87]. On the other hand, the Microcin B17
oxidase (McbC) is part of a heterocyclase/oxidase complex McbBCD [70], which modifies
linear precursor with a leader peptide. Indeed, in the case of McbBCD, only the full
complex is active, and azolines are not produced when the the substrate was reacted with
only the heterocyclase components (McbB and McbD) of it [115]. Other TOMM oxidases
such as BcerB, in contrast, are active oxidases on their own, although they still form
complex with the heterocyclase when the latter is present [113].
Although cyanobactin oxidases have not been characterised biochemically, studies
20
Figure 1.14: Proposed Reaction of Oxidation by EpoB and BlmIII. Figure adapted from
[45].
of homologues from other TOMM pathways have yielded insights into the
specificity/promiscuity of these enzymes, as well as their order of reaction [68, 87,
113]. Like heterocyclases, oxidases from related organisms were successfully employed
interchangeably to produce azoles; however, more distantly related (in sequence terms)
enzymes were less e cient, or failed altogether in doing so [68, 71, 113, 116]. Interesting
observations were made with regard to the reaction order of oxidase enzyme. When
When the oxidase BalhB was present in the same pot with the heterocyclase BalhC/D,
azoles were formed on the substrate (BalhA) in a C to N order, similar to that seen for
heterocyclization alone [65, 68]; when presented with a heterocyclized intermediate that
contains five unoxidised thiazolines, however, BcerB (BalhB homologue) first catalysed
the middle thiazoline, and moved onto the N-terminal and C-terminal ones [113].
1.5.2 Structure of the Cyanobactin Oxidase
The X-ray crystallography structure (Figure 1.15) of the standalone enzyme ThcOx
(Cyanothece sp. PCC 7425) [106] showed a homodimer, each with an FMN-bound oxidase
domain and a N-terminal domain (NTD) that contains two ’peptide-clamp’ motifs that
are prevalent in RiPPs (see section 1.3.4 on page 12). The first peptide-clamp (residues 7-
86) is exposed and may involve in substrate recognition, while the second clamp (residues
87-194) is buried at the dimeric interface, bound to the equivalent domain from the other
monomer. The NTD is conserved in cyanobactin oxidases, but is absent in other known
TOMM oxidases such as BalhB , BcerB and SaciB, which are homologous to the CTD
of ThcOx. Mapping conserved residues (identical or similar in all seven enzymes) on
the ThcOx structure showed clustering around the FMN binding pocket, as expected;
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Figure 1.15: Structure of the Cyanobactin Oxidase ThcOx (PDB: 5LQ4). (A) Homodimer
of ThcOx, shown in green and cyan, in complex with co-factor FMN, shown in spheres.
Each monomer has a N-terminal domain that contains two peptide clamp motifs, and
a C-terminal domain homologous to nitroreductases. (B) Residues that are identical or
similar across all enzymes aligned in Figure 1.13 are shown in stick representation.
additionally, residues near the exterior of the protein also showed some level of grouping,
surrounding strands  18,  19 and helix ↵10 (Figure 1.15B).
1.6 Prenylase
1.6.1 Prenylation in Cyanobactins
Prenylation contributes to the bioactivity and structural adversity of secondary
metabolites, and has been shown to increase cell permeability of peptide substrates
[117]. Prenylated cyanobactins (Figure 1.16) feature O-prenylation of serine, threonine
and tyrosine residues, [16, 21, 50, 118–121], C -prenylation of tyrosines [121–123] and
tryptophans [124], O-geranylation (addition of a C
10
group) of tyrosines [125], and N-
terminal prenylation of short, linear peptides [40, 126]. O-prenylation is carried out
by a LynF-type protein (Figure 1.17). Specifically, PagF (Oscillatoria agardhii) [127]
and LynF (L. aestuarii) [122] catalyse forward and reverse prenylation on tyrosines,
respectively, while TruF1 (P. dimemni) [39] reverse prenylates serine and threonine
residues, using a dimethylallylpyrophosphate (DMAPP) group as isoprenoid donor. In
the LynF pathway (Figure 1.16, aestuaramide), the prenyl group then undergoes non-
enzymatic Claisen rearrangement to yield C -prenylated products [121–123]. Although
PagF-like enzymes had a strong preference for cyclic substrates [101, 122, 127], distantly
related linear cyanobactins viridisamides and aeruginosamides undergo prenylation on
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the N-terminal amine [40], pointing to the existence of homologues that utilise linear
substrates. During aeruginosamides biosynthesis this unusual reaction is carried out by
a fused methyltransferase-prenyltrasferase AgeMTPT, which also caps the C-terminus
of the precursor with a methyl group [126]. Moreover, PirF, recently reported to
forward geranylates a tyrosine residue in piricyclamides using the C
10
donor geranyl
pyrophosphate [128], and KgpF, which catalyses a unique C-3-prenylation of tryptophan
in kawaguchipeptins [124] were shown to be active on linear peptides as well as cyclic
ones in vitro. During cyanobactin biosynthesis in vivo the timing of prenylation might be
flexible, and could take place alongside macrocyclization.
Interestingly, the prenylase gene is present in almost all cyanobactin biosynthetic
pathways, including those that do not have prenylated products, such as the patellamide
pathway [20, 40]. Bioinformatics has clustered F enzymes into groups but the relationship
between genotypes and phenotypes was supported by limited information [127]. LynF and
TruF1 are isolated in their own one-enzyme groups among the 26 enzymes analysed, while
the rest formed two major groups - those resembling to PagF and those closer to PatF.
PagF-related enzymes, include those with identified prenylated/geranylated products such
as AcyF (anacyclamides) [129] and PirF, but also ThcF (cyanothecamides) [130] and ArtF
(arthrospiramides) [119], whose known products do not carry prenylation. Even though
prenylation in several anacyclamides was confirmed by mass spectrometric analysis, it was
not clear on which residues those modifications take place, as some prenylated/geranylated
sequences contain threonines/serines, while others have tyrosines or both [129]. PatF
is found in the other major group along with enzymes such as TenF (tenuecyclamides)
[131] and McaF (microcyclamides) [48], which have also not been reported to prenylate
susbtrates. It is unknown why these likely inactive enzymes have been preserved, or have
appeared to evolve in the same direction.
1.6.2 Structure and Mechanism of the Cyanobactin Prenylase
Similar to the heterocyclase and the oxidase, the cyanobactin prenylase showed remarkable
permissiveness with regard to its substrates [122, 127, 128]. However, LynF’s preference
for macrocyclic substrates [122] precludes the use of a combination of conserved recognition
sequences and hypervariable core as a way of broadening substrate scope, a strategy
employed by the heterocyclase [64, 65, 77]. Kinetic analysis of PagF [127], prenylase
from the prenylagaramide pathway, showed that that enzymes catalyses tyrosine residues
within a peptidic context much more e ciently than L-Tyr on its own, in contrast with
canonical small-molecule prenylases. Structures of PagF in complexed with peptide
substrates and a DMAPP analogue unveiled the reasons for this selectivity. First,
although PagF [127] and PatF [132] both adopt a prenyltransferase fold (Figure 1.18A),
comprising a 12-strand beta barrel surrounded by 12 alpha helices, the barrel is open to
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Figure 1.16: Examples of Prenylated Cyanobactins. O-prenylation of serine, threonine and
tyrosine residues, C -prenlylation of tyrosines and tryptophans, and N-terminal prenylation

























































Figure 1.17: (A) O- and C -prenylation/geranylation of tyrosine. (B) O-prenylation of





















Figure 1.18: Structural basis for the substrate specificity of the Cyanobactin Prenylase.
(A) PagF (PDB 5TTY, cyan) is aligned with PatF (PDB 4BG2, magenta) and the bacterial
ABBA family member NphB (PDB 1ZCW, green). The capping helix, missing from the
cyanobactin prenyltransferases, is highlighted with a black dashed box. (B) The structure
of PagF is complex with cyclo-INPYLYP (PDB 5TU6, yellow) shows that the macrocycle
forms the bottom of the ↵/  barrel in the active conformation. (C) The macrocycle,
shown as yellow sticks, is enclosed by walls and forms hydrogen bonds or hydrophobic
interactions with specific residues from the enzyme, shown in green sticks. (D) Close-up
of the PagF active site showing orientation of the substrate analogue DMSPP (orange)
relative to the macrocycle (yellow), which favours forward prenylation. Residues from the
enzyme are coloured green.
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solvents in these enzymes, whereas it is capped by either a helix or a loop of aromatic
residues in canonical prenylases [133–135]. In the macrocycle-bound structure of PagF
(Figure 1.18B), the peptide plugs the base of the barrel, a↵ording protection to reactive
intermediates within the hydrophobic interior [127]. Smaller molecules do not su ciently
shield the cavity, consistent with them being poor substrates. Second, inside the barrel,
the macrocycle is secured in place by a range of hydrogen bonds and van der Waals
interactions (Figure 1.18C) between cavity wall residues, the modified tyrosine (Y4 of
INPYLYP), and amino acids flanking it. Due to structural constraints imposed by the
wall, macrocyclic substrates, which bend around the target residue, are preferred to
their linear counterparts. Interestingly, despite having two tyrosine residues, only Y4
is prenylated on cyclo-INPYLYP, and complex structures exclusively featured Y4 in the
active site, due to energetical favourability of this conformation [127]. Structural restraints
also underly the use of tyrosine over serine and threonine, as well as the catalysis of
forward rather than reverse prenylation. In cyclo-INPYLYP-bound PagF (Figure 1.18D),
Y4 is placed in such a way that the phenol oxygen is 2.6 Å away from E51, which could
deprotonate it, and 3.1 Å away from C1 of DMSPP. The distance from this oxygen to C3
of DMSPP is much greater (4.0 Å), consistent with the fact that PagF carries out forward
prenylation. Although structures of LynF a d TruF1 have not been obtained, sequence
alignment [127] showed mutation of several of the residues shown in Figure 1.18C in
these enzymes, which could help them accommodate smaller residues at the active site,
or move C3 closer to the prenylated oxygen. To summarise, substrate recognition by the
cyanobactin prenylase largely depends on conformational complementarity rather than
sequence-specific interactions, and this could have resulted in their promiscuity.
1.7 Unknown Aspects of Cyanobactin Biosynthesis
Despite being one of the best characterised RiPP pathways, patellamide biosynthesis
still presents many unanswered questions. The epimerization of the residues next to
the thiazoles (the alanine and phenylanine in the case of the peptide ITACITFC) could
happen spontaneously under non-physiological chemical conditions [136], but it is not
known whether it is catalysed enzymatically in nature. Functions of the nonessential gene
products PatB and PatC, the inactive prenylase PatF, and the DUF domains of PatA and
PatG are yet to be identified. Variabilities in the number of heterocycles, their oxidation
states, and other forms of modifications are only beginning to be explained. Additionally,
it remains an open question whether enzymes in the patellamide pathway (for example)
form protein-protein interactions (PPIs) which could allow intermediates and substrates
to be more e ciently or rapidly funnelled through the pathway. Domains of unknown
function (DUF) could act as sca↵olds facilitating these PPIs.
Moreover, little is known about the natural destinations of cyanobactins after they are
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biosynthesized by cyanobacteria. The natural functions of cyanobactins are unknown,
but could be related to symbiosis - profiles of secondary metabolites produced by
symbionts are host-specific [137, 138]. Isolation of cyanobactins from ascidians means
these compounds are exported to the host organism by the cyanobacterial producer, yet
no transportation mechanism has been described. The natural targets of these molecules
are also unidentified. It is nevertheless possible to explore their potential medical benefits
by screening them against targets of interest. Indeed, e↵orts have been made to create
libraries of cyanobactin derivatives, as described in the next section.
1.8 Current Applications of the Cyanobactin Biosynthetic
Machinery
1.8.1 In-vivo and in-vitro Production of Cyanobactin Derivatives
In-vivo and in-vitro procedures have been established to produce cyanobactins and
derivatives, creating diversity through varying the genetic composition of the precursor
peptide [50, 87, 93, 101, 139, 140]. In vivo production by introducing the whole
biosynthetic gene cluster into a host organism (usually E. coli) is currently ahead of
the game in terms of yield and randomised library generation [93, 101], producing up to
hundreds of milligrams of cyanobactins per litre of growth medium [101]. On the other
hand, in vitro methods benefit from increased manipulability of product formation [87,
140], as PTMEs can be individually selected and combined in di↵erent ways as needed.
The advantages of these biotechnological applications are multifold: employment of the
ribosomal machinery allows facile editing of the peptide sequence by means of molecular
biology, thereby not only providing a medley of possible product sequences but also
enabling the additions of other tailoring facilities, such as peptide cleavage sites [87, 141,
142]; processing of the precursor peptide by PTMEs adds further diversity to the chemical
and structural moieties that underly the activities of the final products [16]. Unfortunately,
exploitation of the ribosomal route, the very basis for the natural diversity of RiPPs, also
poses restrictions on the scope of potential products. A number of non-canonical amino
acids, such as selenazolines [143] and p-acetyl-phenylalanine [139] have been introduced
into the sequence via medium supplementation and orthogonal tRNA, respectively, but
the diversity is limited.
1.8.2 Semi-synthetic Approach Towards Cyanobactin Analogues
A semi-synthetic approach towards cyanobactin derivatives has been adopted by the
Naismith group, thanks to the promiscuous nature of the enzymes, especially the
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macrocyclases from the cyanobactin family. The macrocyclase PatG only requires its
substrate to have a macrocyclization motif AYD (Figure 1.5, page 7), a heterocycle at the
position preceding it, and a free N-terminal amine [45]. Chemically synthesised materials
that contain azidoalanines, dehydroalanines, triazoles and sugars have been successfully
turned into macrocycles using PatG [94–96], making way for further modification by
click chemistry, and in the case of sugars, increases membrane permeation by lowering
the polarity of the molecule. These non-natural residues are tolerated not only by the
macrocyclase, but also by the heterocyclases, allowing the creation of molecules that
contain unnatural moieties as well as azol(in)es [94, 95]. The structure-based design of
a modified LynD (LynD fusion) was crucial in making this practical [64], as the natural
enzyme requires its substrate to have a leader, which makes chemical synthesis di cult,
expensive and wasteful. The substrate-bound structure of LynD (Figure 1.8, page 11)
showed the interaction between residues QLSSQLAELSEE of PatE and LynD [64]. By
measuring the distance between the leader of PatE and the start of LynD in the structure,
LynD fusion was created as a recombinant protein containing residues Q21-A37 of PatE
fused to the N-terminus of LynD, and is capable of using leaderless substrates that contains
only the core sequence (Figure 1.5, page 7) and the macrocyclization motif AYD [64]. As
the requirement for leader is bypassed, chemically synthesised peptides (and hydrids) are
now readily usable as starting materials. The oxidase and the prenylase may also accept
unnatural peptides as substrates, although it has not been directly shown. A summary
of the current advances in creating combinatorial libraries of cyanobactin analogues are
shown in Figure 1.19. It has to be noted that various methods of synthesis discussed here
are primarily laboratory-based, and substantial future work is required to produce them
on an industrial scale and test them against therapeutic targets.
1.9 Aims and Objectives
The work constituting this thesis represents continued e↵orts of exploiting the cyanobactin
biosynthetic pathway. Particularly sought after is a tool that installs (methyl)oxazolines
into peptide backbones, without the need of a in-cis leader sequence. The creation and
characterisation of several of such tools (modified enzymes) are detailed in Chapter 2.
Beside having a biotechnological interest in the cyanobactin biosynthetic system, we also
wish to better understand the fundamental biochemistry of its PTMEs. Chapter 3 and 4
describe, respectively, investigations into the reaction orders of two biosynthetic enzymes of
the cyanobactin pathway, the heterocyclase and the oxidase. Chapter 5 then looks into the
unusual way via which ATP is consumed by the heterocyclase. Finally, Chapter 6 depicts
the characterisation of another biosynthetic enzyme - ATP phosphoribosyltransferase - for








“mix and matching” 
enzymes allow distinct 
modifications to be inserted
shorter sequences 



























Engineer ing and ut i l iz ing chimeric pathways to synthesize 
cyanobact in- inspired molecules
Figure 1.19: Synthesis of Cyanobactin-Like Molecules. Size and sequence of the core
peptide, as well as their post-translational modifications can be diversified. In addition,





Heterocyclases That Catalyse the
Formation of Thiazolines and
Oxazolines
2.1 Summary
A range of modified cyanobactin heterocyclases fused with part of the leader peptide of the
patellamide precursor PatE were designed, expressed and purified. Several of them were
found to capable of catalysing the formation of thiazolines and oxazolines from cysteines
and threonines, respectively, when leaderless core peptides containing heterocyclizable
residues were supplied as substrates. The reaction condition for catalysing the formation
of heterocycles on short peptides was optimised. Variants of the fusion enzymes were
compared in terms of their yields and activities.
2.2 Introduction
Leader peptides have a multitude of important roles, such as providing a secretion signal
and recognition motifs [78]. The latter is particularly crucial in the biosynthesis of
ribosomally synthesised and post-translationally modified peptides (RiPPs), by facilitating
the binding between nascent peptides and the their post-translational modification
enzymes (PTMEs). Leader peptide of RiPPs may contain several elements that interacts
with di↵erent PTMEs [16], and could activate the enzymes and/or regulate the positioning
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Figure 2.1: A schematic illustration of the fusion enzyme principle.
of the core peptide at the active site [64, 80]. Several studies showed that adding the
whole or part of the leader peptide in trans could induce the activity of some PTMEs
on leaderless peptide sequences [77, 82, 83], and this observation led to the idea of fusing
cognate leader peptides to PTMEs, to create constitutively active enzymes. Successful
experiments were carried out on the enzymes LctM, HalCE2 (lantibiotic synthetases) [29,
83] and LynD (cyanobactin heterocyclase) [64] (Fig 2.1). In the last case, Koehnke and
co-workers attached part of the leader sequence, residues Q21-A37, of the patellamide
precursor PatE to the N-terminus of LynD (Lyngbya sp.), and produced an enzyme that
can heterocyclize multiple cysteine residues on a peptide in the absence of a in-cis leader
sequences [64]. One major limitation of LynD fusion is that it only modifies cysteines
but not threonine/serine residues, which poses restrictions on the diversity of compounds
that can be produced. In addition, although the sequence of the fused leader and the
length of the linking region was chosen based on structural data, only one construct was
made without further optimisation, and there may still be room for improvement. It
was unknown whether the other cyanobactin heterocyclases, especially those capable of
producing oxazolines, could be modified in the same way to create their constitutively
active variants. This chapter describes attempts to extend the fusion strategy to other
enzymes. Modifications were carried out on homologues of LynD to create a catalyst that
produces oxazolines, and the activities of those engineered enzymes on leaderless peptides
are demonstrated.
2.3 Materials and Methods
2.3.1 Preparation of Competent Cells
Competent Escherichia coli DH5↵ (DE3) and BL21 (DE3) cells were prepared based on
the Inoue Method [144]. A 10 ml starter culture was made by adding 100 µl of a defrosted
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aliquot of existing competent cells into LB medium and incubated at 37  C, 200 rpm for 12
h. Varied amounts of the starter culture (0.5 ml, 1 ml or 2 ml) were inoculated individually
to 200 ml of fresh LB medium and grown for 12-16 h at 18  C, 200rpm. Optical density
(OD) was monitored until one of the cultures reached an OD between 0.5 and 0.7. The
culture with the appropriate OD was divided into four 50 ml fractions and placed on ice for
10 min and then centrifuged at 2934 g for 10 min at 4  C. The supernatant was discarded
and to each pellet was added 16 ml transformation bu↵er (10 mM PIPES-KOH pH 6.7,
250 mM KCl, 15 mM CaCl
2
and 55 mM MnCl
2
).The bu↵er was prepared in advance and
stored at -20  C. Cells were resuspended gently inside Falcon tubes placed on a spinning
wheel at 4  C. After resuspension the cells were centrifuged again at 2934 g for 10 min at
4  C. The pellets were drained and resuspended in 4 ml Inoue bu↵er each. Resuspended
cells were transferred into the same tube to which DMSO (1.2 ml) was added, and the tube
was slowly reversed several times. The cells were dispensed into autoclaved and pre-chilled
microcentrifuge tubes, flash frozen in liquid nitrogen and stored at -80  C.
2.3.2 Construction of Expression Plasmids for PatD, MicD, TenD and
OscD Fusions
See Fig 2.2 for an illustration of the ‘cut-and-paste’ strategy used and subsection 2.3.4
for polymerase chain reaction conditions and primer sequences. To start with, a HindIII
site (AAGCTT) was introduced to the plasmid pJexpress411 carrying the gene encoding
LynD fusion [64], by mutating the 6 amino acids directly N-terminal to the LynD coding
sequence via site directed mutagenesis [145]. Template DNA was removed by adding 0.5 µl
DpnI and incubating at 37  C for 2 h, and the mixture was purified using a QIAquick Gel
Extraction Kit (QIAGEN) following the PCR clean-up protocol. The purified product (10
µl) was used to transform E. coli DH5↵ (DE3) cells by heat shock. Colonies selected from
a LB-kanamycin agar plate spread with transformed cells were inoculated individually in
10 ml LB-kanamycin medium, and grown at 37  C for 16 h. Plasmids were recovered
using a QIAprep Spin Miniprep Kit (QIAGEN) and the mutation was confirmed by gene
sequencing (GATC). The vector for new fusion enzymes was prepared by sequential digest
of LynD fusion carrying the HindIII mutation with the restriction enzymes HindIII and
XhoI (Promega), followed by incubation with 5 unit alkaline phosphatase (Promega) for
30 min at 37  C and purification by 1% agarose gel electrophoresis, to remove the LynD
fragment. Agarose gels were run at a constant voltage of 120 V for 45 min in Tris-Acetate-
EDTA (TAE) bu↵er and contained 1 µl of the stain SYBR Safe (Life Technologies) per
35 ml. The DNA was recovered using a QIAquick Gel Extraction Kit (QIAGEN).
PatD (from Prochloron didemni) was provided in a pEHISTEV[146] plasmid by the
Naismith lab (University of St Andrews). Codon optimised full-length MicD (from
Microcystis aeruginosa), TenD (from Nostoc spongiaeforme var. tenue) and OscD (from
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Oscillatoria nigro-viridis PCC 7112 ) with an N-terminal Tobacco Etch Virus (TEV)
protease-cleavable His
6
-tag were purchased from DNA 2.0 and were supplied in the
proprietary pJexpress411 vector. MicD fragment carrying HindIII and XhoI sites were
amplified from the above plasmid by PCR using the primers MicD-f and MicD-r, PatD
using the primers PatD-f and PatD-r, and so forth for TenD and OscD. The products were
purified by 1% agarose gel electrophoresis, extracted using the QIAprep Spin Miniprep
Kit (QIAGEN) and then digested with HindIII and XhoI (Promega). Ligations with the
HindIII and XhoI digested LynD fusion vector (as described above) were performed at
16  C for 2 h using DNA ligation kit 2.1 (TAKARA). Plasmids were recovered from E.
coli DH5↵ (DE3) cells and the successful cloning of these constructs were confirmed by
sequencing (GATC Biotech AG). In the case of TenD and OscD, an optimised variant of
the construct that contains leader residues R16-A37 (described in the next subsection)
was used as template instead of LynD fusion.
2.3.3 Sequence Optimisation of MicD Fusion
The initial MicD fusion construct has residues Q21-A37 from PatE2K (MDKKN ILPQQ
GQPVI RLTAG QLSSQ LAELS EEALG DAGLE ASKIT ACITF CAYDG ELEHH
HHHH), five of the amino acid pair GA, followed by the amino acids lysine and leucine
which were introduced to facilitate cloning, on the N-terminus of the protein. Extension of
the leader sequence to R16, G11 and M1 was achieved by PCR amplification of fragments
from PatE DNA borne on a pBMS vector (a gift from Dr Huanting Liu) [146], using
the forward primers LeaderR16-f (for leader residues R16-A37), LeaderG11-f (for leader
residues G11-A37) or LeaderM1-f (full length leader) and the reverse primer Linker 5GA-
r. Shortening or lengthening of the linker to 3GA, 7GA and 9GA was generated by
performing PCR with the MicD fusion plasmid as template, using the forward primer
FusAmpl-f coupled with reverse primers Linker3GA-r, Linker7GA-r and Linker9GA-r,
respectively. All these fragments contained the restriction sites NdeI and HindIII on their
5’ and 3’ end, respectively, and were ligated back into the original MicD fusion vector
after it has been digested with the same restriction enzymes and gel-purified as described
in the last subsection. Lengthening of the linker to 13 GA pairs was achieved by digesting
and ligating a gblock (IDT) with 5’ NdeI and 3’ HindIII sites to the same vector.
2.3.4 Polymerase Chain Reaction Conditions
Reactions were performed in a Thermocycler (Biorad) using the following programmes.
For site-directed mutagenesis, the reaction underwent 12 cycles of denaturation (94  C for
1 min), annealing (55  C for 1 min) and extension (68  C for 1 min 55 s), followed by 3
cycles of 1 min at 95  C, 1 min at 47  C and 1 min 55 s at 68  C. For PCR amplification,
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Figure 2.2: ‘Cut-and-paste’ strategy for construction of varied fusion enzymes.
36 cycles of denaturing at 94  C for 15 sec, annealing at 60  C for 30 sec and extending
at 68  C for 15 sec (leader peptides) or 55 sec (full length heterocyclases) were used. The
reaction mixtures (50 µl) included 1x KOD polymerase bu↵er, 0.2 mM of each dNTP, 1.5
mM (site-directed mutagenesis) or 1 mM (other reactions) MgSO
4
, 1.5 µM of each primer,
10 ng template DNA and 1U KOD hot start polymerase (Novagen). The primers used are
listed in Table 2.1.
Table 2.1: List of Primers used in the construction of fusion enzymes



















2.3.5 Overexpression and Purification of Heterocyclases
Expression and purification of native MicD were performed based on established
protocol.[65] For each protein, 1 µl of plasmid was used to transform 50 µl E. coli BL21
(DE3) competent cells. A single colony was picked on a sterile pipette tip, inoculated
into 10 ml LB-kanamycin medium, and grown at 37  C for 16 h. The starter culture (6
35
ml) was inoculated into 400 ml autoinduction medium prepared according to the Studier
method [147] and incubated at 20  C, 250 rpm for 48 h. Cells were harvest by centrifuging
at 8983 g, 4 C for 15 min and drained. The pellet was frozen and stored at -80  C,
before being defrosted and resuspended in lysis bu↵er (20 mM Tris pH 8.0, 500 mM NaCl,
20 mM imidazole and 3 mM 2-Mercaptoethanol (BME)), supplemented with complete
EDTA-free protease inhibitor (one tablet per 50 ml of suspension) (Roche) and DNase
(0.4 g per gram of cell pellet) (Sigma). The suspension was filtered through a sieve and
passaged through a cell disruptor (Constant Systems Ltd), which was equilibrated with
lysis bu↵er and chilled to 4  C, at 30 kpsi. Cell lysate was cleared by centrifuging at 48384
g for 20 min at 4  C, followed by filtration through a Millipore nitrocellulose membrane
with a pore size of 0.45 µm (Sigma). Cleared lysate was applied to a Ni-NTA column
(GE Healthcare), equilibrated with lysis bu↵er, and eluted with elution bu↵er (lysis bu↵er
substituted with imidazole to the final concentration of 250 mM). The eluate was collected
and concentrated where necessary, and subjected to size-exclusion chromatography on a
16/600 Superdex 200 pg column (GE Healthcare) in gel filtration bu↵er (10 mM HEPES
pH 7.4, 150 mM NaCl, 1 mM Tris(2-carboxyethyl)phosphine hydrochloride (TCEP)).
Where specified, the following steps were included for increased purity. TEV protease
(1 mg per 10 mg protein) was added to the eluate from a nity chromatography and
the protein-TEV mix was dialysed in a SnakeSkin (Thermo) dialysis tubing with 10 kDa
MWCO against 50x volume of low salt bu↵er (20 mM Tris pH 8.0, 100 mM NaCl and 3
mM BME) for 2 h at 20  C. The tubing was transferred to fresh bu↵er and left dialysing
at 4  C for 16 h. After dialysis the protein was applied to a second Ni-NTA column
equilibrated in low salt bu↵er, and the column was washed with 10 column volumes (CV)
of low salt bu↵er. The flow through was passed directly onto a monoQ 10/100 GL column
(GE Healthcare) equilibrated in low salt bu↵er, and the protein was eluted with a linear
gradient of low salt bu↵er and high salt bu↵er (20 mM Tris pH 8.0, 1 M NaCl and 3 mM
BME). The protein eluted at around 250 mM NaCl. The eluate was then subjected to
size-exclusion chromatography using bu↵ers and equipments stated above.
Samples of the protein were heated in NuPAGE LDS sample bu↵er supplement with 50
mM DTT at 100  C for 5 min and examined by electrophoresis on a Novex NuPAGE SDS-
PAGE gel against a unstained Mark12 Protein Standard (Life Technologies) at 220 V for
35 min. Protein bands were visualized by staining with Coomassie Blue and destaining
in water. Concentrations were determined using absorbance at 280 nm measured by
a Nanodrop (Thermo Scientific) and extinction coe cient calculated by the ExPASy
ProtParam tool [148].
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2.3.6 Comparison of Expression Levels of MicD Fusion Enzymes
Freshly transformed E. coli BL21 (DE3) colonies harbouring pJExp411-MicDfusion
plasmids were picked on sterile tips and each inoculated into 10 ml LB-kanamycin medium.
The cultures were incubated for 16 h at 37  C before 6 ml of each was transformed to 400
ml autoinduction medium [147] and grown at 20  C, 250 rpm for 48 h. 1 ml of each culture
was transferred to an microcentrifuge tube and pelleted by centrifugation at 17,000 g for
5 min. 1x Bugbuster (Merck Millipore) solution was prepared by mixing 1 ml of 10 x
concentrate with 9 ml lysis bu↵er (see subsection 2.3.5). Each cell pellet was resuspended
in 100 µl of 1x Bugbuster solution and incubated at 20  C, 200 rpm for 20 min. The
soluble and insoluble fractions were separated by centrifugation at 17,000 g for 10 min,
and analysed by SDS-PAGE to obtain expression levels.
2.3.7 Substrates of Heterocyclization Reactions
The PatE substrate used (PatE2K) was expressed as a C-terminally His
6
-tagged (non-
cleavable), full-length precursor peptide. The plasmid pBMS (a gift from Dr Huanting
Liu, University of St Andrews) carrying the patE gene was transformed into E. coli BL21
(DE3) and recovered from an LB-agar plate containing ampicillin. A single colony was
inoculated into 100 ml LB-ampicillin medium and incubated for 16 h at 37  C, before
10 ml of which was transferred to 1 litre LB medium supplemented with 100 µg per ml
ampicillin. The cultures were incubated at 37  C until their optical density at 600 nm
(OD
600
) reached 0.6, at which point Isopropyl- -D-thiogalactoside (IPTG) was added to
the final concentration of 1 mM. Incubation at 37  C was continued for 5 h and the cells
were harvested by centrifugation at 8983 g for 15 min. To obtain the protein, cell pellets
were resuspended in urea lysis bu↵er (8M urea, 20 mM Tris pH 8.0, 500 mM NaCl, 20
mM imidazole and 3 mM BME), at lysed by sonication at wavelength of 15 micrometres
(SoniPrep 150, MSE). Cell debris were removed by centrifugation at 48384 g for 20 min
at 20  C, and filtration through a Millipore nitrocellulose membrane (Sigma) with a pore
size of 5 µm, followed by one with a pore size of 0.8 µm. Clarified lysate was applied to a
Ni-NTA column (GE Healthcare), equilibrated with urea lysis bu↵er, and eluted with urea
elution bu↵er (8M urea, 20 mM Tris pH 8.0, 500 mM NaCl, 250 mM imidazole and 3 mM
BME). The eluate was supplemented with 10 mM dithiothreitol (DTT) and incubated
at 20  C for 2 h to reduce all the cysteines, before being subjected to size-exclusion
chromatography on a 16/600 Superdex 75 pg column (GE Healthcare) in gel filtration
bu↵er (10 mM HEPES pH 7.4, 150 mM NaCl, 1 mM TCEP). The protein (about 7 kDa
but natively unfolded) was concentrated using a concentrator with 5K MWCO (Sartorius)
to 2 mM, flash frozen and stored at -80  C.
The leaderless peptides were synthesised by Dr B. Nardone (University of St Andrews)
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or purchased from commercial sources. The sequences are listed in Table 2.2. Peptides
are dissolved in dimethylformamide (DMF) to around 50 mM prior to use.
Table 2.2: List of substrates used in heterocyclization reactions. MW, molecular weight
or monoisotopic mass.
Sequence MW (dalton) Source
(M1-K42)-ITACITFCAYDGELEHHHHHH 6989 recombinant expression
NH2-ITACITACAYDGE-CONH 1328.6 Dr B. Nardone
NH2-ITACITACAYDGE-COOH 1329.6 Bio-Synthesis, Inc.
NH2-ITACITFCAYDG-COOH 1276.6 Bio-Synthesis, Inc.
NH2-ITACITFCAYD-COOH 1219.5 LifeTein LLC
2.3.8 Heterocyclization Reaction Conditions
The heterocyclization reactions included 100 µM full-length PatE or synthetic peptides
and the following components: bu↵er, sodium chloride, ATP, magnesium chloride and
enzyme, each varied during the optimisation process. The details are stated with individual
experiments. Temperature and incubation time were also varied in di↵erent experiments.
Reactions were stopped by precipitating the enzyme with the addition of equal volume
of acentonitrile (ACN), followed by vortexing for 20 s and centrifugation at 17,000 g at
4  C for 5 min [149], or by adding Ethylenediaminetetraacetic acid (EDTA) to the final
volume of 50 mM. Samples were analysed by matrix assisted laser desorption ionisation
Time-of-Flight (MALDI-TOF) mass spectrometry on a 4800 MALDI TOF/TOF Analyzer
(ABSciex), or by liquid chromatography-Electrospray Ionisation mass spectrometry (LC-
ESI-MS) on an LCT (Micromass) machine. Data were either visualised using Data
Explorer (ABSciex), or exported as peak intensity versus mass over charge (m/z) and
plotted using Matlab.
2.3.9 Quantitation of MALDI Data
Relative abundance of species were determined by comparing the areas of the peaks
corresponding to each heterocyclization status. Monoisotopic peaks ([M+H]+ and
[M+Na]+) were integrated using the ‘trapz’ function in Matlab, which calculates the
peak area under a curve via trapezoidal approximation. For each spectrum 10 values
(hydrogen and sodium adducts of peptides with 0-4 heterocycles) were obtained and the
each was divided by the sum of all 10. The percentage numbers of H+ and Na+ adducts
were combined to generate the final abundance for that peptide. Although peptide with
di↵erent numbers of may ionise di↵erently, horizontal comparison between the same species
across samples could be drawn. MALDI-based quantitation has been employed before to
monitor heterocyclization by LynD [64].
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2.3.10 Overexpression and Purification of M. tuberculosis
pyrophosphatase
Plasmid pJ411-PPA carrying the gene encoding Mycobacterium tuberculosis
pyrophosphatase (MtPPase) was kindly gifted by Dr Luiz de Carvalho (Francis
Crick Institute). The plasmid was transformed into E. coli BL21 (DE3) cells and a single
colony was inoculated into 100 ml LB medium supplemented with 50 µg/ml kanamycin at
37  C for 16 h. The started culture (10 ml) was inoculated into 1 L fresh LB-kanamycin
medium and grown at 37  C, 200 rpm until OD
600
reached 0.5. The temperature of
the incubator was lowered to 20  C and the cultures were left inside to equilibrate to
the desired temperature for 30 min without shaking. IPTG was added to the final
concentration of 1 mM to induce the cells, which were left to overexpress the protein at
20  C for 16 h. Cells were harvested by centrifuging at 8983 g for 15 min, drained, and
resuspended in PPA Lysis Bu↵er (20 mM HEPES pH 8.0, 20 mM imidazole, 500 mM
NaCl, 5 mM MgCl
2
, 1 mM CaCl
2
), supplemented with complete EDTA-free protease
inhibitor (one tablet per 50 ml of suspension) (Roche) and DNase (0.4 g per gram of cell
pellet) (Sigma). Cells were lysed and clarified as described in subsection 2.3.5. The lysate
was loaded onto a Ni-NTA column (GE Healthcare) equilibrated in PPA Lysis Bu↵er
and eluted with PPA Lysis Bu↵er substituted with 250 mM imidazole. The eluate was
subjected to size-exclusion chromatography on a 16/600 Superdex pg 75 column in 20
mM HEPES pH 8.0. The eluate was concentrated, flash frozen and stored at -80  C.
2.3.11 Steady-State Kinetics of MicD Fusion Enzymes
Coupled assays were conducted using the EnzChek Pyrophosphate Assay kit
(Thermofisher) in 100 µl or 200 µl reactions in 96-well plates and absorbance at 360nm was
monitored by a SpectraMax plate reader (Molecular Devices). The assay requires the pH of
reactions to be within the range of 6.5 - 8.5. The heterocyclase kinetics bu↵er contained
100 mM Tris pH 8.0, 50 mM NaCl, 5 mM DTT, 2-amino-6-mercapto-7-methylpurine
riboside (MESG), purine nucleoside phosphorylase (PNP) from EnzChek kit, and 10 µM
MtPPase. MtPPase was used in place of the PPase included in the assay kit, the quality
of which fluctuated. Standard curves for 100 µl or 200 µl reactions in a transparent 96-
well plate were established using the pyrophosphate standards provided as part of the kit.
A360 values obtained after varied concentrations of PP
i
(in duplicates) were incubated for
30 min at 25 C inside the plate reader chamber were plotted against the corresponding
PP
i
concentrations, and fitted to a linear regression in GraphPad Prism 6. Concentration
of P
i
was obtained by multiplying the concentration of PP
i
by two. The quantities of
peptides and enzymes in each reaction varied as individually specified. Reactions were
conducted in the heterocyclase kinetics bu↵er containing 10 mM ATP and 10 mM MgCl
2
,
and were started by the addition of enzyme followed by 10 s of shaking. Readings were
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taken every 10 s and after each reading the plate was shaken for 5 s to ensure even
mixing of the sample. Initial rate is defined as the rate of reaction when less than 10
percent of the substrate has been consumed. In the absence of peptide, ATP hydrolysis
gave a background rate which was subtracted from the observed rates when the enzyme
is reacted with peptides. Data was fitted using the Morrison’s quadratic equation (Eq
2.1) or its variant (Eq 2.2) [150].  [P
i
], change in inorganic phosphate concentration;  t
change in time; v
int
, initial velocity; V
max





], total concentration of substrate; K
m


































































2.4.1 Constructing Fusion Enzymes that Produce (Methyl)oxazolines
Due to the inability of LynD fusion to heterocyclize threonines and serines, four proteins
were selected for engineering, in an endeavour to create a tool that installs oxazoline
heterocycles on leaderless peptides. PatD (Prochloron didemni), the heterocyclase
involved in the synthesis of patellamides, has been shown to heterocyclize threonines
in vitro [66, 67, 77]. MicD (Microcystis aeruginosa) and TenD (Nostoc spongiaeforme
var. tenue) are YcaO domain-containing proteins found in the gene clusters [21] that lead
to production of the (methyl)oxazol(ine)e-containing cyanobactins microcyclamides [48,
49] and tenuecyclamides [131], respectively, and both been previously shown to induce
four-fold dehydration on a full-length peptide containing the sequence VTVCVTVC [87].
Finally, OscD (Oscillatoria nigro-viridis PCC 7112 ) is homologue from the biosynthetic
pathway of the short, linear cyanobactin Viridisamide A [40]. Although the natural
product of OscD only contains one thiazoline, the enzyme has not been tested on substrates
that have multiple heterocyclizable residues.
The natural substrates of these enzymes have similar leader sequences (Figure 2.3); in
addition, LynD fusion was appended with part of the PatE leader. Therefore it was
decided that the same PatE leader was used to engineer all enzymes. PatD, MicD,
OscD and TenD were fused with the sequence ‘QLSSQLAELSEEALGDA’ to their N-
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OscE      MNKKNILPNPGKPVIRGISGKLPSYLAELSEEALGDAGADAS 42  
MicE      MDKKNILPQQGKPVFRTTTGKLPSYLAELSEEALGGNGLEAS 42  
LynE      MDKKNILPHQGKPVLRTTNGKLPSHLAELSEEALGGNGVDAS 42  
PatE      MDKKNILPQQGQPVIRLTAGQLSSQLAELSEEALGDAGLEAS 42  
TenE      MDKKNILPQQGKPVIRITTGQLPSFLAELSEEALGDAGVGAS 42  
          *:******: *:**:*   *:* * **********. *  ** 
Figure 2.3: Leader peptide sequences from PatE, LynD, MicE, TenE and OscE. The
first eight residues and the heterocyclase recognition element ‘LAELSEEAL’ were highly
conserved, whereas the rest of the sequence were relatively variable.
termini, connected by the amino acids ‘GAGAGAGAGAKL’. The recombinant proteins
(His-tagged) were overexpressed in E. coli and purified using a nity chromatography and
gel filtration chromatography. Purified PatD fusion, MicD fusion, TenD fusion and OscD
fusion were reacted with leaderless substrates in the presence of ATP and magnesium
chloride, in order to test their e cacies.
Figure 2.4 A shows the size of engineered PatD, MicD and OscD. The proteins ran
between the 66.3 kDa and 97.4 kDa molecular weight markers, in agreement with their
calculated MW’s of between 80 and 95 kDa. Identities of these proteins were confirmed
by analysis of trypsin-digested excised gel bands using mass spectrometry. The protein
samples shown in these traces were purified by a nity chromatography and size-exclusion
chromatography, and were over 90% pure.
Each heterocyclization (cyclodehydration) of a cysteine, threonine or serine residues
results in the loss of a water molecule (18 Da), and mass spectrometry has been established
as a method of detecting such reactions. Peaks with mass losses of 54 and 72 Da
could be observed when 5 µM PatD fusion or MicD fusion was applied to the substrate
ITACITFCAYDG (Figure 2.4B and C), corresponding to the heterocyclization of three
and four residues, respectively. As the substrate contained two cysteines, it is likely that
the threonines in the sequence were also heterocyclized. The reactions were not complete,
with the majority of peptides staying in the doubly or triply heterocyclized intermediate
state at the time of analysis, but these results nevertheless demonstrated the ability of
MicD fusion and PatD fusion to catalyse threonines. OscD, on the other hand, was only
able to produce one or two heterocycles after overnight incubation, even at an enzyme
concentration of 10 µM (Figure 2.4D).
TenD fusion did not have the expected molecular weight (Figure 2.4A). The plasmid
might have been contaminated, or a pre-mature stop codon was formed. The purified
protein also showed no heterocyclase activity (Figure 2.4E). Further investigation was not
pursued.
These initial results showed that MicD fusion and PatD fusion make promising
candidates as biocatalysts for oxazolines. PatD fusion appeared to have a small advantage
over MicD fusion (Figure 2.4B and C), but neither would bring the reaction to completion
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in the same time scale of the experiment (16 h). During the first purifications, MicD fusion
had a yield of 37 mg per litre of autoinduction medium, whereas that of PatD fusion was
only 7 mg. Balancing on activity and yield, MicD was selected for further experiments
and optimisation.
2.4.2 Optimisation of Reaction Condition for MicD Fusion
The reaction condition developed for heterocyclization by TruD and LynD (10 mM HEPES
pH 7.4, 150 mM NaCl, 5 mM ATP, 5 mM MgCl
2
) did not appear to be optimal for MicD-
catalysed turnover of leaderless peptides. Moreover, a decrease in pH was observed (using
a pH meter) as heterocyclization progresses, possibly due to the low concentration of the
bu↵ering component (10 mM HEPES) in the system. The reaction performed better in
alkaline environments - only 14% of peptides were fully heterocyclization (4het) in 100
mM Tris pH 7.0 after 16 h of reaction, but at pH 8.0 the number surged to 41%, and
further increased to 53% at pH 9.0 (Fig 2.5A, E). At pH 8.0, raising the concentration
of Tris from 20 mM to 200 mM moderately accelerated heterocyclization (Fig 2.5B,
E), consolidating the hypothesis that the reaction could su↵er from too low a bu↵ering
capacity. In accordance, when the concentration of Tris is above 100 mM, the pH remain
unchanged incubation for 16 h at 37  C, whereas a decrease was observed at 20 mM and
50 mM Tris.
Ionic strength also plays a role on regulating the reaction rate, with high salt conditions
showing a deleterious e↵ect (Fig 2.5C, E). When an incremental amount of NaCl (50 mM,
250 mM and 500 mM of NaCl) was added to the reaction mixture, the percentage of
quadruply heterocyclized peptides reduced from 45.5% to 19% (Fig 2.5E), whereas those
of triply and doubly heterocyclized peptides went up from 30% to 37%, and 15% to 30%,
respectively.
Finally, the e↵ect of temperature on the reaction was tested. Reaction rates generally
increase with temperature; however, as M. aeruginosa is a freshwater species [49], its
enzymes need to adapt to the changing temperatures of water as the level of daylight
varies. Indeed, the MicD reaction appeared to tolerate a wide range of temperatures, with
the reaction rate not decreasing much from 37  C to 25  C (Fig 2.5D, E). Dropping the
temperature to 16  C moderately slowed down the turnover, while further lowering the
temperature down to 4  C greatly reduced the relative abundance of the 4het species (to
18%) after 16 h incubation, compared to the reactions at higher temperatures (45-56%). It
was later noted that the pH of Tris bu↵ers change with temperature and therefore the pH
8.0 bu↵er made at 25  C would become pH 7.7 at 37  C, which may have slowed the rate of
the 37  C experiment down. Nevertheless, reactions at 37  C su↵ered more problems such
as protein precipitation than those at 25  C, and 25  C was therefore set as the standard



























































Figure 2.4: Purity and E cacy of Heterocyclases from Di↵erent Homologues. (A)SDS-
PAGE traces of purified PatD, MicD, OscD and TenD fusion; (B-E) MALDI-TOF
Spectra of leaderless peptides reacted with engineered heterocyclases. (B) the peptide
ITACITFCAYDG reacted with 5 µM PatD fusion; (C) the same peptide reacted with 5
µM MicD fusion; (D) The peptide ITACITACAYDGE reacted with 10 µM OscD fusion.
(E) The peptide ITACITFCAYD reacted with 10 µM TenD fusion. Reactions were carried
out in 10 mM HEPES pH 7.4, 150 mM NaCl, 5 mM ATP, 5 mM MgCl
2
and incubated
at 27  C for 16 h. Starting masses are indicated with black arrows, while singly, doubly,
triply and quadruply heterocyclized species are indicated with purple, red, blue and green
arrows, respectively.
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Figure 2.5: Optimisation of reaction condition for MicD fusion, using MicD Q21 9GA.
(A) 100 µM peptide (ITACITACAYDGE) was incubated with 20 µM enzyme, in 100 mM
Tris pH 7.0, pH 8.0 or pH 9.0, supplemented with 150 mM NaCl,10 mM ATP and 10
mM MgCl
2
; (B)100 µM peptide (ITACITACAYDGE, C-amide)was incubated with 20 µM
enzyme, in 20, 50, 100 and 200 mM Tris pH 8.0, 150 mM NaCl, 10 mM ATP and 10 mM
MgCl
2
; (C) 100 µM peptide (ITACITACAYDGE) and 20 µM enzyme reacted in 100 mM
Tris pH 8.0, supplemented with 50,150, 250 and 500 mM NaCl,10 mM ATP and 10 mM
MgCl
2
. (D) 100 µM peptide (ITACITACAYDGE) was incubated with 20 µM enzyme, in
100 mM Tris pH 8.0 supplemented with 50 mM NaCl,10 mM ATP and 10 mM MgCl
2
at
37, 25, 16 and 4  C for 16 h. Peak intensities are normalised and plotted on Z axes against
mass in m/z on X axes in Matlab. Data from related experiments are stacked with each
other along the Y axes. (E) Relative abundance of each heterocyclization states calculated
from (A)-(D). This is a replot of relative peak sizes and not a rigorous quantitation.
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reduction in reaction rates at 16  C and 4  C should not have resulted from temperature-
associated pH change, based on the results shown in Fig 2.5A).
It should be noted that peptides with di↵erent number of heterocycles may ionise with
varied strengths, thus the numbers in Fig 2.5E do not represent the true abundance of each
species in a sample. Rather, the distribution of species was compared horizontally between
di↵erent samples to determine which conditions produce more heterocycles after the same
duration of reaction. It is possible that peptides with higher numbers of heterocycles were
underrepresented in the MALDI spectra. Figure 2.6 contrasts the spectra of the same
sample run on LCT (ionisation by electrospray) and MALDI - even though the quadruply
heterocyclized (4het) species generated the highest ion counts in both spectra, the former
gave a 4het:3het ratio of about 5:1 in terms of height, and showed residual amount of 2het
species, whereas the latter had a much lower 4het:3het ratio at 2:1, and more prominent
2het peaks, similar to the spectra shown in Figure 2.5. ESI-MS is widely thought as a
more suitable method for the quantitation of small molecules than MALDI [151], and the
LCT spectrum (80% quadruply heterocyclized) is thus likely a better reflection of the true
distribution of peptides in the reaction sample.
A problem that frequently occurred during the initial stage of the optimisation process
was that the peptide was not heterocyclized, despite the reaction mixture having all
components (bu↵er, salt, ATP, magnesium, enzyme and substrate). This issue almost
aways concurred with an ion species that has a mass 2 Da less than the starting material
being present instead of the expected M+H+ species in mass spectra It was therefore
possible that an internal disulphide bridge has formed between the two cysteine residues
(as of the sequence ITACITFC), which precludes the cysteines from being heterocyclized.
Indeed the problem was solved after including a reducing agent such as TCEP or DTT in
the reactions (5 mM DTT determined to be optimal). The reason why the reaction still
sometimes proceeded in the initial tests, without additional reducing agent, may be due
to the fact that a small amount of TCEP was supplemented in the gel filtration bu↵er of
the enzymes, which degraded over time.
2.4.3 Optimising the Sequence of MicD Fusion
In addition to the chemical conditions of the reaction, it is possible that the sequence of the
MicD fusion itself could be optimised to further increase the e ciency of heterocyclization
of leaderless peptides. Moreover, it would also be desirable to improve the yield and
stability of the protein. Multiple MicD fusion constructs were made and those which have
been grown and overexpressed in E. coli are listed in Table 2.3, which states the named
designated to each construct, a description of its modification, its average yield where
applicable, and its molecular weight in kDa. Six fusion constructs were purified, MicD












Figure 2.6: Discrepancy in MALDI and LCT Spectra Results. (A) LCT spectrum and (B)
MALDI spectrum of ITACITACAYDGE reacted with MicD Q21 9GA in 100 mM Tris pH
8.0 supplemented with 150 mM NaCl, 10 mM ATP, 10 mM MgCl
2
and 5 mM DTT, for
16 h at 37  C.
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Table 2.3: Nomenclature, yield and parameters of MicD fusion constructs compared to the
native enzyme. Yields are as of protein per litre of autoinduction medium. MW, molecular
weight in kDa including an N-terminal His
6
-tag and TEV protease site, calculated by
ExPASy ProtParam tool.
Construct Fused sequence Linker Average Yield MW
MicD native N/A N/A 15 mg 88.8
MicD M1 5GA M1-A37 (GA)
5
KL 1 mg 93.6
MicD G11 5GA G11-A37 (GA)
5
KL 30 mg 92.4
MicD R16 5GA R16-A37 (GA)
5
KL 55 mg 91.9
MicD Q21 3GA Q21-A37 (GA)
3
KL N/A 91.1
MicD Q21 5GA Q21-A37 (GA)
5
KL 38 mg 91.4
MicD Q21 7GA Q21-A37 (GA)
7
KL 15 mg 91.7
MicD Q21 9GA Q21-A37 (GA)
9
KL 42 mg 92.0
MicD Q21 13GA Q21-A37 (GA)
13
KL N/A 92.3
Figure 2.7: Expression Levels and Yields of MicD and Fusion Variants. (A) SDS-PAGE
showing soluble expression levels of di↵erent MicD variants. Red boxes indicate areas
selected for integration in Image J. The image is part of a gel which is shown in Appendix
B (Figure S2), and the contrast has been adjusted to aid band selection and quantitation.
(B) Relative expression levels as integrated from (A). (C) Normalisation and replot of
yields recorded in Table 2.3.
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M1 5GA, along with the native enzyme. Native MicD protein had a moderate yield of 15
mg per litre of autoinduction medium. In contrast, average yields of the fusion proteins,
recorded during protein purification, ranged from 38 to 55 mg per litre, with the exception
of MicD M1 5GA (full leader sequence attached), which expressed poorly at 1 mg per litre.
In accordance with the recorded yields (Table 2.3, Figure 2.7C), fusion proteins MicD Q21
9GA, MicD Q21 5GA, MicD R16 5GA and MicD G11 5GA also had higher expression
levels in a small scale test performed in autoinduction medium (Figure 2.7A and B).
Figure 2.8 compares the heterocyclase activities of native MicD and its fusion variants.
MicD native is capable of fully heterocyclizing the core sequence ITACITFC, provided
that it is within a full-length peptide that has a leader sequence (Figure 2.8A). However,
without the leader, MicD native only installs 1 heterocycle on the same core sequence
(Figure 2.8B). Interestingly, it is capable of dehydrating the sequence ITACITAC twice
(Figure 2.8C), suggesting the di↵erences in sequence a↵ects the activity of the enzyme.
The native enzyme was nevertheless unable to fully heterocyclize the substrate over the
course of the experiment. The fusion enzyme MicD Q21 5GA (Figure 2.4C), in contrast,
installs four azolines on the same peptide. In addition, MicD Q21 7GA, MicD Q21 9GA,
MicD R16 5GA and MicD G11 5GA (Figure 2.8E-H) all demonstrated the ability to
fuly heterocyclize leaderless peptides. MicD M1 5GA, the full-leader fusion, was inactive
(Figure 2.8D) as well as having a low yield (Table 2.3). As discussed in section 2.4.2,
signal intensities in MALDI do not accurately represent peptide concentration. To find
out which construct was the most active, a more quantitative method was sought after,
and kinetic assays were employed as such.
Quantitative comparison of the activities of the enzymes MicD Q21 5GA, MicD Q21
7GA, MicD Q21 9GA, MicD R16 5GA, MicD G11 5GA were achieved through steady-
state enzyme kinetics using the EnzChek pyrophosphate assay. The assay employs purine
nucleoside phosphorylase (PNP), which uses MESG (2-amino-6-mercapto-7-methylpurine
riboside) and inorganic phosphate (P
i
) to make ribose 1-phosphate and 2-amino-6-
mercapto-7-methylpurine, a compound that has an maximum absorbance at 360 nm.
One molecule of MESG reacts with one molecule of P
i
, and as a result, changes in
A360 can be used to quantify the amount of phosphate present. As previous studies





, a preliminary reaction was set up, in the presence or absence of an excess amount
of pyrophosphatase (PPase), to see whether MicD makes phosphate or pyrophosphate.
PPase from M. tuberculosis (MtPPase), overexpressed in E. coli and purified as a His-
tagged protein (Figure 2.9A), was used in place of the PPase included in the assay kit,
the quality of which fluctuated. Phosphate is released, as shown by an increase in A360,
in the absence of a peptide substrate (Figure 2.9B, green line). Adding PPase (purple
line) had minimal e↵ect on the readings, an indication that PP
i
was not made in large
numbers by the background ATP hydrolysis. Adding the peptide resulted in an increase
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Figure 2.8: Activity of MicD native and MicD fusions. MicD native was reacted with (A)
full-length PatE2K, (B) ITACITFCAYDG and (C) ITACITACAYDGE; (D-H) Fusion
enzymes MicD M1 5GA, MicD Q21 7GA, MicD Q21 9GA, MicD R16 5GA and MicD
G11 5GA were reacted with the peptide ITACITACAYDGE. Reactions containing 5 µM
of enzyme and 100 µM of substrate were carried out in 100 mM Tris pH 8.0 supplemented
with 50 mM NaCl,10 mM ATP and 10 mM MgCl
2
. Black circles annotates the starting
material in each spectrum. Green, red, cyan and black asterisks annotates singly, doubly,




production (blue line), as the slope of the linear regression curve more than doubled.
PP
i
was also produced, demonstrated by a further increase in the rate of the coupled assay
when PPase is included, with the slope of the red line (+peptide, +PPase) being over six
times steeper than that of the green line (no peptide, no PPase). Two conclusions can
be made from the experiment shown in Figure 2.9B. First, heterocyclization catalysed by




as products; in subsequent reactions, PPase was included





hydrolyses ATP in the absence of peptides. As a result, a peptide-free, background rate
was measured for each enzyme, and subtracted from the readings of peptide-containing
reactions. The phosphate chemistry of MicD is discussed in more details in Chapter 5.
Calibration curves (Figure 2.9C) were established for 100 µl and 200 µl reactions using
the pyrophosphate standards provided with the kit. The pH of the bu↵er was set at pH
8.0 as it was suitable for both the heterocyclase reaction and the coupled reactions. Linear
regression of the 100 µl sample gave a slope of 0.003149 ± 0.0001244 whereas that of the
200 µl samples gave a slope of 0.007477 ± 0.0002630. During coupled assays, changes in
A360 over time were monitored, and the rates were divided by the slopes stated above
to give changes in PP
i




The peptide ITACITFCAYD (10 µM to 500 µM) was reacted with five di↵erent fusion
enzymes (5 µM each). The initial rates were plotted against substrate concentrations and
fitted to Morrison’s Quadratic Equation (Equation 2.1). Data points and regression curves




values were calculated using the equation, while
k
cat
was derived from V
max
. The kinetic parameters are listed in Table 2.4. All fusion
enzymes exhibited similar kinetics, with k
cat
values in the range of 0.0062 s 1 to 0.0087
s 1 and K
m
values ranging from 45 µM to 98 µM. As 100 µM was the concentration of




was calculated as an indicator of the catalytic
e ciency. The first fusion enzyme, MicD Q21 5GA, was the slowest of the enzymes tested,





kinetic parameters were within the same orders of magnitude. On the other hand, when
the native native enzyme was reacted with leaderless peptides, the rate became too small to
measure. These results confirmed that fusion enzymes had increased a nities for leaderless
peptides and could perform tasks that were proven di cult for the native enzyme.
Determination of the kinetics of PatD was also attempted; however, the background
hydrolysis rate (Figure 2.9E, blue empty circles) was much higher compared to that of
MicD (red empty squares). With only a moderate increase of rate when peptide is present
(blue filled circles), it was di cult to distinguish errors from actual readings, especially at
low concentrations. As a result, kinetic parameters were not obtained.
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(1) Background ATP Hydrolysis






















Figure 2.9: EnzChek Assays of MicD, PatD and fusion enzyme. (A) SDS-PAGE showing
purified M. tuberculosis pyrophosphatase; (B) A360 readings of MicD R16 5GA (5 µM)
reaction with 10 mM ATP and when specified, 100 µM ITACITFCAYD, in the presence
of absence of 10 µM MtPPase. Data was fitted to a linear regression. (C) Standard curves
correlating changes in A360 to the concentration of inorganic pyrophosphate; (D) Initial
rates of phosphate release plotted against substrate (ITACITFCAYD) concentrations,
shown for each MicD fusion enzymes (5 µM Data was fitted in GraphPad Prism using
equation 2.1; (E) A360 readings following hydrolysis of ATP by PatD or MicD (8 µM) or
their reactions with 100 µM PatE2K.
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MicD G11 5GA 0.0074 ± 0.0002 45 ± 3.9 9839
MicD R16 5GA 0.0087 ± 0.0003 46 ± 5.2 11322
MicD Q21 5GA 0.0062 ± 0.0006 98 ± 27 3769
MicD Q21 7GA 0.0073 ± 0.0003 51 ± 8.3 8619
MicD Q21 9GA 0.0084 ± 0.0006 59 ± 14 8503
2.5 Discussion
The construction of PatD fusion and MicD fusions reiterated the power of structural
biology and rational design that was demonstrated by LynD fusion [64]. Binding of
the leader peptide of PatE to native LynD induces structural changes which switch the
enzyme into its active form (Figure 1.8 on page 11), and the fusion enzyme is believed
to have the partial leader (recognition sequence) bound to the enzyme at all times,
making it constitutively active. Without being structurally characterised themselves,
PatD and MicD (and to some extent, OscD) acquired activities after modification.
Independent result from Sardar and colleagues showed that the fusion strategy is also
applicable to TruD, which becomes active on leaderless peptides when the sequence
RLTAGQLSSQLAELSEEALG was appended to its N-terminus with a tetra Gly-Ser linker
[126]. Moreover, lantibiotic synthetases have had repeated success with this method of
engineering, similar to cyanobactin heterocyclases. In addition to LctM and HalCE2,
mentioned in the introduction, a recent study fusing NisA leader to NisB [152] has
demonstrated full dehydration activity in the modified enzyme. Based on these results it
is highly likely that the fusion method can be widely extended to other leader-dependent
RiPP PTMEs.
This work represents the first example of modified heterocyclases that synthesise both
thiazolines and oxazolines, which will greatly expand the scope of heterocycle-containing
peptides. The reaction was shown to be optimal in a high strength alkaline bu↵er (100 mM
Tris pH 8.0 or higher) with low salt (50 mM NaCl) and reducing agents (5 mM). The fused
enzyme was robust and tolerates sequential changes to a great level. Piggybacking on the
LynD fusion construct, the leader-derived sequence that o↵ers the strongest activation of
the enzyme was found to be R16-A37 of PatE, which includes but extends beyond the
recognition element ‘LAELSEEAL’ (Figure 2.9D). MicD fusion was also found to prefer a
longer linker, showing enhanced activity when 18 residues instead of 12 (number of linker
residues in LynD fusion) were placed between the protein and the appended sequence
(Figure 2.9D). These optimisations led to a highly active biocatalyst that converts over
80 percent of the leaderless substrate into the fully heterocyclized product (Figure 2.6A).
Compared to the established method [87] of heterocyclizing biologically produced, full-
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length peptides, and then cleaving two thirds of the peptide before further modifications,
vast amounts of material, enzyme and time can be saved by adopting the fusion enzyme,
which uses short substrates that contain only the core sequence and the macrocyclase
recognition signature. Having circumvented the need for a leader sequence on its peptide,
MicD fusion can also be employed to process chemically synthesised peptides, which means
unnatural amino acids and non-amino acids may be incorporated into the compound. This
semi-synthetic approach was adopted by Oueis et al. [94, 95], resulting in the production of
cyclo-peptides containing non-proteinogenic chemical groups as well as thiazoline. There
is no reason why the heterocyclized linear intermediates from these studies cannot be
subjected to other types of further modification such as prenylation, instead of being
macrocyclized. Indeed, unnatural precursor peptides have been made with chimeric leaders
that combine multiple recognition elements into the same leader [30], which was then
reacted with multiple PTMEs, resulting in novel products that contain thiaozline and
lanthionine, thiazoline and dehydroalanine, and so on, proving that heterocycles can co-
exist with many other interesting chemical moieties. Moreover, in addition to the enhanced
activity against a broadened substrate scope, the yield of fusion enzymes was significantly
higher compared to native MicD; in the case of MicD R16 5GA, it was more than tripled
(Table 2.3). Endowed with all the above stated benefits, MicD fusion makes a powerful
piece of apparatus for the biological and chemobiological synthesis of natural and unnatural
products.
An interesting observation was that MicD native (20 µM) heterocyclized a considerable
fraction of the leaderless peptide ITACITACAYDGE twice (Figure 2.8C), while it could
only turnover ITACITFCAYDG once in the same time frame (Figure 2.8B).The apparent
explanation would be that AC heterocycles are easier/faster to form than FC heterocycles,
probably due to the conformational restraints within the active site of the enzymes. This
would however disagree with the observations made of TruD, which heterocyclizes all
C8 cysteines before moving onto the C4 cysteines [65]. In addition, as you will read in
chapter 3, MicD also cyclises FC first when reacted with ITACITFC, both when it is
part of full-length PatE or a leaderless peptide. It is likely that conformational changes
(such as a kink in the backbone) following the formation of thiazoline makes the singly
heterocyclized peptide a less favourable substrate than its unmodified counterpart, and
the FC thiazoline may cause more disruption than the AC heterocycle in this particular
instance. Unlike MicD and TruD, LynD is an intrinsically disordered enzyme which shows
no particular bias towards C4 or C8 on the full-length substrate, nor does LynD fusion
has a preference for either cysteine when reacted with ITACITFCAYDG (chapter 3). In
a previous study native LynD (5 µM) was reported to catalyse one residue only, when
reacted with ITACITFCAYDG [64]. When a higher concentration of LynD (50 µM)
were incubated with 50 µM ITACITACAYDGE and ITACITFCAYDG for 16 h, both
reactions yielded a small amount of doubly heterocyclized peptides, with the latter peptide
appearing to have undergone more turnovers (Figure S5, Appendix B) - contrary to how
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MicD processes these peptides (Figure 2.8B and C). Although fully characterising the core
sequence preferences of heterocyclases are beyond the scope of this chapter, it seems to
vary between individual enzymes, and this variation could be exploited to generate diverse
compounds. With regard to the leader peptide, the observations here showed that it is
not essential for the heterocyclization of the second cysteine, unlike previously thought
[64]; it does nevertheless accelerates the reaction significantly. The role of leader peptide
in heterocyclization will be further explored in chapter 3.
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Chapter 3
Role of Leader Peptide on the
Rate and Order of
Heterocyclization
3.1 Summary
RiPP PTMEs-catalysed precursor modification may follow various directionalities and
orders of reaction. The cyanobactin heterocyclase TruD transfroms cysteines to thiazolines
on the patellamide D core sequence ITACITFC in a C-to-N order. In this chapter, the
directionality of heterocyclization when threonines are also catalysed has been determined
using the homologue MicD, to be C8-C4-T2-T6 (as of ITACITFC). When the leader
peptide is removed from the substrate, the reaction order was partially abolished and
becomes C8-C4-T2/T6-T6/T2. In contrast, LynD, which heterocyclizes only cysteines,
catalyses C8 and C4 without preference even when the leader peptide in present in cis to
the core peptide.
3.2 Introduction
Precursor peptides of RiPPs may have multiple sites where modifications by a certain
tailoring enzyme take place, and knowledge of reaction order with regard to those
residues enhances the understanding of that enzyme’s mechanism. From a biotechnological
perspective, establishing the order of reaction could provide insight on how to capture
specific reaction intermediates, which can be redirected to alternative modifications.
PTME modifications could follow a particular direction (Figure 3.1A and B). Lantibiotic
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Figure 3.1: Schematic showing di↵erent reaction orders of RiPP modifications. (A) N-
to C-terminal directionality. (B) C-to-N directionality. (C) Non-directional but ordered
reaction. (D) Disordered mechanism.
and threonines to 2,3-didehydroalanine (Dha) and 2,3-didehydrobutyrine (Dhb) [89, 153],
respectively, although this directionality was not strict, in the sense that residues in close
proximity (such as S11 and T9 in LctA) could be catalysed in a random order, so long as
both are processed before residues further C-terminal (e.g. S18 and S/T24 in LctA) [88].
In contrast, a class III enzyme LabKC was reported to operate in reverse, dehydrating
residues S13-S10-S4-S1 [154]. Variation of directionality in related enzymes was also seen
in azol(in)e synthetases involved in the biosynthesis of linear azol(in)e-containing peptides
(LAPs) such McbBCD [155], which process in an overall N-to-C order and BalhBCD,
which catalyses the majority of residues in a C- to the N-terminal sequence [68]. Further,
non-directional but ordered reactions (Figure 3.1C) were have been reported, for example
in the lantibiotic synthetase ProcM [156]. Leader peptide appeared to have an important
role in maintaining the directionality and order of modification. Whereas native LctA
sustains T9/S11 dehydration before S18/T24 dehydration, removal of leader from the
substrate results in a change of order, where it becomes S11-T9-T24-S18, S11-T24-T9-
S18, or T24-S11-T9-S18 [88]. Similarly, although the BalhBCD complex, which contains
a leader recognition domain in the C protein, installs thiazolines on BalhA in a C-to-N
direction, when the isolated oxidase BalhB (in the cited experiment, its homologue BcerB)
is reacted pre-heterocyclized substrate, a cysteine located the middle of the sequence was
transformed before the ones on both sides [113].
Cyanobactins PTMEs such as heterocyclase, oxidase and prenylase are capable of
catalysing multiple residues (reviewed in chapter 1), yet little is known about the reaction
order of these enzymes. The only study was that of TruD, a heterocyclase from the
trunkamide pathway [65]. When presented with the patellamide D (Figure 3.2A) core
sequence ITACITFC (as part of a precursor peptide containing leader), TruD transforms
of cysteines to thiazolines in a defined order: the C-terminal cysteine (C51 of full sequence,
C8 of core) first; it is only after all C51 has been catalysed that the enzyme starts to
heterocyclize the other cysteine (C47, C4 of core). This means the enzyme works in a
distributive manner - its dissociates from one substrate molecule and rebinds another
without having catalysed all modifiable residues on the first molecule - with a much
stronger preference for C51. Leader peptide plays a crucial role in the progression of
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Figure 3.2: (A) Structure of Patellamide D. (B) Mechanism for heterocyclase substrate
binding proposed by Koehnke and colleagues [65]. Adapted from [65].
the reaction, as when leader is removed from the substrate, C51 alone, but not C47 can
be processed by TruD [65]. The authors proposed that (Figure 3.2B) the core peptide of
linear PatE binds to the active site of TruD, while the leader peptide plays an auxiliary role
in binding; once C51 is heterocyclized, the a nity for the core peptide lowers significantly,
and the binding between leader and the protein now dominates, which keeps the core
peptide in spatial proximity with the active site, leading to the catalysis of the second
cysteine. However, it is not clear why C51 is favoured over C47 in the first place. It could be
that leader binding creates an anchor point for PatE; as C47 is closer to the anchor, placing
it in the active site could be structurally more strained than when C51 is positioned there.
A further study carried using LynD [64], a homologue from the aestuaramides pathway,
proved that leader peptide makes specific contacts with the enzyme, whilst the lack of
electron density for the core region of peptide in the crystal structure of LynD suggests
that the region is likely flexible. Reaction rates of LynD were compared when full-length
substrate with in-cis leader was used, and when the leader peptide was added in trans
to the core peptide or fused to the enzyme. The latter two scenarios led to a moderate
reduction in the rate of the first heterocyclization and a more pronounced decrease in that
of the second. Although this appears to corroborate core-dominated binding postulated
from observations of TruD, It is worth pointing out that the C51-C47 order was not tested
in the LynD study. On a side note, it seems contradictory that the core binds ‘strongly’
and is simultaneously flexible, and the leader may well be more important than previously
thought in the binding of the unheterocyclized peptide.
In addition to thiazolines, which TruD and LynD are capable of producing, patellamide
D (Figure 3.2) contains two methyloxazolines derived from threonines, and the reaction
order when they are also catalysed is unknown. In this chapter, the full order of four
heterocyclization events by the enzyme MicD was investigated in the context of the
patellamide D core sequence ITACITFC, using a range of biochemical and biophysical
techniques. The role of leader peptide in determining reaction order was then investigated
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with the help of fusion enzymes created earlier in this project (see chapter 2). In
addition, the reaction order of cysteine heterocyclization was revisited using the enzyme
LynD. Lastly, kinetic analysis was carried out to further characterise the role of leader
peptide. Together, these results revealed the complex interplay between chemoselectivity
and spatial arrangement in the activity of cyanobactin heterocyclases.
3.3 Materials and Methods
3.3.1 Overexpression and Purification of Enzymes
LynD, LynD fusion, MicD and MicD fusion were overexpressed in E. coli BL21 (DE3)
cells and purified through immobilised metal a nity chromatography and size-exclusion
chromatography, as described in Section 2.3.5.
3.3.2 Cloning, Expression and Purification of PatE3KK
PatE3KK (MDEEN ILPQQ GQPVI ELTAG QLSSQ LAELS EEALG DAGLE ASKIT
ACITF CAYDG EKLEH HHHHH) was created by introducing a lysine residue C-
terminal to of E56 of PatE3 (MDEEN ILPQQ GQPVI ELTAG QLSSQ LAELS
EEALG DAGLE ASKIT ACITF CAYDG ELEHH HHHH) via site-directed mutagenesis,
following a protocol developed by Liu and Naismith [146]. pBMS-PatE3, supplied
by Dr. Wael Houssen (University of Aberdeen), was used as a template and the
primers 5’-CTGCATCACTTTTTGCGCTTAT GATGGTGAAAAACTCGAG-3’ and 5’-
GTGGTGGTGGTGGTGGTGCTCGAGTTTTTCACCATC-3’ were used to introduce
the lysine. PCR conditions are found in Section 2.3.4 on page 34. The mutated peptide
was overexpressed and purified as described in Section 2.3.7 on page 37.
3.3.3 Preparation of Labelled Substrates
15N-labelled PatE2K (MDKKN ILPQQ GQPVI RLTAG QLSSQ LAELS EEALD GAGLE
ASKIT ACITF CAYDG ELEHH HHHH) was prepared as follows: A 10mL overnight
culture of E. coli BL21 (DE3) cells carrying pBMS-PatE2K was inoculated into 1L M9
minimal medium [157] supplemented with 1 g 15N-labelled NH
4
Cl (Sigma), 0.4% (w/v)
glucose, 1 mM MgSO
4
, 0.1 mM CaCl
2
, 100 µg/ml ampicillin and 0.17% (w/v) yeast
nitrogen base. For 13C, 15N-labelled PatE2K, glucose was replaced with 13C
6
-Glucose
(Cortecnet). Cells were grown at 37  C until OD
600nm
reached 0.5, induced with 0.5 mM
IPTG, and then incubated at 30  C for 16 h. Cells were harvested and the protein was
purified from cell lysates in the same way as non-labelled PatE (described in Section 2.3.7).
58
15N-labelled PatE2K-2het was created by reacting 15N PatE2K (100 µM) with LynD
(5 µM) in 100 mM Tris pH 8 supplemented with 150 mM NaCl, 10 mM MgCl
2
, 10 mM
ATP and 5 mM DTT for 16 h at 25  C. The heterocyclized peptide was purified by size
exclusion chromatography on a 16/600 Superdex 75 pg column (GE Healthcare) in 20 mM
Tris pH 8, 150 mM NaCl.
15N-labelled PatE2K-2het-tryp was made by digesting 15N PatE2K-2het with trypsin
at 100:1 mass ratio at room temperature for 16 h. The reaction mixed was subjected to a
nickel-NTA column (GE Healthcare) equilibrated with 20 mM Tris pH 8, 150 mM NaCl,
and eluted with 20 mM Tris pH 8, 150 mM NaCl and 250 mM imidazole. The eluate
(peptide expected to be 2468 Da) was dialysed into 10 mM Tris-HCl, pH 7.4, 150 mM
NaCl using a dialysis cassette with 2K MWCO.
3.3.4 Nuclear Magnetic Resonance Spectroscopy
Three sets of NMR experiments were performed: (1) The reaction between 2 mM
universally labelled (u)-13C, 15N-PatE2K and MicD, for sequential assignment as well
as reaction monitoring. (2) The reaction between 100 µM universally labelled (u)-15N
PatE2K-2het and MicD. (3) The reaction between 100 µM u-15N PatE2K-2het-tryp and
MicD fusion (R16 5GA). All sets of experiments were performed at 20  C on a Bruker
Ascend 700 MHz spectrometer equipped with a Prodigy TCI probe, with the assistance
of Dr Uli Schwarz-Linek. The instrument was controlled by Topspin (Bruker).
For (1), u-13C, 15N-PatE2K was concentrated to 2 mM and exchanged to a bu↵er
containing 50 mM HEPES pH 7.4 supplemented with 150 mM NaCl, 15 mM ATP, 10
mM MgCl
2
, 5 mM DTT, 0.02% sodium azide and 5% D2O. 1H, 15N-HSQC (heteronuclear
single quantum coherence spectroscopy) spectra using a standard Bruker pulse sequence
incorporating water flip-back and PEP water suppression at 2028 x 128 points and a
digital resolution of 12.3 Hz and 31.0 Hz 1H and 15N dimension were recorded after 15
min, 30 min, 1 h and at each hour afterwards until 66 h after the start of the reaction. The
reaction halted at this stage with the peptide in an intermediate state. 1H, 15N-HSQC
spectra were recorded every hour. HNCACB and CBCA(CO)NH spectra were recorded
using standard Bruker pulse sequences with 1536 x 50 x 104 points and digital resolutions
of 12.8 Hz, 59.6 Hz, and 257 Hz for the 1H, 15N and 13C dimension, respectively, for the
staring material and the final product.
Assignment of PatE2K at 20  C was performed by Dr Ona Miller and Dr Uli Schwarz-
Linek. Assignment of PatE2K-MicD reaction intermediate at 66 h and the final product
was conducted with the assistance of Dr Uli Schwarz-Linek.
All spectra were processed with NMRPipe [158] and analysed with CCPN Analysis 2
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[159].
For (2), 100 µM u-15N-PatE2K-2het was reacted with 5 µM MicD at 20  C and the
reaction was monitored by taking 1H, 15N-HSQC spectra every 30 min for a total of 16 h.
Four transients were recorded at 2048x110 points with spectral resolution of 12.3 Hz and
36.1 Hz for the 1H and 15N dimensions, respectively.
For (3), 100 µM u-15N-PatE2K-2het-tryp was reacted with 5 µM MicD fusion (R16
5GA) at 20  C.1H, 15N-HSQC spectra were collected before and 16 h after the reaction;
six transients were recorded at 1536x80 points with spectral resolution of 12.8 Hz and 26.6
Hz for the 1H and 15N dimensions, respectively.
Spectra collected from experiments (2) and (3) were processed with Bruker Topspin
and analysed with CCPN Analysis 2 [159].
3.3.5 Alkylation of Free Cysteines
PatE2K (100 µM) was reacted with MicD (5 µM) for 1.5 h, 3 h and 16 h in 20 mM
Tris pH 8.0, 150 mM NaCl, 10 MgCl
2
and 10 mM ATP. A sample was removed from the
reaction and quenched with 50 mM EDTA after each time point. 5 mM alkylating agent
iodoacetamide (IAA) was added to each quenched sample, which was then kept away from
light for 30 min at room temperature and subjected to MALDI mass spectrometry.
ITACITFCAYD (100 µM) was reacted with MicD (5 µM) for 1 h, 2 h, 3h and 16 h in
20 mM Tris pH 8.0, 150 mM NaCl, 10 MgCl
2
, 10 mM ATP and 5 mM DTT. The reaction
was quenched as above but was diluted 1 in 10 in water before the addition of 5 mM IAA.
The alkylated samples were incubated at room temperature for 30 min away from light
and subjected to MALDI mass spectrometry.
3.3.6 Mass Spectrometry
Unless specified, mass determination was obtained through MALDI mass spectrometry on
a 4800 MALDI TOF/TOF Analyzer (ABSciex).
For reaction order determination, tandem mass spectrometry (MSMS) data were
collected. MicD and LynD (5 µM each) were reacted with PatE3KK (100 µM)
individuallyfor 1 h and 16 h at 20  C in heterocyclization bu↵er (100 mM Tris pH 8.0, 50
mM NaCl, 10 mM MgCl
2
, 10 mM ATP and 5 mM DTT). The reaction was stopped by
adding EDTA to the final concentration of 50 mM. Trypsin was added at 1:100 mass ratio
followed by incubation at 20  C for 16 h. MicD fusion and LynD fusion (5 µM each) were
incubated with ITACITFCAYDG (100 µM) individually in heterocyclization bu↵er for 1
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h or 16 h, and quenched with 50 mM EDTA. The reaction mixtures were subjected to
high performance liquid chromatography and tandem MS spectrometry (HPLC-MSMS)
on a AB SCIEX Triple TOF 5600 system equipped with Eksignet nanoLC. The samples
were first desalted by being entered into a 0.1 ml/min flow of 98% H
2
O, 2% acetonitrile
(ACN) and 0.05% trifluoroacetic acid (TFA), and washed through a Thermo Pepmap 20
mm x 0.075 mm column (trap column) for 5 min. The trap column was then connected
to an analytical column (150 mm x 0.075 mm) and both were equilibrated in 98% H
2
O,
2% ACN and 0.1% formic acid (FA). Peptides were eluted and separated by switching the
solvent towards 98% ACN, 2% H
2
O and 0.1% FA in a linear gradient over the course of
6 min, with a flow rate of 300 nl/min, and the eluate was passed through a first mass
spectrometer. From there, the most intense peaks within the 400-1250 m/z region were
automatically selected in the Information Dependent Acquisition (IDA) mode and directed
to Collision Induced Fragmentation (CID) followed by a second MS scan in the region of
95-1800 m/z. Alternatively, Product Ion Scan (PIS) mode was employed where specified
masses were entered into the programme prior to experiment so that they are selected for
fragmentation and MSMS. Data were collected by Dr Sally Shirran, Dr Catherine Botting
or Dr Silvia Synowsky from the University of St Andrews mass spectrometry facility.
3.3.7 Enzyme Kinetics
Reaction rates of MicD (1 µM) and MicD fusion (MicD Q21 5GA, 5 µM) enzymes were
measure using a commercially available phosphate assay as described in Section 2.3.11.
Reaction rates of LynD (0.4 µM) and LynD fusion (5 µM) was measured using the same
assay, but the reaction mix contained 1 mM ATP and 1 mM MgCl
2
, instead of 10 mM
of each. MicD and LynD were reacted with PatE2K, while MicD fusion and LynD
fusion were reacted with ITACITFCAYD and ITACITFCAYDGE, respectively. Up to
500 µM leaderless peptides were used due to solubility issues. Experiments were carried
out in triplicates and fitted to the quadratic equation (Eq 2.2). Reaction with higher
concentrations of PatE2K were carried out using 1 µM MicD (triplicates) or 2 µM LynD
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Figure 3.3: MALDI analyses of 15N- (A) and 13C, 15N-labelled PatE2K (B).
3.4 Results
3.4.1 Production of Labelled Substrates for NMR
Singly and doubly labelled PatE2K were purified and subjected to mass spectrometry
(MS). 15N-labelled PatE2K has an expected mass ([M+H]+) of 7078 Da, and the MS
result (Figure 3.3A) showed complete labelling. In contrast, the observed mass of the 13C,
15N-labelled peptide was 7370 Da (Figure 3.3B), 10 Da smaller than the calculated value
of 7380 Da, indicating that carbon labelling has a lower e ciency. A small proportion (less
than 10%) of the peptide was unlabelled, as shown by the 6988 Da peak. A 43 Da adduct
was also observed, which likely arose from carbamylation of lysines during sonication (lysis
bu↵er contained 8M urea). As the unlabelled material will not show in 1H, 15N-HSQC
spectra, and the lysine side chains in the unfolded peptide will be too far away from the
polypeptide backbone to a↵ect mainchain resonances, this sample was deemed to be of
acceptable quality for NMR experiments.
Doubly heterocyclized 15N-PatE2K (15N-PatE2K-2het) was obtained by reacting 15N-
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Figure 3.4: Preparation of heterocyclized full-length and leaderless peptides. (A)
Separation of LynD and PatE2K on Superdex 75 column. (B) SDS-PAGE of elution
fractions from (A). (C) MALDI spectrum of purified 15N-PatE2K-2het. Expected 7041
Da. (D) MALDI spectrum of purified 15N-PatE2K-2het-tryp showing the 0-8000 m/z
range. Expected 2468 Da.
PatE2K with LynD. The modified peptide was then separated from LynD by size exclusion
chromatography (Figure 3.4A and B). MS analysis confirmed that two heterocycles were
formed (Figure 3.4C). Leaderless, doubly heterocyclized 15N-PatE2K (15N-PatE2K-2het-
tryp) was obtained by trypsin cleavage of the N-terminal leader of 15N-PatE2K-2het, while
the remaining C-terminal His-tag (sequence: ITACITFCAYDGELEHHHHHH) was used
for purification by a nity chromatography. Again, MALDI-MS analysis confirmed that
proteolysis of the leader peptide has been complete (Figure 3.4C).
3.4.2 PatE3KK Was Used to Produce ITACITFCAYDGEK
PatE3KK was designed such that the leader peptide
(MDEENILPQQGQPVIELTAGQLSSQLAELSEEALDGAGLEASK) and the His-











Figure 3.5: MALDI Spectra of trypsinated PatE3KK. (A) Ions in the range between 599
and 5015 Da in the reflector mode. (B) Zoom-ion of the region that contains the ion that
corresponds to the core peptide. (C) Ions ranging from 995 to 10047 Da in linear mode,
where the leader peptide ionises more prominently
trypsin cleavage. PatE3KK was used to react with native heterocyclases before being
trypsinated to give the cleaved core peptide, which is highly similar to the leaderless
substrates (such as ITACITFCAYDG) that were reacted with fusion heterocyclases, thus
allowing the activities of native and fusion enzymes to be compared readily. Figure
3.5 shows that PatE3KK is digested into 3 segments after the addition of trypsin, as
expected.
3.4.3 MicD Catalyses C51 First
PatE2K, which encodes the patellamide D core sequence ITACITFC, was used as a
model to study the order of heterocyclization when cysteines and threonines are both
transformed. It was known that TruD catalyses the C-terminal cysteine (C51/C8) before
the internal one (C47/C4) [65], but with MicD the order could change. We reacted PatE2K
with MicD and monitored the formation of heterocycles using nuclear magnetic resonance
(NMR) spectroscopy and mass spectrometry (MS).
First, heteronuclear single quantum coherence spectroscopy (1H, 15N-HSQC)
experiments were set up to track the reaction between unheterocyclized PatE2K and MicD.
This technique reports on the chemical environments of di↵erent amide protons, giving
distinct cross peaks for each residue in a polypeptide chain. Heterocyclization of a residue
would result in the loss of its amide proton, and thus the disappearance of its cross peak
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on the HSQC spectrum. Meanwhile, resonances from adjacent residues will also shift as a
result of the chemical change. The identities of cross peaks are determined by recording
CBCANH and CBCA(CO)NH spectra (Figure 3.6A and B), which are triple resonance
(3D) experiments that establish links between the 1H, 15N and 13C dimensions [160]. Each
amino acid has its distinct pattern of C↵ and C  chemical shifts (Figure 3.6C), and the
carbon resonance profile (shown as strong peaks in the CBCANH spectrum, Figure 3.6D)
at a specific 1H x 15N combination (a cross peak) reveals the residue type of that cross
peak, for example, alanine. Moreover, these experiments allow assignment of residues
to specific positions in a sequence (e.g. A46). As well as showing strong resonances for
the carbons that belong to the same amino acid as an NH group, CBCANH shows weak
signal of the carbons from the preceding residue, thus establishing sequential relationships
between di↵erent cross peaks. CBCA(CO)NH, on the other hand, gives strong signals
that correlates each NH group to the C↵ and C  of its preceding residue, and can be
used to complement CBCANH. Softwares such as Analysis [159] allow users to search for
specific resonance values (Figure 3.6D). If serine is shown to be preceded by an alanine,
the minor resonances from the serine’s CBCANH spectrum can be used to search for the
alanine’s CBCANH spectrum, which will in turn unveil what precedes the alanine. After
this process is repeated several times it is usually possible to obtain a segment (such as
GLEAS) that is unique in the protein so that their residue numbers can be determined.
PatE2K gives a clustered spectrum characteristic of a natively unfolded protein (Figure
3.7C). After reacting with MicD for 4 h at 20  C, the cross peak for C51 has disappeared
(Figure 3.7A), consistent with the loss of its amide proton. Accompanying that was the
shifting of cross peaks for I48, T49, F50, A52, Y53, D54 and G55 (Figure 3.7A and B),
residues that flank C51. The closer to C51 a residue was, the more distance its cross peak
travelled - F50 shifted by 0.26 and 3 ppm in the 1H and 15N dimensions, respectively, while
T49 shifted only by 0.05 (1H) and 0.46 (15N) ppm (Figure 3.7A). These results confirmed
that like TruD [65], MicD had a clear preference for C51 (C8 of core peptide).
After the first heterocyclization, the reaction rate decreased considerably, and the
situation became more complicated. In the spectrum collected 66 h after the addition
of enzyme, the peptide was seen in an ensemble of multiple intermediates states (Figure
3.8A). Cross peaks for C47, T45 and T49 have weakened but not disappeared, suggesting
that heterocyclization of these residues have started, yet not completed. When compared
to uniformly doubly heterocyclized (2-het) PatE2K (Figure 3.8B), which contains two
thiazolines derived from C47 and C51, it was evident that singly heterocyclized (1-het)
peptide still was part of the ensemble after 66 h of reaction with MicD, as T45, A46, C47,
I48, T49, F50 and A50 in the 66 h spectrum (red) showed resonances that overlapped with
those in the 4 h spectrum (blue). In the meanwhile, these residues also gave cross peaks
that corresponded to the C47, C51-heterocyclic state of PatE2K (green). New peaks that

















Figure 3.6: Triple resonance backbone assignment theory. (A) and (B) show how
magnetisation is transferred between atoms in CBCANH and CBCA(CO)NH experiments,
respectively [160]. (C) Typical 13C chemical shifts of 20 amino acids at pH 7.5, 25 C,
plotted using reference numbers given in [161]. (D) Schematic demonstration of sequential































































Figure 3.7: (A)(B) 1H, 15N-HSQC spectrum of PatE2K after 4 h of reaction with MicD
(blue) overlaid with unreacted PatE2K (black). (C) Full spectrum of unreacted PatE2K
















































































Figure 3.8: (A) Overlay of 1H, 15N-HSQC spectra of PatE2K reacted for 66 h (red) and
4 h (blue). (B) Overlay of 1H, 15N-HSQC spectra of PatE2K reacted for 66 h (red) and
PatE2K with two C47 ad C51 heterocycles (green).
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Figure 3.9: CBCANH (black and blue) and CBCA(CO)NH (red) spectra of key residues.
in the MicD-reacted sample (red) - S42 at [8.01, 113.55] (1H and 15N ppm, respectively),
I44 at [7.95, 119.66], A46 at [8.32, 129.38], I48 at [7.97, 121.74], F50 at [8.14, 125.04]
and A52 at [8.01, 126.25] - showing that additional chemical shifts have occurred as a
result of threonine heterocyclizations. To conclude, MicD does not heterocyclize all the
C47 residues before it moves on to T45 and T49, in contrast to how it catalyses C51.
This however does not rule out an ordered reaction mechanism - if C47 heterocyclization
precedes that of T45 and T49, but once C47 is catalysed latter transformation are carried
out at a similar rate, changes corresponding to all three azoline formations will show on
the NMR spectra.
In an attempt to infer the reaction order through further analysis, 3D spectra of
residues directly C-terminal to the heterocyclization residues, namely A46, I48, F50,
and A52, were used to determine if T45, C47, T49 and C51, respectively, have been
catalysed. Heterocyclization change the carbon shifts of a residue drastically. Both A52
peaks from the red spectrum in Figure 3.8A are preceded by a thiazoline (Figure 3.9,
strip 1), which gives a prominent C↵ (i-1) shift at around 80 ppm, not typical of any
amino acid (Figure 3.6C). The peak [7.89, 126.26] which matches A52 in PatE2K-2het
(Figure 3.8B) probably formed first, upon C47 heterocyclization, and then shifted to
[8.01, 126.25] when a threonine is cyclized, most likely T49 due to its relative proximity
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to A52. Presuming both T49 and C47 cyclodehydration a↵ect the chemical shifts of A52,
a di↵erent intermediate/cross peak should have resulted if T49 is cyclized before C47.
Similarly, I48, which follows C47, has two (out of three) peaks with CBCANH spectra
that show carbon resonances of thiazoline (Figure 3.9, strips 2 and 3), one of which
([7.79, 122.70]) overlaps with I48 from the uniformly doubly heterocyclized PatE2K. In
contrast, only one of the three A46 peaks ([8.32, 129.38], strip 6) and one of the three
F50 peaks ([8.14, 125.04], strip 9) are preceded by a methyloxazoline, which gives C↵ and
C  shift values at around 76 and 84 ppm, respectively. Unless C47 heterocyclization has
no e↵ect on A46/F50 after T45/T49 is transformed, there should be additional peaks if
C47 is sometimes heterocyclized after either threonine. While these observations point to
C47 being catalysed before T45 and T49, more concrete evidence is needed to prove or
disprove that, as well as whether there is an reaction order of methyloxazoline formation.
Experiments described in the next two subsections were therefore carried out.
3.4.4 Cysteines are Heterocyclized Before Threonines
Iodoacetamide (IAA) is an alkylating agent that reacts with the thiol group of free
cysteines and as a result adds 57 Da to the mass of the modified peptide/protein.
Unmodified PatE2K, which contains two free cysteines, would acquire a +114 Da mass
shift after alkylation. If one of the cysteines is heterocyclized the mass shift would be +57
Da, whereas if both are catalysed there would be no mass addition upon reaction with
IAA. By alkylating modified PatE2K with di↵erent numbers of heterocycles, mass shifts
could be used to determine how many free cysteines are left, and thereby to calculate
how many of those heterocycles are thiazolines. Figure 3.10A shows PatE2K after 4 h
of reaction with MicD. A mixed state with species corresponding to the starting material
(SM), singly heterocyclized (1het), doubly heterocyclized (2het) and triply heterocyclized
(3het) peptide was observed. Upon reaction with 5 mM IAA (Figure 3.10C), the 1het
species made a mass shift of +57 Da, except for a residual level peak at the original
mass, suggesting that the first heterocyclization was carried out on one of the cysteine
residues. In contrast, masses of the 2het and 3 het species did not change, consistent with
a scenario where both cysteines were no longer susceptible to alkylation. The majority of
unheterocyclized peptide (6989 Da) was modified twice, although a noticeable fraction of it
showed only one 57 Da mass adduct, which could be due to formation of disulphide-linked
PatE dimers/aggregates which competed with IAA labelling, as DTT was not added prior
to alkylation.
After 16 h of reaction with MicD (Figure 3.10B), a small fraction of the peptide
(close to noise level) remained in the 1het state, which was modified by IAA like in
the 1.5 h sample (Figure 3.10D). The vast majority of PatE2K has undergone two to
four heterocyclizations (Figure 3.10B), giving mass over charge (m/z) peaks that did not
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* 3het* 4het * 2het * 1het º SM
*
Figure 3.10: Alkylation of PatE2K Reacted with MicD. (A)(C), PatE2K reacted with
MicD for 1.5 h. (B)(D), PatE2K reacted with MicD for 16 h. (B) and (D) were treated
with 5mM iodoacetamide (IAA) l; 1het - 4het, peptide with one to four heterocycle(s);
‘+’ and ‘++’ signify mass shifts of +57 Da and +114 Da, respectively.
shift after IAA modification (Figure 3.10D). The high abundance of 2het-4het species
consolidated the conclusion from Figure 3.10A and C that they do not contain free
cysteines. It logically follows that the first two heterocyclization events take place at
cysteine residues; in other words, cysteines are heterocyclized before threonines.
3.4.5 T45 is Heterocyclized before T49
After establishing that C51 and C47 are the first two residues to be heterocyclized, the
reaction order between T45 and T49 was analysed. NMR spectroscopy was employed
again, this time using doubly heterocyclized PatE2K (PatE2K-2het) as a starting material,
with 1H, 15N-HSQC spectra collected every 30 min after the addition of MicD. The
black spectrum in Figure 3.11 represents purified PatE2K-2het is equivalent to the green
spectrum in Figure 3.8. Cross peaks corresponding to residues S42, K43, I44, A46, I48,
F50, and A52 shifted as the peptide was transformed by the enzyme, notably only once
each (Figure 3.11, blue and red spectra). After 8.5 h of reaction with MicD at 20  C,
resonance for K43, I44 and T45 disappeared, and that for S42 were significantly weakened.
A46, I48, T49, F50 and A52 also reduced in intensity, albeit to a lesser extent. After 16
h of reaction all residues have completely shifted or disappeared except for a residual
amount of A52. Quantitative analysis of peak volumes corroborated the rate di↵erences
(Figure 3.12). Although residues varied in their maximum intensity (Figure 3.12A), after
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normalisation they formed two distinct clusters with regard to the rate of intensity decay
(Figure 3.12B) - cross peaks S42, I44 and T45 diminished from their original position more
rapidly than A46, I48, T48, A50 and F50. The fact that the A46 cross peak decreased at a
similar rate to residues that are closer to T49 was unexpected, as it is closer to T45; also,
the new A46 peak (Figure 3.11, blue and red spectra) has the same shift ([8.32, 129.38])
of the A46 peak in the Figure 3.8 (red spectrum), which is known via 3D experiments to
be C-terminal to a oxazoline. Despite this oddity, as rates were consistent between S42,
I44 and T45, as well as between T49, F50 and A52, these residues were used as indicators
of T45 and T49 heterocyclization, respectively. Normalised peak volumes of the two sets
of peaks were converted to peptide concentration, averaged and fitted to linear regression
(Figure 3.12C) to obtain an approximation of reaction rate. The average rate of T45
heterocyclization, between the beginning of reaction and when signals of relevant cross
peaks were not detectable, was 11± 0.5 µM/h, whilst that of T49 was 7 ± 0.3 µM/h.
The results showed that MicD catalyses T45 faster than it does T49; nevertheless, it is
not clear whether T49 heterocyclization takes place on the triply heterocyclized peptide
as it is formed, or it occurs along side the T45 reaction at a slower rate. As discussed
in section 3.4.3, the fact that multiple varied intermediates were not observed makes the
former mechanism more plausible, but further experiments are required to validate this
hypothesis.
It was then reasoned that as triply heterocyclized PatE could contain either T45 or T49
heterocycle, subjecting this peptide to tandem mass spectrometry (MSMS) would reveal
whether the methyloxazoline preferentially formed at one position. Figure 3.13A gives an
brief overview of the principles underlying MSMS: primary ions are separated by their
mass (m/z) and those of a specific mass can be selectively directed to fragmentation. The
separation and selection is particularly important for this study, as PatE tends to be in an
ensemble state with multiple intermediates after reacting with MicD (Figure 3.8, Figure
3.10). Figure 3.13B shows the ions that commonly result from peptide fragmentation. In
this experiment, the locations of heterocycles on the peptide were determined following
two rules, using b ions and y ions, which arise from breakage of the peptide bond. First,
if a particular fragment (e.g. ITA) exhibits a -18 Da shift compared to the calculated
mass, that ion likely contains a heterocycle. Second, once a heterocycle forms, the amide
bond N-terminal to the modified residue (i) no longer exists, and therefore the b
i 1 and the
y
n i+1 ions would disappear, where n equals the total number of residues in the peptide. A
list of the mass calculations taken into account heterocyclization is shown in Table 3.2 and
Table 3.3 for b ions and y ions of ITACITFCAYDGEK, respectively, with nomenclature
of the heterocyclized intermediates/product given in Table 3.1.
PatE3KK was reacted with MicD and cleaved by trypsin to release the peptide
ITACITFCAYDGEK. An total ion count (TIC) scan for the mass corresponding to the







































































+MicD, 8.5h +MicD, 16h
PatE2K-2het PatE2K-2het
Figure 3.11: 1H, 15N-HSQC Spectra of PatE2K-2het Reacted with MicD. PatE2K-2het
(100 µM) was reacted with MicD (5 µM) at 20  C for 16 h. The black spectrum (A and
B) shows resonances from the unreacted peptide. The blue (A) and the red (B) spectra
were taken 8.5 h and 16 h after the addition of enzyme, respectively. All spectra were set
to the same contour level.




















































Figure 3.12: Rate of PatE2K-2het-MicD Reaction. (A) Intensities of cross peaks S42,
K43, I44, T45, A46, I48, T49, F50, and A52 (original position) over the course of reaction.
(B) Normalisation of data in (A) using maximum intensity of each dataset as 100% and
0 as 0%. (C) Normalised intensities of S42, I44 and T45 are averaged to monitor T45
heterocyclization; those of T49, F50 and A52 are averaged to monitor T49 reaction. Error





Figure 3.13: Simple overview of the principles underlying tandem mass spectrometry. (A)
Ions are separated by mass and specific masses can be selected for fragmentation and
secondary analysis. (B) Ion series resulting from fragmentation. b and y ions are used for
analyses in this chapter. Figures taken from nationalmaglab.org.
Table 3.1: Possible heterocyclized derivatives of ITACITFCAYDG(EK) and their
nomenclature. Chet denotes a thiazoline formed from a cysteine and its preceding amide
bond, whereas Thet denotes a methyloxazoline formed from a threonine and its preceding
amide bond.




IV ITAChetITFChetAYDG(EK) C4, C8
V IThetAChetITFChetAYDG(EK) T2, C4, C8
VI ITAChetIThetFChetAYDG(EK) C4, T6, C8
VII IThetAChetIThetFChetAYDG(EK) T2, C4, T6, C8
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Table 3.2: Calculated mass of b ions generated from peptide species listed in Table 3.1.
Reisude ion I II III IV V VI VII
I b1 114.09 114.09 114.09 114.09 N/A 114.09 N/A
T b2 215.14 215.14 215.14 215.14 197.13 215.14 197.13
A b3 286.18 286.18 N/A N/A N/A N/A N/A
C b4 389.19 389.19 371.18 371.18 353.16 371.18 353.16
I b5 502.27 502.27 484.26 484.26 466.24 N/A N/A
T b6 603.32 603.32 585.31 585.31 567.29 567.29 549.28
F b7 750.39 N/A 732.38 N/A N/A N/A N/A
C b8 853.40 835.39 835.39 817.37 799.36 799.36 781.34
A b9 924.43 906.42 906.42 888.40 870.39 870.39 852.37
Y b10 1087.50 1069.49 1069.49 1051.47 1033.46 1033.46 1015.44
D b11 1202.52 1184.51 1184.51 1166.49 1148.48 1148.48 1130.46
G b12 1259.54 1241.53 1241.53 1223.51 1205.50 1205.50 1187.48
E b13 1388.59 1370.58 1370.58 1352.56 1334.55 1334.55 1316.53
K b14 1516.68 1498.67 1498.67 1480.65 1462.64 1462.64 1444.62
Table 3.3: Calculated mass of y ions generated from ITACITFCAYDGEK-derived peptide.
Reisude ion I II III IV V VI VII
K y1 147.11 147.11 147.11 147.11 147.11 147.11 147.11
E y2 276.16 276.16 276.16 276.16 276.16 276.16 276.16
G y3 333.18 333.18 333.18 333.18 333.18 333.18 333.18
D y4 448.20 448.20 448.20 448.20 448.20 448.20 448.20
Y y5 611.27 611.27 611.27 611.27 611.27 611.27 611.27
A y6 682.30 682.30 682.30 682.30 682.30 682.30 682.30
C y7 785.31 N/A 785.31 N/A N/A N/A N/A
F y8 932.38 914.37 932.38 914.37 914.37 914.37 914.37
T y9 1033.43 1015.42 1033.43 1015.42 1015.42 N/A N/A
I y10 1146.51 1128.50 1146.51 1128.50 1128.50 1110.48 1110.48
C y11 1249.52 1231.51 N/A N/A N/A N/A N/A
A y12 1320.56 1302.55 1302.55 1284.53 1284.53 1266.52 1266.52
T y13 1421.61 1403.60 1403.60 1385.58 N/A 1367.57 N/A
I y14 1534.69 1516.68 1516.68 1498.66 1480.65 1480.65 1462.63
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time (Figure 3.14A). Fragmentation pattern from the three peaks were similar, with the
later peak (12-12.5 min) giving the highest ion intensities (Figure 3.14B). MSMS spectra of
the other two peaks are found in Appendix B (Figure S3). IThetAChetITFChetAYDGEK









(Table 3.3) are used to di↵erentiate the two. These
masses are plotted as stars (b ions) and circles (y ions) at given x values in order to
signify peaks that correspond to each intermediate (Figure 3.14B). The strongest peaks






of peptide V (Table 3.1), suggesting that T2 (T45)
has been heterocyclized, whereas T6 (T49) remains unmodified. Particularly, y
9
would
have disappeared if T4 was cyclised. There is a small, but noticeable peak (around 2.5%
intensity) with the mass of y
13
of peptide VI, which could be noise, or an indication that
a small amount of triply heterocyclized peptide has been modified on T49. However, it
can be concluded that in the majority of cases, T45 is transformed before T49, giving an
overall reaction order of C51-C47-T45-T49.
3.4.6 Reaction Order of MicD is Partially Leader-Dependent
Having established the reaction order when all four heterocycles are formed, we then
investigated whether this is leader-dependent or intrinsic to the heterocyclase enzyme.
First, an alkylation experiment was carried out to determine if chemoselectivity for
cysteines still predominate. ITACITFCAYD was reacted with MicD fusion (MicD R16
5GA) and analysed by MALDI MS, before and after 5 mM IAA was added to the sample
(Figure 3.15). After 1 h of reaction, the sample contained a mixture of singly, doubly and
triply heterocyclized peptide, as well as the starting material (Figure 3.15A). Alkylation
of this sample led to a +57 Da mass shift of the 1het species and a +114 Da mass shift of
the unreacted peptide (Figure 3.15B), suggesting that like full length PatE2K, leaderless
peptides are catalysed on the two cysteine residues first.
Next, the reaction order between the two cysteines was studied. ITACITFCAYDG
was reacted with MicD fusion for 1 h to obtain singly heterocyclized ITACITFCAYDG-
1het ([M+2H]2+=630.3 Da). Meanwhile, PatE3KK (contains full leader sequence) was
reacted with native MicD, followed by tryptic digest to yield ITACITFCAYDGEK-1het
([M+2H]2+=758.8 Da). The former and latter peptide will be aliased as leaderless and
‘full-length’, respectively, to reflect their state when heterocyclization took place, although
when subjected to MSMS they were both devoid of the leader peptide. Both species were
selected and fragmented so as to determine the site of heterocyclization (Figure 3.16).
As it has been proven that the C8/C51 was catalysed first when native MicD reacts
with full-length PatE (Figure 3.7), the full-length peptide was used as a control, against
which the leaderless peptide was analysed. It needs to be noted that the two peptides
are not exactly the same, so there are natural variations between the ions resulting
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Figure 3.14: Fragmentation of Triply Heterocyclized ITACITFCAYDGEK. PatE3KK was
reacted with MicD and cleaved by trypsin to release the peptide ITACITFCAYDGEK,
which was subjected to LC-MSMS. (A) shows total ion count of the triply heterocyclized
peptide (740.84 Da); blue box highlights the peak that was used to generate fragmentation
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Figure 3.15: IAA Alkylation of Leaderless Peptide Reacted with MicD. ITACITFCAYD
(100 µM) was reacted with MicD R16 5GA (5 µM) for 1 h at 25  C. (A) MALDI mass
spectrum before addition of IAA. (B) MS after the sample was reacted with 5 mM IAA
for 30 min. [M+H]+ species are labelled on their left and [M+Na]+ species are labelled
on their right.




) generated from ITACITFCAYDG- and
ITACITFCAYDGEK-derived peptides share the same masses (Table 3.2), whereas y ions
di↵er. Calculated masses of y ions originating from the ITACITFCAYDG series are listed
in Table 3.4.









for the leaderless peptide, onto the








(II) yielded the highest peaks
(Figure 3.16A). Other ions, corresponding to both peptide II and III, were observed at








were annotated on the spectrum
of the ‘full-length’ peptide (Figure 3.16B); the strongest signals were again attributed






(II)). Even though this sample
was expected to be uniformly C51/C8 heterocyclized, fragmentation of it still yielded
ions that matched masses of b and y ions from peptide III. These could be fragments
resulting from tryptic digest of the enzyme that coincided with the masses of interest,
or they could have arisen due to hydrolysis of the C8-derived thiazoline on an originally
doubly heterocyclized peptide during the LC stage, as the solvent contained 0.05% TFA.
Regardless, the influences should be similar on the MicD + PatE3KK (Figure 3.16B), MicD
fusion + ITACITFCAYDG (Figure 3.16B) samples. As fragmentation of the leaderless
peptide was overall more extensive than that of the ‘full-length’ one, direct comparison of
ion intensities was not drawn. However, a pairwise comparison of b ions was made focusing
on the ratio of II:III (Figure 3.16C), where the magnitude of the MSMS spectrum of the
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Table 3.4: Calculated mass of y ions generated from ITACITFCAYDG-derived peptide
species, following nomenclature given in Table 3.1.
Reisude ion I II III IV V VI VII
G y1 76.04 76.04 76.04 76.04 76.04 76.04 76.04
D y2 191.07 191.07 191.07 191.07 191.07 191.07 191.07
Y y3 354.13 354.13 354.13 354.13 354.13 354.13 354.13
A y4 425.17 425.17 425.17 425.17 425.17 425.17 425.17
C y5 528.18 N/A 528.18 N/A N/A N/A N/A
F y6 675.24 657.23 675.24 657.23 657.23 657.23 657.23
T y7 776.29 758.28 776.29 758.28 758.28 N/A N/A
I y8 889.38 871.37 889.38 871.37 871.37 853.35 853.35
C y9 992.39 974.38 N/A N/A N/A N/A N/A
A y10 1063.42 1045.41 1045.41 1027.39 1027.39 1009.38 1009.38
T y11 1164.47 1146.46 1146.46 1128.44 N/A 1110.43 N/A
I y12 1277.55 1259.54 1259.54 1241.52 1223.51 1223.51 1205.49
‘full-length’ peptide was amplified five times for illustrative purposes. The II:III ratios
were consistent between the two, indicating that N-to-C order of thiazoline formation was
retained in the absence of an in-cis leader peptide.
The order of threonine (T2/T45 and T6/T49) heterocyclization when the leader is not
within the precursor peptide was then investigated. ITACITFCAYDG was reacted with
MicD fusion (Q21 5GA) for 16 h, and after LC-MS the mass that matched the triply
heterocyclized intermediate was subjected to MSMS. It was reasoned that the order of


















, which are only present in one of the triply heterocyclized peptides. Four peaks
were observed during LC (Figure 3.17A) and analysed individually. Raw spectra of them
are found in Appendix B. Although intensities of all peaks of interest were low (below 5%,
with the intensity of the unfragmented precursor as 100%), trends were observed when
they were examined in detail (Figure 3.17B). The earlier eluting peaks (peak 1 and 2,
Figure 3.17A) exhibited similar fragmentation patterns between the two (Figure 3.17B),
and so did the peaks with longer retention times (peak 3 and 4, Figure 3.17A) to a less
extent. In LC-MS peaks 1 (blue) and 2 (green), neither b
2





(VI) ratio (about 5:1 in terms of peak height) pointed to T2 heterocyclization
in these species. This was however contradicted by the reverse V:VI ratio (about 1:3) of y
8
.







ions. The MSMS peak for b
4
(V) was stronger than that for b
4
(VI), but
the ratio is much lower than that observed for the early eluting species (green and blue),
again indicating that peptide V was less abundant at least in the later eluting species (red
and orange). Like those from peaks 1 and 2, y
8
originated from peaks 3 and 4 showed a
reverse pattern, with y
8
(V) being stronger than y
8
(VI). Attempts were made to obtain
clearer MSMS spectra, such as varying collision voltage, but the e↵ect was limited. Based
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b4 (II) b4 (III) b5 (II) b5 (III) b6 (II) b6 (III)
C
Leaderless (1het)
precursor = 630.3 Da
Full-length (1het)
precursor = 758.8 Da
Figure 3.16: MSMS of Singly Heterocyclized ITACITFCAYDG(EK). (A) MSMS spectrum
of singly heterocyclized ITACITFCAYDG processed by MicD fusion. (B) MSMS spectrum
of singly heterocyclized ITACITFCAYDGEK that has been reacted with native MicD.
Both annotated with b ions (stars) and y ions (circles) that di↵erentiate peptide II (red)
and III (black). (C) Pairwise comparison of II:III ratios of native (green) and fusion
(blue) MicD processed peptides. As the green spectrum is overall weaker its magnitude is
amplified five times, hence the intensity should not be compared between the two di↵erent









































































































































































Figure 3.17: MSMS of triply heterocyclized ITACITFCAYDG. (A) TIC of ions with the
mass 612.3 Da. Boxed peaks gave MSMS spectra of corresponding colours in (B). (B)
MSMS spectra of di↵erent peaks zoomed to mass regions that di↵erentiate peptide V
from peptide VI. Peak 1, blue; peak 2, green; peak 3, red; peak4, orange.
on the available results it was concluded that the later eluting peaks contained, whether or
not exclusively, triply heterocyclized peptides with T6-derived methyloxazolines. Hence,
the reaction order with regard to threonines appears lost when the leader is not attached
to the core peptide.
3.4.7 LynD Heterocyclizes Both Cysteines on the Linear Substrate
As the partial leader-dependence of reaction order observed in MicD-catalysed
heterocyclization was unexpected, another homologue, LynD, was examined with regard
to the sequence of thiazoline formations from C4 and C8. Interestingly, native LynD did
not exhibit preference for either cysteine residue, as shown by MSMS analysis of the singly
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heterocyclized intermediate of PatE3KK which has been reacted with LynD for 1 h and
then trypsinated (Figure 3.19A, Figure 3.18A). A good signal to noise ratio was seen in the



















peptide II and III showed very similar intensities, suggesting that ITACITFCAYGEK-1het
consisted of both species. This observation was unanticipated both TruD [65] and MicD
operate in an defined C-to-N order . Unsurprisingly though, loss of in-cis leader did not
result in gain of reaction order, demonstrated by LynD fusion not preferring either C4
or C8 on ITACITFCAYDG (Figure 3.18B). Again, the more intense peaks matched ions
from both peptide II and III, in contrast to the spectra of MicD-reacted peptides which
showed biases towards II (Figure 3.16A and B).
When the reaction was allowed for another 2 h, the reaction progressed and more
heterocycles were installed (Figure 3.19B). MS/MS of the 1het species from this sample
gave a highly similar fragmentation pattern (Figure 3.19C), meaning that neither
ITAChetITFCAYDGEK nor ITACITFChetAYDGEK was preferentially used in the second
heterocyclization event, further confirming the random order of LynD-catalysed reactions.
3.4.8 Leader Peptide Dominates Binding
The disorder of LynD-catalysed reactions further showcased the great flexibility of the
cyanobactin heteorcyclase with regard to the sequence of the core peptide. To understand
the relative importance of core sequence and leader sequence to binding, steady-state
kinetics of native and fusion heterocyclases-catalysed reactions were compared using a
commercially available assay that monitors the rate of phosphate/pyrophosphate release
(described in chapter 2, section 2.3.11). As the assay was carried out on much shorter
time scale (10 min) than the NMR and mass spec experiments, it was thought to primarily
report on the first heterocyclization. LynD and MicD were reacted with PatE2K, whereas
LynD fusion and MicD fusion (R16 5GA) were reacted with ITACITFCAYDGE and
ITACITFCAYD, respectively. It was postulated that if the core dominates binding
initially, similar kinetic parameters would be observed when the enzyme is reacted with
full-length PatE2K and its leaderless counterpart. Indeed, when the observed data
fitted to the quadratic equation (Eq 2.2), k
cat
values were consistent in the native and
fusion enzymes-catalysed reactions (Figure 3.20A and B), although it di↵ered between
the enzymes with LynD and LynD fusion being faster than MicD and MicD fusion. K
m
on the other hand varied significantly when the leader is present or absent in cis, with
native MicD and LynD exhibiting a nanomolar range K
m
for PatE2K, whereas the fusion
enzymes’ K
m
for leaderless substrates were nearly three orders of magnitude higher (Table
3.5). It was therefore likely that enzyme-substrate binding is dominated by the leader
peptide from the beginning. Admittedly, the sequence di↵erence between PatE2K and
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Figure 3.18: (A) ESI-MS/MS of trysinated PatE3KK which has been heteroccyclized once
by LynD. (B) MSMS of ITACITFCAYDG-1het after reaction with LynD fusion.
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Figure 3.19: MALDI-MS of PatE3KK Catalysed by LynD Native. (A)(B) PatE3KK
(unmodified MW = 7093 Da) was reacted with native LynD before 1 h (A) and 3 h (B)
and subjected to MALDI-MS. (C) The 3 h sample was digested with trypsin and subjected
to and ESI-MS/MS. Trace showing fragmentation of the ion species of 758.85 Da. SM,
starting material; 1het, single heterocyclized; 2het, doubly heterocyclized.
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Figure 3.20: Steady-state Kinetics of Native and Fusion Heterocyclases. (A) LynD fusion
(5 µM) was reacted with ITACITFCAYDGE whilst MicD fusion (Q21 5GA, 5 µM) was
reacted with ITACITFCAYD. (B)Native MicD (1 µM) and LynD (0.4 µM) were reacted
with 0.5 - 10 µM PatE2K. (C) Native MicD (1 µM) and LynD (2 µM) were reacted with
higher concentrations of PatE2K. Data from (A) and (B) were fitted to Eq 2.2 (page 40)
in Graphpad Prism; data from (C) were fitted to Eq 3.1.
ITACITFCAYD(GE) are large and other elements from PatE2K (apart from the leader)
may also play a role in a nity, but this is unlikely as previous biophysical experiments have
not demonstrated binding between other regions of PatE and TruD or LynD [64, 65]. It
was noted that higher concentration of PatE2K appeared to have an adverse e↵ect on the
initial rate of reaction (Figure 3.20C), possibly due to substrate inhibition - preliminary
data obtained from reacting LynD was high concentrations PatE2K (not in replicates)





listed in Table 3.5 were derived from the ascending phase (Figure
3.20B) only.
Table 3.5: Steady-state kinetics of MicD and LynD with full-length and leaderless


















MicD PatE2K 0.007 ± 0.0003 0.20 ± 0.07 0.035
LynD PatE2K 0.036 ± 0.0005 0.53 ± 0.33 0.25
MicD fusion ITACITFCAYD 0.005 ± 0.0005 459 ± 74 1.1x10 5
LynD fusion ITACITFCAYDGE 0.011 ± 0.0014 160 ± 48 6.9x10 5
Another interesting observation, which corroborates the importance of the leader
peptide in binding, was the inability of MicD fusion to further modify doubly
heterocyclized leaderless peptides. Along with the MSMS experiments described in section
3.4.6, NMR spectra were collected to monitor the changes of 15N-PatE2K-2het-tryp
(ITACITFCAYDGELEHHHHHH) after the addition of MicD fusion, in order to determine
the reaction order between threonines. No changes signifying cyclodehydration was
















+MicD fusion, 16 h
Figure 3.21: 1H,15N-HSQC spectra of PatE2K-2het-tryp before (black) and after 16 h
reaction (blue) with MicD R16 5GA. This peptide was also used to study oxidation, as
described in chapter 4, where sequential assignment is shown. Here, no di↵erence was
observed before and after the reaction.
experiments triply heterocyclized peptides were made from linear ITACITFCAYDG
(Figure 3.17A). It was thought that the pH 7.4 condition used in the NMR experiment
might hindered the reaction (see chapter 2), and parallel reactions were set up with 15N-
PatE2K-2het-tryp and MicD R16, in either 50 mM HEPES pH 7.4 or 50 mM Tris pH 8.0
(Figure 3.22A and B). Neither reaction showed further heterocyclization when subjected
to MALDI-MS. To ensure the enzyme was active, a control with and the fully linear version
of PatE2K-tryp; in this reaction a significant 3het species was observed (Figure 3.22C).
3.5 Discussion
The current study has expanded the knowledge on the order of the heterocyclases from
the cyanobactin family. Whilst it was originally thought these enzymes would all exhibit a
C-to-N order of reaction, the results surprisingly showed that individual enzymes di↵er in
their preferences with regard to heterocyclizable residues, despite their relatedness (Figure
1.10). Being a catalyst of both thiazolines and (methyl)oxazolines, MicD is chemoselective
for thiols over alcohols. It proceeds from the C- to the N- terminus like TruD, but then
takes a U-turn after installing the first methyloxazoline. LynD, evolutionarily more distant
to TruD and MicD (Figure 1.11), interestingly showed a natural disorderedness (Figure
3.18). Determining the reaction orders of other heterocyclases such as PatD and OscD may
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Figure 3.22: Trypsin Cleaved PatE2K Reacted With MicD. (A)(B) 15N-PatE2K-2het-tryp
was reacted with MicD R16 5GA in a reaction bu↵er containing 50 mM HEPES pH 7.4
and 50 mM Tris pH 8.0, respectively. (C) Unlabelled PatE2K-tryp (no heterocycle) was
reacted with MicD R16.
provide a more convincing link between genotypes and phenotypes. The variation between
homologous enzymes may also apply to other RiPP systems. For example, there was a
discrepancy in the order of dehydrogenation when the oxidase BcerB was reacted with
pre-heterocyclized peptides, and when the BalhBCD complex was used to heterocyclize
and oxidise the precursor (see section 3.2) [113]. The authors argued that the BalhCD
(heterocyclase) reaction order dominates when the complex is formed, as BalhCD and
BalhBCD showed the same overall C-to-N directionality. However, since the oxidation
reaction was carried out with BcerB, intrinsic di↵erences between this enzyme and BalhB
may also have caused the change in order.
The leader peptide appeared to be involved in determining the reaction order, but
is not the sole factor. The heterocyclization order of MicD was partially abolished -
changing from C8-C4-T2-T6 to C8-C4-T2/T6-T6/2, when the leader peptide was detached
from the core. This observation makes it less likely that heterocycles flanking T6 were
restricting its accessibility; rather, orientation of the core in the active site may di↵er
when the leader is and is not docking it to the protein, with the leaderless peptide
having a larger degree of freedom. A similar reset of order was seen in the lantibiotic
synthetase LctM (see section 3.2) [88], although LctM is not only partially ordered to
begin with. Reaction order may arise from reduced or increased substrate a nity for
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each subsequent intermediate, associated with changes in chemistry and conformation.
Haloduracin (lantibiotic) biosynthetic enzyme HalM2, which is highly substrate specific,
exhibits increased rates of thioether ring production as the precursor peptide matures
[162]. In contrast, ProcM, a permissive lantibiotic synthetase, cyclises the peptide at a
reduced rate after the first reaction [162]. Like in ProcM, relaxed selectivity of cyanobactin
heterocyclases is coupled to the decreasing rate of reaction as the number of heterocycles
grow [64, 65]. This trade-o↵ between catalytic and e ciency substrate tolerability was
also seen in other RiPP PTMEs; for example, the promiscuous cyanobactin macrocyclase
PatG is drastically slower than its more substrate-specific counterpart from plants, PCY1
[45, 91, 163]. Rather than maintaining reaction order, the leader peptide plays a more
crucial role promoting substrate binding. The K
m
of MicD/LynD for full-length PatE
is several orders of magnitude lower than that of MicD fusion/LynD fusion for leaderless
peptide with the same core sequence (Figure 3.20). At first this appears comparable to the
pharmacological concepts of avidity and target residence time, where a a bi/multivalent
ligand such as an antibody binds to two sites on the same target protein [164]. The
binding of the first pharmacophore increases the apparent a nity of the second (avidity)
due to forced spatial proximity, as well as enhancing the likelihood of the conjoined ligand
rebinding to the protein once it has dissociated (longer target residence time), for the same
reason. The leader and core peptides are considerably farther apart than epitopes on an
immunoglobin, but leader binding still limits the di↵usion of core peptide into a smaller
space, thereby increasing the its local concentration. The latter e↵ect, however, would not
benefit the first heterocyclization, or the subsequent one as of TruD [65] and MicD 3.7,
both of which are distributive, meaning that after modification of C8 on one peptide they
go onto the next peptide to carry out the same reaction, rather than switching to another
residue on the same peptide. Hence, the leader peptide dissociates alongside the core
peptide after the first reaction. Avidity on the other hand could assist in the binding of
the linear and heterocyclized core peptides, as leader biding brings them into proximity of
the active site. Nevertheless, even when it is not adjacent to the core, leader peptide still
activates the heterocyclase, demonstrated by the elevated reaction rate of fusion enzymes
(chapter 2) and trans-activated enzymes [64] towards leaderless peptides compared to
native enzymes. This might be viewed as allosteric activation, by increasing the enzyme’s
a nity for the core and/or its catalytic e ciency as the crystal structure of LynD shows the
leader making specific contacts with the protein, which is conformationally di↵erent from
its apo form (as of TruD) [64, 65]. The schematic below shows the hypothetical kinetic
pathways involved in allosteric activation (Figure 3.23). For simplicity, ATP is assumed
to bind to the enzyme first, and substrate inhibition is not taken into account. Fusion
enzymes can be seen as the activator-bound form ENL, under the premises that the leader
is constantly bound to the enzyme in the same way as when is it part of PatE - in reality,
the e ciency of leader-binding in a fusion enzyme depends on the exact architecture of
that protein, but after testing various fusion constructs similar kinetic parameters were







Figure 3.23: Kinetic model for leader peptide induced allosteric activation. For simplicity
ATP is assumed to bind first. EN, nucleotide-bound enzyme; S
p
, core peptide; L, leader
peptide; P
p








could reveal crucial information about the activation type - if these values are
the same, only ENLS
p
is catalytically competent [165]. This is clearly not the case as
native enzyme does process leaderless peptide, although the reaction rate is so slow that
accurate velocity measurement using the phosphate assay is prevented due to noise from




have not been obtained. Kinetic details
about leader-activation may be achieved by measuring the rate of reaction using in trans
leader and core peptides, thereby allowing the variation of each component independently.
Finally, the high velocity at apparently low concentrations of PatE (low Kapp
m3
) seen in the
native enzyme assays (Figure 3.20), compared to leaderless peptides, have likely benefited
from an avidity-type inflation of local concentration.
It remains a mystery why MicD (fusion) would not further process doubly
heterocyclized leaderless peptides (Figure 3.21), as it does install methyloxazolines on
peptides with 2 thiazolines when they have the leader attached (Figure 3.11), as well as
on leaderless peptides that do not initially have any heterocycles (Figure 3.15). Another
open question is whether the reduction in rate seen with higher amounts of PatE is a
consequence of substrate inhibition. Further work needs to be carried out, covering a wide
range of peptide concentrations (up to mM levels) to fully establish this. The decline
in rate was not seen with the concentrations of leaderless peptides used (limited due to
solubility issues), but may appear if concentration could be further increased.
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Chapter 4
E↵ect of Leader Peptide On
Azoline Oxidation
4.1 Summary
The cyanobactin oxidase contains a C-terminal FMN-containing, and an N-terminal
domain, which contains two peptide clamps of unknown function(s). Due to the structural
resemblance of the clamps in the N-terminal domain of oxidase to the peptide clamp
in the cyanobactin heterocyclase LynD, which mediates leader peptide binding, it was
hypothesised that these elements may perform the same function in the oxidase. Yet,
employing NMR spectroscopy it was demonstrated that the enzyme ArtGox preferred
peptide substrates that do not have a leader sequence; in addition, oxidation proceeds in a
specific order that is not altered by the cleavage of leader peptide. The oxidase’s preference
for leaderless substrates suggests that oxidation takes place after proteolysis of the leader
peptide during cyanobactin biosynthesis. These findings fit with other biochemical and
biophysical data in establishing that the peptide clamps in the oxidase are vestigial and
do not participate in leader binding.
4.2 Introduction
Azolines within cyanobactin precursors are frequently subjected to oxidation by an FMN-
dependent protein, known as the oxidase or dehydrogenase (Figure 1.15). The general
di↵erences between oxidised and unoxidised heterocycles are discussed in section 1.5. The
e↵ect of azoline oxidation in cyanobactins is exemplified by lissoclinamide 5, which di↵ers
from lissoclinamide 4 only by the change of one thiazoline to thiazole, yet demonstrates a
two orders of magnitude increase in cytotoxicity against bladder carcinoma cells compared
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Figure 4.1: Schematic showing domains in cyanobactin oxidases. ThcOx (Cyanothece sp.
PCC 7425 ), standalone oxidase. PelOx (Nostoc sp. Peltigera membranacea cyanobiont
232 ), putative standalone oxidase. PatG (Prochloron didemni), ArtG and LynG (Lyngbya
sp. PCC 8106 ), fused oxidases. DUF, domain of unknown function. Domains were
assigned by the HHpred server [167].
to the latter [166]. Cyanobactin oxidases, as opposed to their equivalents in other RiPP
and NRP pathways, uniquely possess two peptide clamp motifs (also known as RiPP
recognition elements, RRE, or RiPP domains) in addition to the FMN-containing oxidase
domain. These two clamps appear to be prevalent in cyanobactin oxidases, regardless if
they are standalone enzymes or fused to the G protein (Figure 4.1), but their function
remains unknown. In the crystal structure of ThcOx [106], one of them is seen buried in the
dimeric interface, while the other is exposed to solvent. Although it was hypothesised that
the solvent-accessible clamp may engage in leader peptide binding in a similar fashion to
the peptide clamp in LynD [64], protein-peptide interaction was not observed in the crystal
structure of ThcOx. This chapter describes the biochemical and biophysical studies carried
out to validate the potential e↵ect of leader-binding on the activity of the oxidase. In order
to achieve that aim, the reaction rate and order of ArtGox (Arthrospira platensis) reacted
with full-length and leaderless substrates were determined, compared and contrasted.
The enzyme used, ArtGox (Arthrospira platensis), is a fused (to macrocyclase)
cyanobactin oxidase from the arthrospiramides biosynthetic pathway [119]. Four natural
products, arthrospiramide A (GLPGMPCF), arthrospiramides B (GLVLMPCP) and a
sulfoxide variant of each (Figure 4.2), have been isolated to date, all of which contain
two thiazoles. (Methyl)oxazole(in)es were not found in these compounds, but serine and
threonine residues were found in several ArtE core sequences whose natural products have
not been isolated, leaving the possibility that natural products of ArtG could contain
oxazoles [119]. The ability of ArtGox to oxidise oxazolines was thus investigated.
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Figure 4.2: Structures of Arthrospiramides A, B and sulfoxide variants.
4.3 Materials and Methods
4.3.1 Overexpression and Purification of ArtGox
ArtGox, encoding the oxidase domain of ArtG, was cloned into pEHISTEVSUMO vector
by Dr Andrew Bent, and expresses and a recombinant protein containing a N-terminal
His-tag and SUMO-tag followed by a TEV cleavage site. The plasmid was transformed
into E. coli BL21 (DE3) cells and recovered from a LB-kanamycin plate. A single colony
was transferred to 100 mL LB-kanamycin medium and incubated at 37  C for 16 h. 6 ml
starter culture was then inoculated into 400 ml autoinduction medium [147] supplemented
with 50mg/l kanamycin and 50 µM riboflavin. Cells were incubated at 20  C, 250 rpm for
48 h and harvest by centrifuging at 8983g, 4  C for 15 min. Pellets were resuspended in
oxidase lysis bu↵er (20 mM Tris pH 8.0, 500 mM NaCl, 20 mM imidazole, 3 mM BME and
50 µM flavin mononucleotide (FMN)) supplemented with complete EDTA-free protease
inhibitor (one tablet per 50 ml of suspension) (Roche) and DNase (0.4 g per gram of cell
pellet) (Sigma). The suspension was filtered through a sieve and passaged through a cell
disruptor (Constant Systems Ltd), which was equilibrated with lysis bu↵er and chilled
to 4  C, at 30 kpsi. Cell lysate was cleared by centrifuging at 48384 g for 20 min at 4
 C, followed by filtration through a Millipore nitrocellulose membrane with a pore size
of 0.45 µm (Sigma). Cleared lysate was applied to a Ni-NTA column (GE Healthcare),
equilibrated with oxidase lysis bu↵er, and eluted with oxidase elution bu↵er (20 mM Tris-
HCl, pH 8.0, 500 mM NaCl, 250 mM imidazole, 3 mM BME and 50 µM FMN). The
eluate was collected and concentrated where necessary, and subjected to size-exclusion
chromatography on a 16/600 Superdex 200 pg column (GE Healthcare) in gel filtration
bu↵er (10 mM HEPES, pH 7.4, 150 mM NaCl, 1 mM TCEP).
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4.3.2 NMR Experiments with full-length E2K
15N- and 13C, 15N-labelled PatE2K-2het were produced as described in section 3.3.3.
Experiments were carried out on a Bruker AVANCE 500 MHz spectrometer equipped with
a TXIz probe, controlled by the Bruker Topspin software. For oxidation monitoring, 0.2 M
15N-labelled PatE2K-2het was reacted with 10 µM ArtGox in 10 mM HEPES pH 7.4, 150
mM NaCl, 5 mM FMN and 5% D2O. HSQC spectra were also recorded at 10  C for the
starting material, and 12 h and 60 h after the start of reaction. Between these time points
the sample was incubated at 20  C. 1H, 15N HSQC spectra were acquired using a standard
Bruker pulse sequence with Watergate water suppression with 8 transients at 2048⇥128
points with spectral resolutions of 9.8 Hz and 19.0 Hz in the direct (1H) and indirect (15N)
dimensions, respectively. For sequential assignment, HNCACB spectra were acquired with
16 transients at 1024⇥50⇥128 points and spectral resolutions of 13.7 Hz, 44.6 Hz, and
157.1 Hz for the 1H, 15N and 13C dimensions, respectively. CBCA(CO)NH spectra were
acquired with 8 transients at 1024⇥50⇥114 points and spectral resolutions of 13.7 Hz, 44.6
Hz, and 176.4 Hz for the 1H, 15N and 13C dimensions, respectively. Equivalent spectra were
recorded for fully oxidized u-13C, 15N-PatE2k-2het (concentration 1.0 mM) and a sample
where the enzymatic transformation was interrupted after 12 h by gel filtration on a 16/600
Superdex 75 pg column (GE Healthcare) in heterocyclization bu↵er supplemented with 5
mM FMN, thus allowing assignment of the reaction intermediate. Raw spectral data were
processed with NMRPipe [158] and analysed with CCPN Analysis 2 [159]. Sequential
assignment was carried out by Dr Uli Schwarz-Linek.
4.3.3 NMR Experiments with Leaderless E2K
15N-labelled PatE2K-2het-tryp was prepared as described in 3.3.3. NMR experiments
with the leaderless substrate were performed at 20  C on a Bruker Ascend 700 MHz
spectrometer equipped with a Prodigy TCI probe, controlled by Bruker Topspin software.
For oxidation monitoring, 0.2 M cleaved peptide (PatE2K-2het-tryp) was reacted with 10
µM ArtGox in 10 mM HEPES pH 7.4, 150 mM NaCl, 5 mM FMN and 5% D2O at  C.
1H, 15N HSQC spectra were recorded before the addition of enzyme, 5 min and 20 min
afterwards, and then every 30 min. Six transients were recorded at 1536⇥80 points with
spectral resolutions of 12.8 Hz and 26.6 Hz in the direct (1H) and indirect (15N) dimensions,
respectively. 1H, 15N HSQC spectra were recorded at 10  C for the unreacted substrate
and the final product. Sequential assignment of the full-length peptide was transferred to
the 1H, 15N HSQC spectrum at 10  C and then to the corresponding spectrum at 20  C.
Raw spectral data were processed by Topspin and analysed with CCPN Analysis 2 [159].
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4.3.4 Oxidation Reaction with Heterocyclized ITACITFCAYDGEK
100 µM PatE3KK (see section 3.3.2) was reacted with MicD (5 µM) in 100 mM Tris pH
8.0 supplemented with 50 mM NaCl, 10 mM MgCl
2
, 10 mM ATP and 5 mM DTT for 16
h at 20  C to introduce heterocycles. Following heterocyclization trypsin was added at
1:100 mass ratio and incubated for 2 h at 37  C, and inactivated by heating the sample at
100  C for 10 min. ArtGox (various concentrations) and FMN (200 µM) was then added
and the reaction was carried out at 20  C for 16 h. Reacted samples were subjected to
ESI-MS on a AbSciex 5600 system, as described in section 3.3.6.
4.4 Results
4.4.1 Oxidation by ArtGox proceeds in an N-to-C order
To investigate the reaction order of ArtGox, its reaction with 15N-labelled PatE2K-
2het was monitored by 1H, 15N HSQC NMR (Figure 4.3). Having lost their amide
proton, the heterocyclized residues (C47het/Thn47 and C51het/Thn51) do not themselves
give cross peaks on these spectra. However, oxidation alters the chemical environment
of neighbouring residues A46, I48, T49, F50, A52, Y53, D54 and G55, causing their
resonances to shift. These changes can therefore be traced to indicate Thn47 and Thn51
oxidation. When the doubly hetereocyclized, full-length substrate (PatE2K-2het) was
reacted with ArtG at 20  C, changes took place in two distinguishable stages. The first
period took around 12 h, demonstrated by the shifting of cross peaks corresponding to
A46, I48, T49 and F50, residues close to Thn47. The second stage, which saw shifting
of residues closer to C51 (F50, A52, Y53, D54 and G55), was complete in 60 h at 20  C.
These results showed that similar to the heterocyclase TruD, the oxidase ArtGox works
in a distributive manner with an N-to-C order - preferentially catalysing the N-terminal
thiazolines on di↵erent molecules before moving onto the C-terminal ones - in contrary to
the C-to-N order shown by TruD.
4.4.2 Reaction with Leaderless Peptide Follows Same Order
Next, 15N-labelled PatE2K-2het that has been digested by trypsin to remove the leader
sequence was reacted with ArtGox, so as to determine whether the reaction order is
dependent on leader-protein interaction. Similar to PatE2K-2het, the leaderless peptide
was oxidised first on the N-terminal thiazoline (Figure 4.4), accompanied by chemical shifts
of A46, I48, T49 and F50. Surprisingly the reaction rate was substantially faster than that
between ArtGox and the full-length substrate, with the first stage being completed in 20



























































Figure 4.3: Oxidation Order of Doubly Heterocyclized PatE2K. 1H, 15N HSQC spectra
of doubly heterocyclized PatE2K (200 µM) reacted with ArtGox (10 µM). The starting
material is shown in black, while the 12 h intermediate and the 60 h final product are shown
in blue and red, respectively. Cross-peaks are annotated with their residue sequences; the
colour of a label corresponds to the spectrum where the cross-peak it designates first
appears. Note that the cross-peaks for A46 after 12 h and 60 h are aliased in the 15N







































Figure 4.4: Oxidation Order of Doubly Heterocyclized Leaderless PatE2K. 1H, 15N HSQC
spectra were recorded for doubly heterocyclised, leaderless PatE2K (black), and after it
was reacted with ArtGox for 20 min (blue) and 16 h (red). Cross-peaks are annotated with
their residue sequences as of the full-length substrate; the colour of a label corresponds
to the spectrum where the cross-peak it designates first appears. Note the cross-peaks
for A46 and G55 after 20 min and 16 h are aliased in the 15N dimension; the actual 15N
chemical shift for these signals is 133.8 ppm and 109.3 ppm, respectively.
was finished within 16 h. The consistent N-to-C reaction order indicates the reaction order
is intrinsic to ArtGox and the core substrate sequence (ITAChetITFChet). Sequential
assignments were transferred from the full-length peptide spectra to the leaderless peptide
spectra (both taken at 20  C), then to the leaderless peptide at 10  C (Figure 4.5).
4.4.3 Oxidation of Oxazolines is Kinetically Hindered
As arthrospiramides discovered to date (Figure 4.2) contained only thiazoles, ArtG’s
ability to oxidise methyloxazolines was tested. 100 µM PatE3KK was reacted with MicD
to introduce four heterocycles and subjected to proteolysis by trypsin to remove the leader
and his-tag. The resulting peptide IThetAChetIThetFChetAYDGEK was then reacted was
ArtGox and analysed by ESI-MS (Figure 4.6). 1 µM of ArtGox was able to oxidise the
peptide twice - corresponding to the formation of two thiazoles. However, increasing the
enzyme concentration up to 10 µM did not result in further oxidation within the time
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Figure 4.5: Sequential assignment of doubly heterocyclised, leaderless PatE2K and
its oxidised product. Doubly heterocyclised full-length PatE and its oxidised product
were assigned using triple resonance data. The sequential assignments were transferred
to equivalent leaderless peptides at 10  C. The assignments were then transferred to
equivalent resonances at 20  C. Cross-peaks marked with an asterisk are aliased in the
15N dimesion; the actual 15N chemical shifts for these signals are 133.8 ppm (A46) and
109.3 ppm (G55).
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Figure 4.6: ESI-MS of IThetAChetIThetFChetAYDGEK reacted with ArtGox. PatE3KK
(100 µM) was reacted with MicD, trypsinated and then reacted with ArtGox. Unoxidised
mass of ITACITFCAYDGEK-4het ([M+2H]2+)is expected to be 731.8 Da, while each
oxidation results in a 2 Da mass loss (1 Da in the [M+2H]2+ species). Note that the third
isotope of the once oxidised peptide coincides with the unoxidised peptide, and so forth,
and the less oxidised species are therefore likely overrepresented. The peaks labelled
‘unrelated’ were not generated from the peptide of interest, as they exhibit a di↵erent
isotope pattern.
observed when ArtGox concentration was raised to 50 µM. Even at such high enzyme
concentration, a fourth oxidation did not take place. These results suggest it is unlikely
that this enzyme would catalyse methyloxazole formation on leaderless linear peptides
under natural circumstances.
4.5 Discussion
The work described in this chapter showed that the cyanobactin oxidase ArtGox catalyses
multiple thiazolines in a distributive manner, following an N-terminal to C-terminal order
(Chet47 then Chet51), in an interesting contrast to that of heterocyclization seen in TruD
and MicD (C51 then C47). This reversion of reaction order could provide a check point
which ensures heterocyclization precedes oxidation. It is however also possible that the
heterocyclase and oxidase work in tandem, and C51 is oxidised immediately after it is
heterocyclized. Further experiments need to be carried out to determine whether C47
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thiazoline is required for oxidation to initiate, or that C51 thiazoline alone is su cient.
In either case, the reaction order is attributed to intrinsic properties of ArtGox and the
core peptide used, rather than the leader-mediated positioning, as removal of the leader
peptide from the substrate did not a↵ect the order of reaction.
It was also observed that leaderless peptides are processed at a higher rate compared to





leaderless peptide is used) was seen in the enzyme ThcOx when subjected to steady-state
kinetics measurements [168]. Based on isothermal calorimetric data, Gao et al. [168] also
reported that there was no interaction between ThcOx and the leader peptide, leaving it
unexplained as to how the reaction is slowed down. The additional bulkiness of the leader
sequence (38 residues) in PatE, as opposed to the leaderless peptides, could be one of the
contributing factors. The large di↵erence in reaction rates may suggest that proteolytic
removal of the leader peptide by PatA occurs before oxidation in the native system.
It is unclear why the peptide clamps are conserved among cyanobactin oxidases (Figure
4.1), given they are not involved in leader binding. A similar observation was made of the
peptide-modifying radical SAM enzyme SuiB [169], which contains a peptide clamp, but
uses a di↵erent site for leader recognition. For ThcOx specifically, the N-terminal domain
appears to play a stabilising role, as truncation of this domain resulted in the loss of the
co-factor FMN and inactivation of the enzyme [168]. As natural product biosynthetic
enzymes tend to be clustered on a genetic level, it is possible that lateral transfer of
domains have arisen during evolution, leading to the fusion of RREs to enzymes that do
not require them for substrate recognition. These examples demonstrate the importance of
biochemical and biophysical characterisations of proteins of interest, and caution against






YcaO-class heterocyclases have been proposed to operate via a kinase mechanism, where
the peptide forms a hemiorthoamide intermediate which is phosphorylated, and the
phosphate group is subsequently eliminated, yielding one each of heterocycle, ADP and
inorganic phosphate. However, AMP and PP
i
have also been observed in multiple
studies. Specifically, an 18O-labelling experiment showed that PP
i
contained peptide-
derived oxygen atoms. ATP analogues were employed to probe the mechanism, and it
was shown that a cleavable bond between  , -phosphates is essential for reaction. Next,
ATP/AMP-CPP metabolites and heterocycles were quantitated using HPLC-MS and
radioactive methods, which demonstrated that ADP/AMP-CP production was correlated
with heterocycle production, while AMP was generated from ADP hydrolysis. The
phosphorylation theory was proposed that unify these observations, where the  -phosphate
dissociates from the  -phosphate in order to phosphorylate the hemiorthoamide, but then
returns to the latter and form PP
i
with it, simultaneously releasing AMP. In accordance
with this theory PP
i
was observed in place of P
i
when AMP-CPP and ADP were added
to the same reaction.
5.2 Introduction
Phosphoryl transfer forms the basis of fundamental aspects of biology such as DNA
synthesis and ATP hydrolysis [170, 171]. As discussed in section 1.3.2, YcaO-catalysed
heterocyclization is believed to proceed via a tetrahedral hemiorthoamide intermediate
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Figure 5.1: A schematic illustration of how adenylases, diphosphokinases and kinases
cleave ATP.
formed when the side chain alcohol/thiol group of a Ser/Thr/Cys attacks the carbonyl
carbon of its preceding amide bond. Following that, an ATP-derived phosphate group is
attached to the former carbonyl oxygen to assist its elimination, but the exact identity of
this electrophile is unknown. AMP, PP
i
, ADP and P
i
have all been observed as products
of heterocyclization, giving possibilities that the reaction proceeds via a mechanism which
will be referred to as adenylase, diphosphokinase or kinase here (Figure 5.1). In the





respectively, are attached to the tetrahedral oxygen via the diphosphokinase and kinase
routes. In this chapter the phosphate chemistry of the cyanobactin heterocyclase is studied
in depth, to address these seemingly irreconcilable observations.
5.3 Materials and Methods
5.3.1 Protein Expression and Purification
LynD, LynD fusion, MicD, MicD fusions and OscD were purified as described in section
2.3.5.
5.3.2 Heterocyclization Reactions
ATP, ADP, AMP and various ATP analogues were reacted with heterocyclases in 100 mM
Tris pH 8.0 supplemented with 150 mM NaCl, 20 mM MgCl
2
and 5 mM DTT at room
temperature. Unless specified, the following concentrations of reactants were applied: 5
µM heterocyclase, 100 µM PatE, 5 mM nucleotide.
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5.3.3 Phosphate versus Pyrophosphate Assay
EnzChek (Invitrogen) phosphate assay (see section 2.3.11) was carried out in the presence
and absence of pyrophosphatase. Experiments were performed at 25  C in 100 mM Tris
pH 8.0 supplemented with 50 mM NaCl, 10 mM MgCl
2
, 5 mM DTT, 200 µM MESG and
1unit PNP (as supplied by the manufacturer).
For determination the products of MicD- and LynD-catalysed reactions, MicD (5 µM)
was reacted with 20 µM PatE2K and 10 mM ATP or 10 mM ATP only, and LynD (5 µM)
was reacted with 100 µPatE2K and 1 mM ATP or 1 mM ATP only. 10 µM MtPPase was
included in the reaction where indicated.
For the assay probing transphosphorylation, LynD (5 µM) was reacted with 100 µM
PatE2K and 10 mM each of ATP, ADP, AMP-CPP or AMP-CPP + ADP. 10 µMMtPPase
was included in the reaction where indicated.
5.3.4 HPLC Assay
Heterocyclization of ITACITFCAYD by MicD fusion in the presence of ATP, ADP or
AMP-CPP were carried out in HPLC assay bu↵er (100 mM Tris pH 8.0, 50 mM NaCl,
10 mM MgCl
2
, 5 mM TCEP). Reactant concentrations, reaction time and temperature
varied and are specified individually. Reactions were terminated by the addition of two
volumes of urea quench bu↵er (8 M urea, 20 mM Tris pH 8.0, 500 mM NaCl, 10 µM L-
tryptophan), where L-tryptophan is used as an internal standard, and then incubated with
120 µM Ni-NTA agarose resin (ABT) placed in a Corning centrifuge tube filter (Sigma) for
30 min at room temperature. After centrifugation at 4000 g for 10 min the flow through
was collected and applied to a EC 250/4.6 NUCLEODUR 300-5 C18 column (Thames
Restek) connected to a G6130B Single Quad LC-MS instrument (Agilent Technologies).
The column was pre-equilibrated in solvent A (5 mM Ammonium Bicarbonate pH 7.0),
and after sample application a step-wise isocratic programme was run at a flow rate of 1
ml/min for a total of 11 min to separate the reactants and products: 80% solvent A, 20%
solvent B (95% Acetonitrile) for 3 min, followed by 50% A, 50% B for 3 min, and finally
100% B for 5 min. Separation of linear and heterocyclized peptides was not achieved by
this method and therefore di↵erent selected ion monitoring (SIM) channels were set up
to give separate ion chromatograms of these peptides. The following three SIM channels
(negative mode) were set up: (1) AMP or AMP-CP and ITACITFCAYD, (2) ATP or
AMP-CPP and ITACITFCAYD-1het, (3) ADP and L-tryptophan. Ion intensity peaks
were integrated using the Agilent ChemStation software, and corrected against the area of
the L-tryptophan peak. Standard curves for the quantitation of AMP, ADP, ATP, AMP-
CP, AMP-CPP and ITACITFCAYD was obtained by diluting each compound to various
concentrations in HPLC assay bu↵er and adding two volumes of urea quench bu↵er, before
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applying the samples to the HPLC-MS system.
Duplicated time course experiments were carried out with MicD Q21 9GA (20 µM)
with ITACITFCAYD (50 µM) and ATP or AMP-CPP (10 µM). The reaction containing
ATP was performed at 25  C , with samples withdrawn from the reaction mix at 15
s, 30 s, 60 s, 120 s, 300s and 600 s after the start of the reaction, and quenched by
being mixed with two volumes of urea quench bu↵er. The AMP-CPP reaction was
carried out in separate aliquots and incubated at 30  C; reactions were quenched after
15 min, 30 min, 60 min, 120 min and 240 min after initiation. Areas of ion intensity
peaks (peptides, nucleotides and typtophan) were integrated and the plotted as a ratio of
peptide or nucleotide over tryptophan, against time. Standard curves for ATP, ADP, AMP
and AMP-PNP were employed to calculate the concentrations of these nucleotides. Due
to di culties in obtaining pure, singly heterocyclized peptide, the concentration of this
compound was also obtained from normalised data. The AMP-CPP reaction was assumed
to have reached completion by the end of the incubation period, and the readings at time
0 and 240 min, respectively, were used as minimum (0%) and maximum (100% or 10
µM), and a linear relationship between area ratio and peptide concentration was supposed
to exist within this range. The same slope (area ratio/concentration) was then used to
normalise data from the ATP reaction. AMP-CP concentrations were estimated based on
normalised data, with the peak ratio value at time 0 set as 0 and the peak ratio value at
240 min as 100% (10 µM), assuming linearity within the range.
For determining the degree of heterocyclization, reactions were set up between 25 µM,
50 µM and 100 µM ITACITFCAYD and 1 mM AMP-CPP, catalysed by MicD Q21 9GA
(5 µM). The reactions were incubated at room temperature for 16 h, and quenched with
2x volumes of urea quench bu↵er. The enzyme was removed, and the flow-through was
subjected to HPLC-MS as described above, except that a di↵erent solvent gradient was
run: 20%-60% B from 0 -10 min, 95% B from 10 -15 min. Masses corresponding to the
unmodified, singly and doubly heterocyclized peptides were entered into SIM channels
MSD2, 3 and 4, respectively.
5.4 Results
5.4.1 The Conundrum of ATP Consumption
Amajor di↵erentiating factor between a kinase mechanism and adenylase/diphosphokinase
mechanism lies in the phosphoester bond that is cleaved. Kinases transfer the  -phosphate
of ATP to another molecule, thereby requiring the cleavage of the bond between  - and  -
phosphates; the separation of AMP and PP
i
, on the other hand, severs the bond between
the ↵- and the  -phosphate (Figure 5.1). Four ATP analogues, two with a non-cleavable
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↵, -bond, AMP-CPP and AMP-NPP, and two with a substituted  , -oxygen, AMP-
PCP and AMP-PNP, were employed to probe the phosphate chemistry of cyanobactin
heterocyclization. MicD is capable of heterocyclizing PatE2K (core sequence ITACITFC)
four times when supplied with ATP (Figure 5.2A). When AMP-PCP/AMP-PNP was used
in place of ATP, activity was not observed (Figure 5.2D, E). In contrast, heterocyclization
was carried out when AMP-CPP and AMP-NPP were supplied as the phosphate donor,
albeit at reduced rates (Figure 5.2B, C). AMP-CPP appeared to be a better substrate
than AMP-NPP, although both allowed the reaction to take place. Since the peptide
reacted with AMP-CPP/AMP-NPP but barely went beyond one heterocyclization, we
considered whether the first reaction may have a di↵erent mechanism from the rest (one
that produces pyrophosphate). To test this, PatE2K was reacted first with AMP-CPP for
16 h before the addition of AMP-PCP and 24 h further hours of incubation, in order to see
if progression of further heterocyclization could be promoted (Figure 5.2F). However, the
additional AMP-PCP did not make a di↵erence to the reaction. These results agree with
a kinase mechanism, where cleavage of the  , -phosphoester bond, but not that of the
↵, -bond, is required for heterocyclization. The first reaction was faster than the rest, but
it is likely down to kinetic properties rather than di↵erences in phosphate chemistry. To
show that the selectivity over nucleotides is not an exclusive characteristic of MicD, but
common to the heterocyclase class of enzyme, PatE2K was reacted with the enzymes LynD
and OscD in the presence of AMP-CPP and AMP-PCP (Figure 5.3). Both enzymes were
capable of utilising AMP-CPP, but not AMP-PCP, to catalyse heterocyclization, echoing
the behaviour of MicD.
If MicD-type heterocyclases operate via a kinase mechanism, when ATP is supplied
instead of its analogues, it is expected to be broken down into ADP and inorganic
phosphate, while the bond between the ↵- and  -phosphates remain intact. However,
when measuring reaction rates of heterocyclases using the EnzChek phosphate assay, it
was observed that including a pyrophosphatase (PPase) in the assay increased the readings.
As the assay detects phosphate, a rational explanation would be that pyrophosphate was
produced by the heterocyclization reaction and only became detectable after being broken
down into phosphate by the pyrophosphate. This was first noticed when PatE2K was
reacted with MicD fusion (Figure 2.9B). To rule out that a change in chemistry was
induced by enzyme engineering, native MicD-catalysed reaction was subjected to the
same analyses. MicD native was incubated with 20 µM PatE2K and 1 mM ATP for
600 s, without or without pyrophosphatase. In the presence of PPase, the increase in
A360 was about three times higher than when PPase was not included, suggesting that




were produced during this period (PP
i
breaks
down into 2 P
i
and therefore yields double the reading). Both rates were significantly
higher than when the enzyme was incubated with ATP alone (Figure 5.4A), showing that
PP
i
was associated with the reaction rather than background hydrolysis. A consistent, and
more pronounced di↵erence was seen when LynD was employed to catalyse the reaction
104
6850 6900 6950 7000 7050
50
100
6850 6900 6950 7000 7050
50
100
6850 6900 6950 7000 7050
50
100
6850 6900 6950 7000 7050
50
100
6850 6900 6950 7000 7050
50
100
6850 6900 6950 7000 7050
50
100
































Figure 5.2: Usage of ATP Analogues by MicD. (A)-(E) 100 µM PatE2K (unreacted mass
6989 Da) was incubated with 5 µM MicD and 5 mM of varied nucleotides at 25  C for 16
h. (F) 100 µM PatE2K was reacted with 5 µM MicD in the presence of 2 mM AMP-CPP
for 16 h at 25  C before 2 mM AMP-PCP was added and the sample was incubated for a
further 40 h.
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Figure 5.3: Usage of ATP Analogues by LynD and OscD. MALDI spectra of 100 µM
PatE2K (unreacted mass 6989 Da) that has been incubated with 5 µM LynD (A and B)
or OscD (C and D) and 5 mM of AMP-CPP or AMP-PCP at 25  C for 16 h.
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Figure 5.4: Pyrophosphate Production by Heterocyclases. Pyrophosphatase increases
the amount of phosphate detectable following MicD (A) and LynD (B) reactions. PEP,
peptide; PPase, pyrophosphatase.
between PatE2K and ATP (Figure 5.4B), with the addition of PPase boosting the reading
for over 10 times. Without PPase, the LynD catalysed reaction yielded phosphate at a
rate comparable to background (no peptide). It is therefore reasonable to conclude that
PP
i
is the main product of the heterocyclization reaction by LynD.
An alternative explanation for the PPase-related increase in A360 would be that a
small amount of PP
i
is produced by background ATP hydrolysis, but exerts an inhibitory
e↵ect on heterocyclization; breaking it down accelerates the reaction which produces more
phosphate (in addition to the phosphate arisen from pyrophosphate hydrolysis). However,
previous studies of LynD and TruD observed AMP and PP
i
as reaction products [64,
65]. Specifically, the LynD study [64] showed, via 18O-labelling of the carbonyl carbon
preceding the cysteine to be heterocyclized, incorporation of 18O into pyrophosphate,
meaning that PP
i
did not arise purely from background ATP hydrolysis.
The apparent contradiction between the detection of pyrophosphate and the need for
a cleavable  , -phosphoester bond suggested that MicD-type heterocyclases may give rise
to a novel, unusual mechanism.
5.4.2 Nuclease and Heterocyclase Activities of MicD
Having demonstrated that AMP-CPP/AMP-NPP, but not AMP-PCP/AMP-PNP could
be used by MicD to produce heterocycles, experiments were carried out to show ATP
is indeed cleaved to yield ADP and P
i
. An LC-MS assay was developed to monitor
the concentration of ATP and its metabolites ADP and AMP, as well as the peptide
ITACITFCAYD and its heterocyclized forms (Figure 5.5). Nucleotide were separated
by HPLC, and their masses were entered into di↵erent SIM channels to facilitate peak
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Figure 5.5: HPLC-MS Chromatograms of ATP/AMP-CPP Metabolites and
ITACITFCAYD. Example chromatogram showing peaks for ATP, ADP, AMP, AMP-
CPP, AMP-CP, the peptide ITACITFCAYD and its singly heterocyclized form, and L-
tryptophan. 1het, singly heterocyclized peptide; tryp, L-tryptophan.
integration. The unreacted peptide was not separable using the current method from its
singly heterocyclized product, and their quantitation relied on using di↵erent selective
mass detectors (MSD). Separation of peptides was possible using acidic solvents (such
as formic acid) but the nucleotides did not ionise to su cient intensities under those
conditions. In addition, azoline rings risk re-opening at low pH values. Tryptophan was
included in the reaction quenching bu↵er to provide an internal standard for the assay.
As MicD is distributive with a strong preference for C8 of the peptide, all peptides
are expected to be modified once at the same position (C8). It was experimentally
validated that even when the nucleotide concentration far exceeds that of the peptide
(multiple turnovers condition), singly heterocyclized peptide was exclusively produced
as the starting material was consumed (Figure 5.6). Therefore the number of azolines
were assumed to be equal to the amount of the singly heterocyclized peptide during the
quantitation experiments. 20 µM MicD Q21 9GA was reacted with 10 µM ATP and 50
µM peptide, to create a pseudo-single turnover scenario; The reaction was quenched at 5,
10, 30 and 60 min by adding two volumes of urea quench bu↵er and subjected to LC-MS.
The mass peaks were integrated and normalised against tryptophan, then plotted against
time (Figure 5.7). The reaction appeared to have finished within the first 5 min, with
concentration of the singly heterocyclized staying unchanged over the rest of the time
course (Figure 5.7A, red circles). ATP (orange squares) was converted into AMP (green
squares). In contrast, when ADP was added in place of ATP, only a residual level of
1het peptides were seen (Figure 5.7B), which could be attributed to noises in the mass
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Figure 5.6: HPLC-MS Chromatograms showing masses corresponding to unmodified and
heterocyclized ITACITFCAYD. 25 µM (black), 50 µM (red) and 100 µ(green) peptide was
reacted with 1 mM AMP-CPP for 16 h prior to analysis. MSD2, unmodified mass; MSD3,
singly heterocyclized (1het) mass; MSD3, doubly heterocyclized (2het) mass.
spectra. Interestingly, ADP was broken down to AMP gradually, although this process
was not coupled with heterocyclization. Next, reactions were set up using AMP-CPP
as phosphate donor, and the level of the degradation product AMP-CP was measured
alongside the peptide. An increase in both was seen over the course of 60 min (Figure
5.7C), with the concentration of singly heterocyclized peptide approaching that of the
ATP-reaction (Figure 5.7D) by the end of the incubation period.
These data suggested both ATP and AMP-CPP are used as substrates by the
heterocyclase. ADP appeared to be hydrolysed into AMP, possibly in an enzyme-
dependent way. In section 5.4.3, the reaction with ATP is examined at shorter time
points after initiation, to reveal details about earlier stages of the reaction, and the reaction
with AMP-CPP was monitored for a longer period of time. A method of quantitation of
peptides and nucleotides was also developed to further facilitate the understanding of the
chemistries involved in heterocyclization.
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Figure 5.7: Association Between ATP, ADP and AMP-CPP Usage by MicD and
Heterocyclization. ITACITFCAYD (50 µM) was reacted with 20 µM MicD Q21 9GA in
the presence of 10 µM ATP, ADP or AMP-CPP for 5 min, 10 min, 30 min and 60 min. LC-
MS peaks were integrated and corrected against an internal standard (tryptophan). P/W,
area of the peak of interest over the area of tryptophan peak; 1het, singly heterocyclized
ITACITFCAYD.
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5.4.3 Quantitation of Nucleotides and Heterocycles
Based on the results (Figure 5.7) showing that ATP and AMP-CPP are broken down
as heterocycles form, a method of quantitation of nucleotides and heterocycles were
sought so as to determine the stoichiometry between products. Standard curves were
established for ATP, ADP, AMP and AMP-CPP, (Figure 5.8A), as well as for the peptide
ITACITFCAYD (Figure 5.8B). Reactions were carried out between 20 µM MicD Q21
9GA, 50 µM peptide and 10 µATP or AMP-PCP. The ATP reaction was conducted at
25  C for a total of 10 min, whereas the AMP-PCP reaction was incubated at 30  C for
4 h. Consistent with previous observations (Figure 5.7), when ATP is used as phosphate
donor, heterocyclization occurred rapidly (finished within the first 200 s) and plateaued
afterwards (Figure 5.8C). A rapid but temporary accumulation of ADP was observed
(peaked at around 100 s), which subsequently diminished. In contrast, AMP concentration
increased over the entire 600 s period, even after ATP had been depleted (peaks became
too small to integrate after 300 s), and concurred with ADP hydrolysis. Due to sensitivity
limits of the HPLC-MS instrument, the reactions were not carried out under strict single
turnover conditions. Concentrations of AMP, ATP and the singly heterocyclized peptide
were fitted to a first-order association/decay equation to demonstrate the trend.
AMP-CPP, on the other hand, was degraded over a much longer period of time (Figure
5.8D), even though the incubation temperature was higher (30  C) than that of the ATP
reaction (25  C). As the metabolite AMP-CP could not be further converted to AMP, it
accumulated over the course of the reaction. It was assumed that its concentration of it
at 240 min was 10 µM (while that at time 0 was 0), based on the observation that AMP-
CPP had been exhausted by that time, and that within this range the relationship between
concentration and ion intensity was linear (Figure 5.8A). Concentrations of AMP-CP over
the course of the reaction was approximated based on this simplified calibration curve.
Similarly, quantitation of the singly heterocyclized peptide was based on the assumption
that it has reached 10 µM at the end of the reaction (Figure 5.8B). This was not an
accurate calibration, which was hindered by di culties in achieving and purifying singly
heterocyclized peptides, but allowed comparisons of reaction rates. Under the premise
that 10 µM of heterocyclized peptides were produced, it appeared that the number of
heterocyclized peptide was nearly identical to that of AMP-CP throughout the reaction
(Figure 5.8D), indicating that the breakdown of AMP-CPP and the heterocyclization
of peptide was tightly coupled, with a 1:1 stoichiometry. Had the concentration of the
singly heterocyclized peptide been di↵erent (e.g. 8 µM heterocycles were made in total),
there would still be a linear, albeit not equivalent, relationship between the amount of
AMP-CP and heterocycles, in coherence with a phosphorylation-related mechanism. In
such case, background hydrolysis of AMP-CPP could have contributed to the discrepancy.
Regardless, the data clearly demonstrated that AMP-CPP was broken down into AMP-CP
as heterocyclization occurs, proving that AMP-CPP is a genuine substrate, in agreement
110













































































































Figure 5.8: HPLC Quantitation of Nucleotides and Heterocycles. (A) Calibration curves
for HPLC quantitation of the nucleotides ATP, ADP, AMP, AMP-CPP and AMP-CP. (B)
Calibration curve for the peptide ITACITFCAYD and its singly heterocyclized derivative.
Y axes represent the ratio between the area of the ion intensity peak and that of the
tryptophan peak. (C) Progression of heterocyclization when the peptide was reacted with
ATP. (D) Concentrations of metabolites when AMP-CPP was used as phosphate donor.
(E) ATP degradation over time when MicD was incubated with ATP with and without
the peptide. (F) AMP-CPP degradation when MicD was incubated with the nucleotide
with and without the peptide. Data in (A) and (B) were fitted to linear regressions; Data
in (C)-(F) were fitted to one-phase association/decay regressions.
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with the observation of dehydrations by mass spectrometry (Figure 5.2) when this
nucleotide is supplied as phosphate donor.
Even without knowing the exact number of heterocycles produced, it was clear that
more (above twice the amount) was made during the AMP-CPP reaction (Figure 5.8D)
compared with the ATP reaction (Figure 5.8C). ATP appears more prone to futile
consumption, as when the peptide is absent ATP is hydrolysed not only faster than AMP-
CPP in absolute terms, but the rate is more comparable to that observed during the
reaction (Figure 5.8E, F).
The degradation pattern of ATP was iterated by a radioactive assay utilising ↵-32P-
labelled ATP (Figure 5.9), kindly carried out by Dr Clarissa Czekster (University of St
Andrews). Native MicD (20 µM) was reacted with 0.25 µM ATP and a saturating amount
of PatE2K (150 µM), and quenched with a final concentration of 62.5 mM EDTA at
discontinuous time points (15 s to 1800 s). ATP was consumed at a rate highly similar
to that seen in the HPLC experiment, with nearly 90% being degraded within the first
300 s (Figure 5.9B); ADP was produced, with a peak concentration of 0.134 µM at 120 s,
and subsequently broken down into AMP. The increase in AMP (0.1 µM) approximately
equalled the decrease of ADP (0.09 µM) between the 300 s and 1800 s time points, as was
expected if AMP derived primarily from ADP hydrolysis. In the meanwhile, background
ATP hydrolysis was measured (Figure 5.9B) by omitting PatE2K from the reaction. The
overall ATP consumption di↵ered little from the reaction when the peptide was present.
However, a smaller amount of ADP accumulated (peaked at about 0.075 µM at 60 s), and
AMP levels rose much more rapidly (nearly 90% AMP at 600 s). One possible explanation
for the di↵erence is that ADP is made from ATP at a slower rate compared to when the
peptide is present, as the hemiorthoamide is not available to receive to the  -phosphate
from ATP now. Alternatively, ADP hydrolysis could be faster in the reaction shown in
Figure 5.9A, although it is di cult to see how the presence of peptide would make a
di↵erence in that process. Lastly, the surplus of AMP could have been made directly
from ATP, alongside PP
i
- this would however contradict the observation that more PP
i
is made when the peptide is present than when it is absent (Figure 5.4). On the current
time scale (earliest point at 15 s after reaction started), a definite lag in AMP production
behind that of ADP was not identified. It is therefore uncertain whether AMP was made
exclusively from ADP hydrolysis, or originated from both ATP and ADP.
Taken together, the results descried in this section confirmed that MicD is capable of
heterocyclizing peptide via a process that involves the transfer of a  -phosphate group,
and provided a convincing account for the generation of AMP that complies with this
mechanism. The discovery of ADP hydrolysis into AMP, however, further compounded the
author with regard to the origin of PP
i
, which was originally thought to have derived from
the degradation of ATP into AMP and PP
i
. In addition, the observation that ATP was a
better substrate than AMP-CPP in terms of reaction rate (Figure 5.8C, D), but worse in
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Figure 5.9: 32P-labelled ATP broken down into ADP and AMP by MicD. (A) Degradation
of ATP by MicD alone. (B) Breakdown pattern of ATP when PatE2K was present in the
reaction mixture. The experiment was carried out by Dr Clarissa Czekster.
economy (fewer heterocycles produced using 10 µM ATP than 10 µM AMP-CPP) was an
interesting one. The rate di↵erence was intuitive, as substitution of the ↵, -oxygen with
the less electronegative carbon atom reduces the reactivity of the molecule. The change
in bond angle (from 120  to 109.5  - may vary due to magnesium co-ordination) could
also a↵ect how well the nucleotide binds to MicD. The apparent waste of ATP might be a
mere side e↵ect of its high reactivity, but it is not impossible that background hydrolysis
of ATP contributes to the reaction in a constructive way.
5.4.4 The E↵ect of ATP Metabolites on Heterocyclization




) on heterocyclization, AMP-
CPP (2 mM), which is not naturally broken down into ADP , AMP or PP
i
, was used











were supplemented individually to the reaction. After 16 h of reaction at 20  C, the
reaction with ATP as a substrate yielded a substantial amount of triply and quadruply
heterocyclized peptides (Figure 5.10A), whereas when AMP-CPP was used the reaction
went at a reduced rate, with the majority product being singly heterocyclized (Figure





both had an inhibitory e↵ect. It is tempting to relate this
back to the EnzChek assay (Figure 5.4) where the addition of pyrophosphatase increase
the apparent rate of reaction, and conclude that the breakdown of PP
i
expedites the
progression of heterocyclization; however, as P
i
was also shown to hinder the reaction, the
alleviation of inhibition should be minimal.
In conclusion, ATP hydrolysis does not contribute positively to heterocyclization.




as the reaction progresses, either as a result of the
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Figure 5.10: The E↵ect of ATP Metabolites on Heterocyclization. MicD (5 µM) was
reacted with 100 µM PatE2K and (A) ATP, (B) ADP, (C) AMP, (D) AMP-CPP, (E)











in 100 mM Tris pH 8.0 supplemented with 150 mM NaCl, 10 mM MgCl
2





productive (heterocyclization) or the side reaction (hydrolysis), will likely cause product
inhibition and slows down further catalysis.
5.4.5 A Unifying Mechanism
Having shown that AMP could be made from ADP hydrolysis (section 5.4.3), the origin of
PP
i
, which appears when the heterocyclase is incubated with both peptide and nucleotide,
remains unresolved. An interesting observation was made when di↵erent nucleotides were





during each reaction was monitored using the EnzChek assay. When 10 mM ATP was
included in the reaction, a large discrepancy in  A360 was seen between the samples that
contained pyrophosphatase and those that did not (Figure 5.11A), consistent with previous
observations (Figure 5.4B). In contrast, when AMP-CPP was used instead of ATP, the
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Figure 5.11: EnzChek Assay comparing the level of inorganic pyrophosphate during LynD
(5 µM) reaction with PatE2K (100 µM) and 10 mM of (A) ATP, (B) AMP-CPP, (C) ADP
and (D) ADP + AMP-CPP. Experiments were carried out in duplicates.  A360, changes
in absorbance at 360 nm. PPase, inorganic pyrophosphatase.
reading remained the same ( A360=0.022 over 600 s) with or without the addition of
pyrophosphatase (Figure 5.11B), indicating that only phosphate was produced during the
reaction. Incubation with ADP gave rise to residual level readings only (Figure 5.11C),
as it is not a substrate of heterocyclization. An interesting result was seen when AMP-
CPP and ADP were both incubated with LynD and PatE2K (Figure 5.11D). The rate
of phosphate release without added PPase was suppressed (compared to Figure 5.11B),
suggesting that very little inorganic phosphate was produced. Upon the addition of
PPase, phosphate release resumed to a level similar to when AMP-CPP alone was used as
substrate ( A360=0.023 over 600 s). As neither AMP-CPP nor ADP could be hydrolysed
to yield pyrophosphate, it must have arisen from a di↵erent mechanism. It should be noted
that this level of increase in A360 needs 14.6 µM P
i
to be reacted with MESG, but only
7.3 µM PP
i
. Therefore, the consumption rate of AMP-CPP was around half of what it
was when ADP was not supplemented.
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Figure 5.12: MALDI-MS analyses of PatE2K (100 µM) that have been reacted with MicD
(5 µM) and (A)10 mM AMP-CPP or (B) 10 mM AMP-CPP + 10 mM ADP.
The rate of heterocyclization with AMP-CPP as substrate, with and without the
addition of ADP, was then measured. Data from Figure 5.10 (D and F) showed that
adding 2 mM ADP to 2 mM AMP-CPP did not change the level of heterocyclization of
PatE by MicD after 16 h of reaction, compared to when AMP-CPP alone was added.
After raising the concentrations to match the EnzChek assay (10 mM AMP-CPP plus
10 mM ADP), at which level PP
i
appeared to be made (Figure 5.11), the reaction was
subjected to MALDI-MS analysis. The overall pattern was still the same (Figure 5.12) as
when 10 mM AMP-CPP only was supplied, with the singly heterocyclized peptide being
the dominant species. The intensities of the peaks corresponding to multiple dehydrations
increased relative to that of the singly heterocyclized species, but so did the peak for the
unmodified peptide. These increases were therefore at least partly due to variations in
ionisation strengths, rather than an actual change of the degree of heterocyclization. It
might be interesting to carry out a quantitative study on a shorter time scale to show
whether the change in phosphate chemistry indicated by Figure 5.11 alters reaction rate.
Another unexpected, but interesting observation was the frequent appearance of a peak
at around 7106 Da, when PatE2K that have been reacted with AMP-CPP was subjected
to MADLI-MS (Figure 5.13). This peak does not match that of PatE2K with a phosphate
adduct and was originally believed to be enzyme-derived. However, it was present only
when AMP-CPP (but not ATP) was supplied as phosphate donor, regardless of the enzyme
used, and hence noteworthy to future investigators.
Based on our observations we devised a hypothesis (Figure 5.14) for pyrophosphate
formation when AMP-CPP and ADP are incubated with PatE2K and LynD: first,
the  -phosphate of AMP-CPP is used to phosphorylate the precursor peptide; this
phosphate, instead of being hydrolysed, is redirected to the  -phosphate of ADP, yielding
PP
i
and AMP. For AMP-CPP, this process could take longer than the hydrolysis
of the phosphorylated hemiorthoamide, as ADP needs to replace AMP-CP, while for
ATP the delay would be smaller, with ADP already optimally located after the first
phosphorylation. Whether or not it is mechanistically beneficial for heterocyclization, this
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Figure 5.13: MALDI-MS data from (A) Figure 5.2B and (B) Figure 5.3A replotted to
show a wider mass range. The black arrows point to the unknown peak that frequently
comes up in AMP-CPP reactions.
importantly those that contain a peptide derived oxygen (shown via 18O-labelling, [64]).





as products of YcaO-catalysed azoline formation.
5.5 Discussion
The work described in this chapter dissected the ATP requirements of cyanobactin
heterocyclization and analysed it in details. The experiments with ATP analogues (Figure
5.2) strongly suggest that the heterocyclase employs a kinase mechanism. This is further
supported by the HPLC-MS results (Figure 5.8) and the radioactive assay results (Figure
5.9) which show the production of ADP, and its subsequently degradation into AMP.
With the origin of AMP explained, the only observed metabolites that could not
have been generated by the kinase followed by ADP-hydrolysis mechanism was inorganic
pyrophosphate. A transphosphorylation hypothesis was therefore proposed, which
provides a plausible account for the presence of PP
i
following heterocyclization. Current
evidence suggests this could indeed happen: the combination of AMP-CPP and ADP,
neither of which can be broken down to yield PP
i
on its own, led to the observation of
PP
i
when incubated with LynD and PatE2K (Figure 5.11). It might be worth employing































































Figure 5.14: Schematic illustration of the cyclodehydration of a cysteine residue via the
proposed kinase-transphosphorylation mechanism. (A) Formation of a hemiorthoamide
intermediate from a cysteine residue; (B) phosphorylation of the hemiorthoamide; (C)
transphosphorylation between the phosphorylated hemiorthoamide ; (D) formation of
thiazoline, AMP and inorganic pyrophosphate.
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detect ATP and metabolites [65]), to confirm the production of PP
i
from the reaction.
To further validate that PP
i
is derived from both AMP-CPP and ADP, labelling of the
 -phosphate of the former and/or the  -phosphate of the latter might be required.
It is intriguing why such a process would have evolved to take place. The
hydrolysis of ADP could yield energy, but formation of the unstable pyrophosphate
would be energetically costly. Moreover, the transfer of a phosphate group onto
the hemiorthoamide (Figure 5.14C) already introduces a good leaving group whose
elimination creates the five-membered the ring structure of azolines, making it di cult
to see how transphosphorylation would be preferred over simple hydrolysis. Yet if the
phosphate donated by AMP-CPP can be transferred onto the  -phosphate of ADP, the
phosphorylated hemiorthoamide must be stable enough to allow the release of AMP-CP
and the binding of ADP. The observation of such an intermediate would provide a strong
piece of evidence for this mechanisms. It is possible that cyanobactin heterocyclases
are configured in a way that protects the phosphorylated intermediate, poising it for
transphosphorylation, while other YcaO-family heterocyclases, which do not produce
PP
i
[69], are not. Although adding ADP to the AMP-CPP reaction did not accelerate
heterocyclization, the duo was not a perfect mimic of ATP, owing to issues such as
AMP-CP displacement. When ATP is used, the process may take place more readily.
Computational analysis of the energy landscapes surrounding heterocyclization and
transphosphorylation, and a structure of the ternary complex between enzyme, peptide
and nucleotide might provide insights into the situation.
In summary, not only does the kinase-transphosphorylation mechanism provide





heterocyclases, it has revealed a previously uncharacterised type of phosphate chemistry.
Precautions should be taken, however, in ascertaining the significance of the discovery.
Apart from the recommendations for further experiments stated above in this section, it
would be worth checking other types of YcaO enzymes, such as the enigmatic E. coli YcaO
protein, which is known to produce AMP and PP
i
[72].
5.6 Summary of Work on Cyanobactin Enzymes
Before moving onto Chapter 6, which describes the study of an enzyme involved in
histidine biosynthesis, it is perhaps pragmatic that the work laid out in this and the
three preceding chapters is summarised. These chapters describe investigations into
the fundamental biochemistry of several post-translational modification enzymes from
cyanobactin biosynthetic pathways, and biotechnological applications based upon such
research. The similarities and di↵erences between these PTMEs are a reflection of one of
the strategies used by biological systems to generate diverse secondary metabolites, that is,
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ribosomal production of peptides followed by post-translational modifications. Diversity
arises partly through combinations of di↵erent PTMEs, but even highly homologous
enzymes, such as PatD and TruD (both heterocyclases), could carry out di↵erent
modifications on the same precursor peptides. This diversity-generating functional
variation in also seen in the oxidases and the prenylases, as discussed in Chapter 1. Despite
our e↵orts, the mechanistic di↵erences in homologous enzymes have not been deciphered
on a molecular level, and may be of interest to future researchers.
On a broader scale, there are much more to be understood about PTMEs involved in
RiPP biosynthesis. Not only are novel proteins and domains widely present in biosynthetic
clusters, the ones with seemingly apparent functions are often found inactive. Through
studies of the peptide clamp domain in the cyanobactin heterocyclase and oxidase, we show
that the former is active while latter is vestigial, an observation that cautions against
automatic assignment of protein functions. As commercial interests in RiPPs and the
development of genome mining tools have accelerated the discovery of biosynthetic clusters
through bioinformatics, an ever expanding myriad of PTMEs will provide exciting targets
for academic studies and industrial exploitations alike.
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Chapter 6




L-Histidine is produced by bacteria, archaea, fungi and plants via a common 10-step
biosynthetic pathway. ATP phosphoribosyltransferase (ATPPRT) is the first enzyme of
this pathway and the key point of regulation, as it is inhibited by the end-product histidine
and cellular metabolites such as AMP. ATPPRT’s catalytic activity is encoded by the
gene hisG, which exists in a long form (HisG
L
) and a short form (HisG
S
). The long
form contains a regulatory domain in addition to the catalytic domain, which responds to
histidine inhibition, while the short form has a partner protein (HisZ) that allosterically
activates it and provides a di↵erent allosteric site for histidine inhibition. Although His
L
is
well characterised, understanding of HisG
S
is limited. This work describes the purification
and crystallisation of the proteins HisG and HisZ from Psychrobacter arcticus, which form
a hetero-octamer consisting of four copies of each protein.
6.2 Introduction
6.2.1 Overview of Histidine Biosynthesis
L-Histidine (histidine) is one of the 20 canonical amino acids used to build proteins in all
living organisms. Its uniquely versatile role as both an acid and a base at neutral pH makes
it one of the commonest active site residues. While mammals have to acquire histidine
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through diet, plants, bacteria, fungi and archaea have a common histidine biosynthetic
pathway that is essential to their survival [172–175]. Enzymes from this pathway therefore
provide potential targets for the development of drugs against pathogenic microorganisms,
such as Mycobacterium tuberculosis and Salmonella typhimurium, that exert minimal
e↵ects on their human hosts.
The histidine biosynthetic pathway involves 10 catalytic steps (Figure 6.1), starting
from the compounds adenosine triphosphate (ATP) and phosphoribosyl pyrophosphate
(PRPP). The reactions on the pathway are conserved across kingdoms, although
genetic variations exist between organisms. ATP and PRPP are condensed by the
enzyme ATP phosphoribosyltransferase (ATPPRT), product of the gene hisG, to
generate phosphoribosyl-ATP (PR-ATP) and inorganic pyrophosphate (PP
i
) [176]. PR-
ATP is subsequently hydrolysed to phosphoribosyl-AMP (PR-AMP), by a PR-ATP
pyrophosphatase, encoded by the gene HisE. and then turned into 1-(5-phosphoribosyl)-5-
[(5-phosphoribosylamino) methylideneamino] imidazole-4 carboxamide (5’ProFAR) by the
PR-AMP cyclohydrolase HisI, which breaks the bond between the N1 and C6 atoms of the
adenine ring [177]. In organisms like E. coli and S. typhimurium, HisE and HisI are fused
into a bifunctional enzyme, while in Actinobacteria such as Corynebacterium glutamicum
they form separate polypeptides [178]. The fourth step of histidine biosynthesis
is catalysed by HisA, which isomerises 5’ProFAR into 5-[(5-phospho-1-deoxyribulos-1-
ylamino)methylideneamino]-1-(5-phosphoribosyl)imidazole-4-carboxamide (PRFAR), via
an internal redox reaction called Amadori rearrangement[177]. PRFAR is then split
into two parts. The ATP-derived structure gives rise to 5-aminoimidazole-4-carboxamide
ribonucleotide (AICAR), which can be recycled by the de novo purine biosynthesis
pathway. The rest of the molecule receives an amino group from glutamine to form
imidazole-glycerol phosphate (IGP). This reaction is cataylzed by the IGP synthase,
a heterodimer formed by the proteins HisF and HisH [177]. However, research by
Kulis-Horn and colleagues suggested that C. glutamicum does not require the glutamine
amidotransferase HisH, when growing in medium containing ammonia [178]. In the sixth
step of the pathway, IGP is dehydrated by the HisB protein, and the enol intermediate
is then non-enzymatically ketonised to imidazole-acetol phosphate (IAP). The oxygen is
subsequently displaced with an amino group, donated by L-glutamate, yielding L-histidinol
phosphate (Hol-P). Hol-P phosphatase HisN then hydrolyses the phosphate group of Hol-
P. In E. coli and S. typhimurium, HisN and HisB are encoded by the same gene, hisNB, as
a bifunctional enzyme, but in C. glutamicum they are encoded separately. The product,
L-histidinol then undergoes two oxidations by the histidinol dehydrogenase HisD, giving














































































































































































































































de novo purine biosynthesis
HisB
Figure 6.1: Schematic illustration of the histidine biosynthetic pathway. Substrates,
products and key intermediates are highlighted in black boxes.
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6.2.2 ATP Phosphoribosyltransferase
Adenosine 5-triphosphate phosphoribosyltransferase (ATPPRT, EC 2.4.2.17) is the first
dedicated enzyme in histidine biosynthesis, catalysing the condensation of ATP and PRPP
to generate PR-ATP and inorganic pyrophosphate (PP
i
) [176]. It is found in a wide range
of organisms including fungi, plants, bacteria and archaea, encoded by the gene hisG.
ATPPRT is the key regulatory point of histidine production which responds to metabolic
status of the cell/organism signalled by histidine, AMP and ADP levels [176, 179, 180]. In
Arabidopsis the availability of ATPPRT has been shown to be the most important factor
in controlling histidine levels, while that of other biosynthetic enzymes had very limited
e↵ects [181].
There are two major types of the catalytic protein HisG - the long form HisG
L
and
the short form HisG
S
. Biochemical properties of HisG
L
are well characterised [176, 179,
180, 182–192], having been subjected to investigation since mid 20th century. In addition,
multiple molecular structures are available from di↵erent organisms with a range of ligands
[189, 191, 193, 194]. The HisG
L
protomer consists of a catalytic subunit and a regulatory
subunit, the latter providing a histidine binding site involved in allosteric inhibition [193].
It was originally thought that the enzyme is active in its homodimeric form, but forms
an inactive homohexamer when the concentration of either the enzyme or histidine was
high [193]. Later reports [188–190] however showed that both the active and inactive
enzyme forms are predominantly hexamers in solution, with ligand-induced conformational
changes, rather than variations in quaternary structure, being responsible for inhibition.
More recently, crystal structures of the Medicago truncatula ATPPRT (HisG
L
) captured
the enzyme in a relaxed and a tense state, corresponding to the free (active) and the
histidine-bound forms, respectively [195].
On the other hand, relatively little was known about HisG
S
. Lacking the the regulatory
domain, HisG
S
does not bind histidine, but instead forms a equimolar hetero-octameric
complex with a partner protein, HisZ, which activates HisG
S
while simultaneously
rendering it susceptible to histidine inhibition. HisZ is a paralogue of histidyl-tRNA
synthetase [196, 197], although no activity of HisZ itself has been reported. Prior to
this study, it was believed that HisG
S
is active only as the hetero-ocatmeric holoenzyme
[196–198]. Now it has been demonstrated that HisG
S
is also active as a homodimer,
albeit showing reduced e ciency [199, 200]. Due to the insensitivity to histidine
inhibition brought by the absence of HisZ, the homodimeric form of the enzyme displays
increased potentials as a biocatalyst compared to the hetero-octameric holoenzyme and
HisG
L
. Two crystal structures of short form ATPPRTs were available (Figure 6.2), both
hetero-octamers, from Lactococcus lactis [196] and Thermotoga maritima [197]. In both
structures, HisG and HisZ are organised in dimers. Two dimers of HisZ pair up in an
crossed-over manner and form the core of the octamer, while one pair each of HisG dimer
124
ATPPRT from L. lactis (PDB: 1z7n)
PRPP-bound






Figure 6.2: Structure of ATPPRT from (A) Lactococcus lactis (PRPP-bound, PDB: 17ZN)
and (B) Thermotoga maritima (histidine-bound PDB: 1USY). HisG and HisZ subunits are
shown in green and magenta, respectively. Black dashed boxes highlight the bound ligands.
occupy on the top and bottom of this core.
A recent study showed that both forms of ATPPRT operate via the same transition




, despite their di↵erent modes
of regulation.
6.2.3 Aims and Objectives
The work described in this chapter was carried out in order to determine the molecular
structure of ATPPRT from Psychrobacter arcticus, a cold adapted enzyme that was first
isolated from Siberian permafrost. The hisG gene in this organism encodes a short form
HisG, and a hisZ gene is present. As the two existing structures of HisG
S
-type ATPPRT
are from mesophilic [196] and thermophilic [197] organisms, a cold-adapted version of this
enzyme would be a valuable addition to the understanding of the family. This project
was carried out in collaboration with Dr Rafael da Silva’s group, the members of which
characterised PaATPPRT kinetically.
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6.3 Materials and Methods
6.3.1 Expression and Purification of PaHisG and PaHisZ
Condon-optimised genes encoding P. arcticus HisG and HisZ were purchased from DNA
2.0 on a pJexpress431 and a pJexpress414 vector, respectively. The plasmid for PaHisG
was transformed into E. coli C43 (DE3) cells, and recovered from an LB-kanamycin agar
plate. A single colony was inoculated into 100 ml LB broth supplemented with 50 µg/ µl
kanamycin and incubated at 37  C for 16 h, before 10 ml of which was transferred to 1
litre of fresh LB-kanamycin medium. The culture was incubated at 37  C until its OD
600
reached 0.8, at which pointed the temperature was lowered to 16  C . ITPG (to the final
concentration of 1 mM) was added to the culture after 30 min of equilibration at 16  C,
and the cells were allowed to overexpress the protein for 20 h. Cells were harvested by
centrifugation at 8983 g for 15 min and stored at -80  C. The expression construct for
PaHisZ was transformed into E. coli BL21 (DE3) cells, and a single colony recovered from
LB-kanamycin agar plates was inoculated into 100 ml LB broth supplemented with 100 µg/
µl ampicillin. After growing at 37  C for 16 h, 10 ml of the seed culture was transferred to
1 L of fresh LB-ampicillin medium. The incubation, expression and harvest methods were
identical to those used for PaHisG. Both constructs contained an N-terminal cleaveable
TEV protease site.
PaHisG and PaHisZ were purified separately and all steps were carried out at 4  C
or on ice. Cells were resuspended in HisG/Z lysis bu↵er (50 mM HEPES, pH 8.0, 10
mM imidazole and 500 mM NaCl), supplemented with 0.2 mg/ml lysozyme, 0.4 mg per
g of cell DNase and 1 tablet of complete EDTA-free protease inhibitor (Roche) per 50 ml
of suspension. The lysate was passed through a cell disruptor (Constant Systems) at 30
kpsi and clarified by centrifugation at 48384 g for 20 min at 4  C, followed by filtration
through a Millipore nitrocellulose membrane with a pore size of 0.45 µm (Sigma). Filtered
lysate was applied to a Ni-NTA column (GE Healthcare), equilibrated with lysis bu↵er,
and eluted with a gradient of 0-60% HisZ/G elution bu↵er (50 mM HEPES, pH 8.0,
500 mM imidazole and 500 mM NaCl) over 20 min. Elution fractions were subjected to
SDS-PAGE analysis and those that contained the protein of interested were collected and
dialysed into HisG/Z dialysis bu↵er (20 mM HEPES, pH 7.5, 150 mM NaCl, 2 mM DTT,
10% Glycerol). TEV protease (1:10 mass ratio) was added for the removal of his-tag.
The cleavage processed was carried out at 4  C for 6 days, with one changes of bu↵er
in between and finally re-dialysed into HisG/Z lysis bu↵er. The portein was then passed
through a second Ni-NTA column equilibrated with HisG/Z lysis bu↵er. The flow-through
was collected, concentrated and dialysed into 20 mM HEPES, pH 8.0, before being flash
frozen and stored at -80  C. The identity and purity of the proteins were confirmed by
SDS-PAGE and mass spectrometry.
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6.3.2 Crystallisation of PaATPPRT
Purified PaHisG and PaHisZ were mixed at a 1:1 molar ratio and subjected to PCT
pre-crystallisation test (Hampton Research) to determine the optimum concentration
for crystallisation. The protein mix was concentrated to 8 mg/ml and mixed with
various concentrations of ATP, NaCl, MgCl
2
and or L-histidine, before being subjected to
stochastic screening in 96-well Intelli-Plates Gryphon crystallization robot (Art Robbins
Instruments), with protein:precipitant mixed at 1:1 and 2:1 volume ratios. Hits were
visualised on a Rigaku Minstrel HT UV instrument. The protein bu↵er used which yielded
di↵racting crystals was 20 mM Tris-HCl, pH 7.0 supplemented with 50 mM KCl, 10 mM
ATP, 10 mM MgCl
2
, 2 mM DTT and 0.5 mM L-histidine. Initial hit was obtained in 0.1 M
Bicine pH 8.5, 15.73% PEG 3350, 0.12 M CaCl
2
, and 2.16% 1,6-hexanediol. Optimisation
was carried out using the hanging-drop vapour-di↵usion method in 24-well plates with
protein and precipitant mixed in a 1:1, 1:2 and 2:1 volume ratios. Crystals (0.3 mm x 0.1
mm x 0.1 mm) were obtained from the optimised condition (0.1 M Bicine pH 8.5, 11%
PEG 3350, 0.15 M SrCl2, 0.15 M KBr, and 2% 1,6-hexanediol) after growing for 21 days
at 4  C.
6.3.3 X-ray Data Collection and Processing
Crystals were cross-linked by vapour di↵usion with a 25% (v/v) aqueous solution of
glutaraldehyde for 1 h prior to being cryoprotected in 15% 2,4-methylpentanediol (MPD)
freshly prepared in a reservoir solution and then flash-cooled in liquid nitrogen. Di↵raction
data were collected on a Rigaku 007 MM HFM generator with a Saturn 944+ CCD
detector. Data were processed with iMosflm [201] and scaled with Aimless [202].Matthews
coe cient [203] calculations indicated that the asymmetric unit contained four copies
each of PaHisG and PaHisZ. The structure was determined using molecular replacement
(with the help of Dr Garib Murshudov, University of Cambridge) employing the Phaser
programme [204] from the CCP4 Suite [205]. The following 3 structures were used as
search models: Protein Data Bank (PDB) entries 1Z7M (L. lactis ATPPRT, containing
both subunits) [199], 2VD2 (HisG homologue from Bacillus subtilis , unpublished), and
3OD1 (HisZ homologue from Bacillus halodurans, unpublished). CCP4 Buccaneer [206]
was used to assign the majority of correct side chains to the PaATPPRT model. Missing
side chains and residues were added with Coot [207] and the model was refined with
Refmac [208].
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6.3.4 In-solution Cross-Linking of PaHisG and PaHisZ
PaHisG (40 µM), PaHisZ (40 µM) and an equimolar mixture of the two proteins (40 µM
each), in the bu↵er 100 mM HEPES pH 8.0, 100 mM KCl, 10 mM MgCl2 and 4 mM
DTT, were applied to a coverslip and sealed in a 24-well crystallisation plate. A solution
of 25% glutaraldehyde was also applied to the coverslip and used to cross-link to proteins
via vapour di↵usion at 4  C for 16 h. The process was repeated with 2 mM ATP, 1 mM
histidine or both added to the protein bu↵er, and with elevated protein concentrations
(133 µM, concentration used crystallisation). The cross-linked proteins, along with an
uncrosslinked 1:1 mixture of PaHisG and PaHisZ (40 µM or 133 µM each), were analysed
by SDS-PAGE on a NuPAGE Novex 4-12% Bis-Tris gel (Invitrogen) against the Precision
Plus Protein Dual Color Standards (Bio-Rad) marker.
6.3.5 Multiangle Light Scattering Analysis of PaHisG
To determine the oligomeric status of PaHisG in solution, purified PaHisG (3.3 mg) was
subjected to size exclusion chromatography (SEC) on a HiLoad 16/600 Superdex 200 pg
column (GE healthcare) equilibrated in 20 mM HEPES pH 8.0. The sample was eluted
in the same bu↵er at a flow rate of 1 ml/min. The flow was passed through and analyzed
by multi-angle light scattering (MALS) detector DAWN HELEOS-II and refractive index
detector Optilab T-rEX (Wyatt Techonologies). The elution peak, shown as changes
in refractive index, was divided into 1 mL fractions in the ASTRA 6.1 software (Wyatt
Techonologies) for calculations of molecule size in mean square radius (nm2) and molecular
mass.
6.4 Results
6.4.1 Purification of PaHisG and PaHisZ
PaHisG (25.2 kDa) and PaHisZ (43.1 kDa) were purified to homogeneity by Nickel
a nity chromatography, followed by TEV-cleavage of the N-terminal His-tag and a second
Nickel column. The purified samples were subjected to SDS-PAGE (Figure 6.3) and mass
spectrometry to confirm their purity and identity. Size-exclusion chromatography was not
performed as both subunits were assumed to be in an equilibrium of di↵erent oligomeric
status, which will change upon mixing.
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Figure 6.3: SDS-PAGE analysis of PaHisG and PaHisZ.
Figure 6.4: Crystallisation of PaATPPRT. (A) Crystals from the initial hit condition; (B)
a crystal from the optimised condition (size 0.3 mm x 0.1 mm x 0.1 mm).
6.4.2 Crystallisation of PaATPPRT
A 1: 1 molar mix of PaHisG and PaHisZ (8 mg/ml) was subjected to stochastic screens,
and initial crystals (Figure 6.4A) were found in the condition 0.1 M Bicine pH 8.5,
15.73% PEG 3350, 0.12 M CaCl
2
, and 2.16% 1,6-hexanediol. These crystals exhibited
two di↵erent morphologies, a relatively long but flat one, and a hexagonal cylindrical one.
The crystallisation condition was optimised to 0.1 M Bicine pH 8.5, 11% PEG 3350, 0.15
M SrCl
2
, 0.15 M KBr, and 2% 1,6-hexanediol, in which larger crystals formed (Figure
6.4B). Crystals grown in this condition were of the elongated form, but has increased in
thickness. The crystal shown in Figure 6.4B was 0.3 mm x 0.1 mm x 0.1 mm in size.
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A B
Figure 6.5: Structure of ATPPRT from Psychrobacter arcticus (PDB: 5M8H). HisG
subunits are coloured in red and magenta; HisZ subunits are coloured in blue and cyan.
(A) front view; (B) top view.
6.4.3 Crystal Structure of PaATPPRT
The three-dimensional structure of the PaATPPRT was determined and refined to 2.34
Å resolution. Refinement statistics are summarised in Table 6.1, and atomic coordinates
were deposited in the PDB as entry 5M8H. Four copies each of HisG and HisZ formed a
hetero-octamer, arranged in the same architecture as the L. lactis and the T. maritima
ATPPRTs (Figure 6.2). Two HisZ dimers form the middle section of the complex, while
two dimers of HisG cover the top and bottom of the structure (Figure 6.5). Although
10 mM ATP and 0.5 mM histidine were present in the crystallization mixture, no clear
electron density was observed for either ligand. Density for glutaraldehyde was not also
not observed, suggesting that the proteins may not have been cross-linked in the crystal.
6.4.4 HisG Subunits
The four HisG molecules in this complex are homologous and overlay with an r.m.s.d. of
0.32, 0.18, and 0.38 Å over 208 C↵ atoms, when comparing chain E to chains F, G and H,
respectively. PaHisG displays two domains (Figure 6.6A). Domain 1 comprises residues
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Table 6.1: Crystallographic data and refinement statistics of PaATPPRT. Numbers in
































hkl being the observed and calculated structure








resolution (Å) 30.63-2.34 (2.38-2.34)
total no. of reflections 390223
no. of unique reflections 110587
multiplicity 3.5 (2.4)

















no. of reflections (working set) 105092








rmsd for bond distances (Å) 0.010
rmsd for bond angles (deg) 1.438
no. of molecules per asymmetric unit 4 HisG , 4 HisZ
no. of protein atoms 18229
no. of ligands 37
no. of water molecules 629









1-115 and 197-228, whilst residues 115-197 (residues preceding E20 are disordered and
have not been included in this model) form the second domain (domain 2). Domain 1 has
6  -stranded core surrounded by 5 ↵-helices. The central  1 forms a 3-stranded parallel
sheet with  3 and  4, each of which in turn form 2 small anti-parallel sheets in conjunction
with the lateral strands ( 2- 3; and  4- 9- 5). These sheets are encircled by helices ↵1,
↵2, ↵3, ↵7, and ↵8. Domain 2 displays a similar global fold, with 5  -strands arranged
as a 3-stranded parallel sheet ( 7- 6- 8) and a 3-stranded antiparallel sheet ( 8- 5- 9).
The strands are sandwiched between ↵4 on one side and ↵5 and ↵6 on the other.  5
and  9 are common to both domains. Overlaying domain 2 on to domain 1 results in an
r.m.s.d. of 3.5 Å over 95 C↵ atoms, despite the architectural similarities between the two.
Each of the two homodimers of HisG in the HisGZ complex comprises a head to
tail arrangement (Figure 6.6B), with domain 1 of monomer 1 interacting with domain
2 of monomer 2, and vice versa. The PISA server [210] gave a CSS score of 0.343
between subunits E and H (CSS scores vary from 0, which indicates no interaction, to
1, which means the interactions are essential to complex formation). The interactions
cover approximately 1190 Å2 of surface from each monomer, equivalent to 10.8% of the
solvent-accessible area. 31 residues (Figure 6.6C) contribute to the interface, mainly from
↵2,  2,  3,  7, and ↵5. R73 (chain E only), D76, Y159, and G170 formed a hydrogen
bond network (Figure 6.6F), while hydrophobic residues including L58, I59, L70, L72,
Y80, A85 from domain 1, and L164, V168, and L170 from domain 2 were buried by the
interface.
Residues 163-184 of PaHisG forms a conserved ATPPRT signature motif (identified
by PROSITE [211]) that contains the phosphate-binding P-loop (residues 179-183) - a
commonly found motif in ATP and GTP-binding proteins. Although the electron density
observed was insu cient for substrates to be modelled in the structure, the location of
the active site can be inferred from that identified in homologues, to lie in a crevice
between domain 1 and domain 2 (Figure 6.6E). Side chains that interact with PRPP in
the LlATPPRT structure [196], are conserved in PaHisG (Figure 6.6F), namely E142,
D155, E158, T159 and T162 (E163, D176, D179, T180, T183 of PaHisG).
6.4.5 HisZ subunits
The four HisZ molecules overlay with an r.m.s.d. of 0.80, 0.92, and 0.13 Å (chains B,
C and D, respectively, compared to chain A). PaHisZ comprises two distinct domains
(Figure 6.7A), an N-terminal domain (residues 1-318) and a C-terminal domain (residues
324-387), connected by an elongated loop. The four HisZ molecules are arranged in two
homodimers (Figure 6.7B) in the centre of the hetero-octameric complex. As well as an
extensive N-terminal interface, the C-terminal domain from each HisZ molecule crosses



































Figure 6.6: The PaHisG Subunit. (A) Secondary structures in PaHisG assigned by
STRIDE [209]. ↵1-↵8 designates ↵-helices while  1- 9 denotes  -strands. The molecule is
coloured on a reverse rainbow spectrum from N- to C-terminus. Labels are coloured black
or white for illustrative clarity. (B) Dimer of PaHisG shown as chain E (red) and chain
H (purple) of PDB entry 5M8H. (C) Residues involved in the homodimeric interface, as
identified by the PISA server [210]. (D) Residues participating in hydrogen bonding at
the interface. Black dotted lines represent hydrogen bonds. (E) Alignment with LlHisG
(white, PDB: 1Z7N, chain F), showing the location of the active site. (F) Active site
residues in LlHisG (residues in white sticks and labels in black) and PaHisG (residues in







































Figure 6.7: The PaHisZ Subunit. (A) Secondary structures in PaHisZ assigned by
STRIDE [209]. ↵,   and ! denote ↵-helices,  -strands and 3-10 helices, respectively.
The molecule is coloured on a reverse rainbow spectrum from N- to C-terminus. Labels
are coloured as the secondary structure they represent. (B)The HisZ homodimer between
chain A (blue) and chain C (cyan). (C) Overlay of PaHisZ (cyan), LlHisZ (1Z7N, yellow)
and human HisRS (1WU7, green), showing that LlHisZ lacks the CTD that is common
to the other two. (D) Overlay of CTDs of PaHisZ (cyan) and human HisRS (green).
When viewing the PaATPPRT as a whole, C-terminal domains of HisZ face outwards
(Figure 6.5B), and have few interactions with other parts of the enzyme.
In each HisZ subunit, a six-stranded anti-parallel  -sheet ( 5- 6- 11- 10- 9- 7) core,
flanked by two smaller strands ( 1,  8) parallel to either end, forms the centre of the
N-terminal domain, with  1 on the homodimeric interface side and  8 near the periphery
of the complex. The sheets are embraced by eight alpha or 3-10 (denoted with ‘!’) helices
(↵1, ↵5-9, !10, !11 and ↵12), which occupy the peripheral side of the subunit, forming a
bowl-like structure. Three long alpha helices, (↵1, ↵5 and ↵12) runs along the bottom (as
in Figure 6.7A) of the beta sheets, while the smaller helices (↵6-9, !10 and !11) stacks on
top of ↵12 in two columns, forming an L-shaped corner and extending to the other side
of the  -sheet core. On the other side of the beta sheet core is another alpha helix (↵4)
and above it a 2-helices (↵2, ↵3) and 3-strands ( 2-4) insertion. The C-terminal domain
134
comprises 4  -sheets ( 12-15), and 2 ↵-helices (↵14-15).
PISA server gives the HisZ homodimer a relatively low interface score of 0.231 (chains
C and A), despite the apparently entangled arrangement of the two monomers and the
involvement of both the CTD and the NTD. The interface covers 3313.7 Å2, which accounts
for 15.6% of the solvent-accessible area. A total of 30 hydrogen bonds and 27 salt bridges
are involved in homodimer interactions. Interface residues are clustered in both the N-
and C- terminal areas, mainly in the regions 1-134 and 352-369, with only one exception
(N248).
HisZ has shown evolutionary links with the aminoacyl(histidyl)-tRNA synthetase
HisRS [212]. Interestingly, nine out of the ten top hits from the DALI server (identifies
structural homologues) [213] are HisRSs. The structure of PaHisZ resembles several of
these protein, such as 3OD1 from Thermoplasma acidopilumand and 1WU7 from Homo
Sapiens, more than it does L. lactis (1Z7M) T. maritima (1USY) HisZs. The main
di↵erence between LlHisZ/TmHisZ and PaHisZ is that PaHisZ is longer than the other
two, with the additional residues corresponding to its CTD, which is absent in the other
two HisZs that have been structurally characeterised (Figure 6.7C). The CTD of PaHisZ
overlays with that of HsHisRS with an r.m.s.d of 0.87 over 93 C↵ atoms (Figure 6.7D).
It is unclear what function does C-terminal domain serve in PaHisZ; most likely it is an
evolutionary remnant from a common ancestor with HisRS.
6.4.6 HisG-HisZ Interface
Each of the four HisZ subunits form contacts with two HisG subunits that are homodimeric
partners with one another (Figure 6.8A). The NTD of HisZ interacts with domain 1 of
one HisG and domain 2 of the other. Neither group of interactions were very extensive,
with PISA giving a CCS store of 0.025 to the first group and 0.012 to the second. The
total interface area between HisZ and domain 1 and 2 of HisG are around 850 Å2 and 350
Å2, respectively. Multiple hydrogen bonds and salt bridges were found at both interfaces
(Figure 6.8B), involving residues K93, N102, Y105, E106, Q206, K210, K244 of HisG and
D155, A184, N185, K186, L188, E190 and D256 of HisZ at one site, and residues P3, D12
(HisZ) and N129, Q152 (HisG) at the other. Additionally, multiple hydrophobic residues,
primarily from HisG, are buried in the surface, contributing to the binding between the
subunits.
6.4.7 B-Factor Analysis of PaATPPRT
Enzymes from psychrophilic organisms must adapt to maintain catalytic activity within
cold environments, as chemical reaction rates decrease with temperature; for a mesophilic
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Figure 6.8: Interface Between PaHisZ and PaHisG Subunits. (A) Interfaces are found
between HisZ (cyan) and domain 1 of one HisG subunit (red) and domain 2 of its partner
(magenta). (B) Interface between HisZ (green) and HisG (red and brown) subunits
showing interactions between residues. Black dotted lines indicate polar contacts. (B)
was created by Dr Magnus Alphey.
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enzyme, the impairment on rate can be up to 250-fold when the temperature drops from
37  C to 0  C [214]. Reactions catalysed by cold-adapted enzymes tend to have a lower
activation enthalpy and a more negative entropy [215–217], which reduces the e↵ect of
temperature on their reaction rates, but the structural basis of these thermodynamic
adaptations are not fully understood. It is thought that global or local (active site)
flexibility could contribute to increase activity, and the choice between these two strategies
may lie in the size of the substrate, with enzymes using larger substrates exhibiting global
flexibility, and vice versa [214, 218]. An alternative, emerging theory based on computer
simulations states that increased flexibility at protein surfaces, rather than the active site,
is key to cold adaptation [219, 220].
The distribution of B-factors throughout the PaATPPRT holoenzyme was analysed on
shown in Figure 6.9. Overall the hetero-octamer appears to be ‘hotter’ on the outer side
Figure 6.9A. The inflexible regions are concentrated in the HisZ subunits, which situate
in the middle of the protein. Within a HisZ subunit (Figure 6.9C), it is ‘colder’ in the
core and normal on the peripherals. The catalytic subunit, HisG, (Figure 6.9B) is more
flexible. However, within this subunit the outer regions again appear to be ‘hotter’ than
the active-site cleft (shown by the thickness of the ‘tube’). As both the catalytic site
and the periphery of the protein are more flexible compared to the core, it is not obvious
how much each factor contributed to the psycrophilicity of the enzyme. Computational
analysis of PaATPPRT and its mesophilic/thermophilic homologues might provide insight
on the thermodynamics of these enzymes.
6.4.8 Oligomeric Status of PaHisG and PaHisZ in Solution
To confirm that the hetero-octameric form is the active enzyme in solution, rather than a
crystallographic artefact. cross-linking experiments with glutaraldehyde were carried out.
It was presumed that if two or more subunits are in close proximity with each other in
solution, glutaraldehyde (covalently links lysines) will introduce covalent bonds between
them that are resistant to boiling and electrophoresis. HisG, HisZ or a mixture of both (40
µM each - at this concentration both HisG and the holoenzyme have exhibited enzymatic
activity [200]) were treated with glutaraldehyde via vapour di↵usion and then analysed
via SDS-PAGE (Figure 6.10). The experiments were repeated with 2 mM ATP, 1 mM
histidine, or both added to the protein to see if ligand-binding changes the oligomeric state
of the subunits. For both HisG and HisZ (Figure 6.10, left panel), the monomeric and
homodimeric forms are the most abundant after cross-linking, while higher oligomers were
also observed. The addition of ATP and/or histidine did not alter the patterns (middle
panel). When HisG and HisZ were mixed, new bands appeared (left panel, lanes 7 and
8), corresponding to the formation of hetero-oligomers. Several of the newly observed





Figure 6.9: B-factor distribution in PaATPPRT. (A) B-factor distribution throughout
the PaATPPRT holoenzyme. The protein is coloured based on b-factors on a rainbow
spectrum with higher b factors shown in warmer temperatures. The thickness of the
‘tube’ also increases with b-factor values.(B) B-factor distribution in the HisG subunit.
(C) B-factor distribution in the HisZ subunit.
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Figure 6.10: SDS-PAGE of Cross-Linked PaHisG and PaHisZ. Ctrl, uncross-linked HisG
and HisZ (mix); A, 2 mM ATP; H, 1 mM histidine; G, HisG; Z, HisZ. Bands marked with
red asterisk were subjected to MS analysis.
were identified in all of them. The most intense band located between the 50 kDa and
75 kDa markers, was mostly likely a heterodimer (calculated MW = 68.3 kDa), while
the identity of higher bands were more di cult to interpret. Regions above the 250 kDa
marker were smeared and it was not possible to see a clear band for the hetero-octamer
(273 kDa). Raising the concentration of proteins to 133 µM to match that used in the
crystallisation trials yielded highly similar results (Figure 6.10, right panel).
While the results were di↵erent to what we expected and the hetero-octameric form
was not clearly identifiable, the consistency between lower (40 µM) and higher (133 µM)
enzyme concentrations means that oligomeric states are unlikely to di↵er significantly
between the two. Later kinetic and structural studies [200, 221, 222] have shown that
allosteric activation requires that HisZ binds to HisG in the hetero-octameric fashion. The
reason for the tendency towards lower oligomers may have been due to the ine↵ectiveness
of cross-linking by glutaraldehyde. Lysine residues are found at both homodimeric (such
as K61 from HisZ and K157 of HisG) and heterodimeric (such as K186 from HisZ and K210
from HisG) interfaces in the crystal structure, but they were not seen cross-linked, even
though the crystals were treated with glutaraldehyde. On the other hand, free surface
lysine residues that are not involved in interface formations (e.g. K242 of HisZ) could
potentially be cross-linked to other non-interface residues when di↵usion of molecules
placed them in the vicinity of each other, forming complexes that showed on the SDS-
PAGE analysis but lacked physiological relevance.
Due to the observation that PaHisG alone exhibits ATPPRT activity [200], the
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Figure 6.11: SEC-MALS analysis of PaHisG. Refractive index changes when a substance
that di↵ers from the bu↵er (in this case, the protein) passes through the detector; Mean
square radius is correlated to molecular weight.
to SEC-MALS and eluted primarily as a highly homogenous peak (Figure 6.11), with a
calculated molecular mass of 47.5 kDa, close to the predicted mass of a homodimer (50.4
KDa). A small amount of higher oligomers were also present.
6.5 Discussion
The structure of PaATPPRT added to the existing family of enzymes that employ a
short-form HisG and a regulatory subunit HisZ. Although the structure described here
did not show any ligands, further work led by Alphey et al. [221] captured this enzyme in
complex with PRPP, PRPP+ATP, PRPP+ADP and PR-ATP. In the meanwhile, kinetic
analysis by Fisher et al. [222] also established that PRPP forms a binary complex with
the enzyme before ATP is able to bind. The order of binding may explain the inability to
achieve complex structures in this study.
E↵orts were also made to crystallise the enzyme in complex with histidine. The
TmATPPRT structure was histidine-bound due to the presence of histidine in their
crystallisation bu↵er. However, co-crystallisation and soaking were both attempted for
PaATPPRT, with no success; oftentimes the crystals were visibly damaged or their
di↵raction quality was significantly poorer (6 Å or worse) compared to unsoaked ones
(around 3 Å). These experiments were mainly carried out with histidine as the sole ligand
or with ATP+histidine, and on a few occasions with ATP+PRPP+histidine. It is possible




enzyme ternary complex. It could be worthwhile to determine the mode of inhibition by
histidine kinetically in addition to crystallisation experiments.
The finding that PaHisG is primarily homodimeric in solution is consistent with later
studies that crystallised it as a dimer [221]. In addition to PaHisG, LlHisG
S
[199] and a
truncated form of Campylobacter jejuni HisG
L
containing only the catalytic domains [223]
also demonstrated ATPPRT activities. Due to the absence of histidine inhibition, these
enzymes could potentially be exploited as biocatalysts for histidine synthesis. PaHisG
may have a particular advantage in this aspect as psychrophilic enzymes tend to have
higher activities at lower temperatures, which could result in saving a sizeable amount of
energy when employed on an industrial scale.
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219. Isaksen, G. V., Åqvist, J. & Brandsdal, B. O. Protein surface softness is the origin
of enzyme cold-adaptation of trypsin. PLoS Comput Biol 10, e1003813 (2014).
220. Isaksen, G. V., Åqvist, J. & Brandsdal, B. O. Enzyme surface rigidity tunes the
temperature dependence of catalytic rates. Proc Natl Acad Sci U S A 113, 7822–7
(2016).
221. Alphey, M. S., Fisher, G., Ge, Y., Gould, E. R., Machado, T. F. G., Liu, H., Florence,
G. J., Naismith, J. H. & da Silva, R. G. Catalytic and Anticatalytic Snapshots of a
Short-Form ATP Phosphoribosyltransferase. ACS Catalysis 8, 5601–5610 (2018).
222. Fisher, G., Thomson, C. M., Stroek, R., Czekster, C. M., Hirschi, J. S. & da Silva,
R. G. Allosteric Activation Shifts the Rate-Limiting Step in a Short-Form ATP
Phosphoribosyltransferase. Biochemistry 57, 4357–4367 (2018).
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Heterocyclases (MicD, PatD, LynD, OscD, TenD and fusion enzymes)
Lysis bu↵er (A) 20 mM Tris pH 8.0, 500 mM NaCl, 20 mM imidazole, 3 mM BME
Elution bu↵er (B) 20 mM Tris pH 8.0, 500 mM NaCl, 250 mM imidazole, 3 mM BME
Low salt bu↵er 20 mM Tris pH 8.0, 100 mM NaCl, 3 mM BME
High salt bu↵er 20 mM Tris pH 8.0, 1 M NaCl, 3 mM BME
Gel filtration bu↵er 10 mM HEPES pH 7.4, 150 mM NaCl, 1 mM TCEP
PatE
Lysis bu↵er Lysis bu↵er (A) + 8M Urea
Elution bu↵er Elution bu↵er (B) + 8M Urea
Gel filtration bu↵er 10 mM HEPES pH 7.4, 150 mM NaCl, 1 mM TCEP
Oxidase (ArtGox)
Lysis bu↵er Lysis bu↵er (A) + 50 µM FMN
Elution bu↵er Elution bu↵er (B) + 50 µM FMN
Gel filtration bu↵er 10 mM HEPES pH 7.4, 150 mM NaCl, 1 mM TCEP
160
Purification Bu↵ers (continued)
PaATPPRT (HisG and HisZ subunits)
Lysis bu↵er 50 mM HEPES pH 8.0, 10 mM imidazole and 500 mM NaCl
Elution bu↵er 50 mM HEPES pH 8.0, 500 mM imidazole and 500 mM NaCl
TEV-proteolysis bu↵er 20 mM HEPES pH 7.5, 150 mM NaCl, 2 mM DTT, 10% Glycerol
Storage bu↵er 20 mM HEPES pH 8.0
MtPPase
Lysis bu↵er 20 mM HEPES pH 8.0, 20 mM imidazole, 500 mM NaCl,
5 mM MgCl
2
, 1 mM CaCl
2
Elution bu↵er 20 mM HEPES pH 8.0, 250 mM imidazole, 500 mM NaCl,
5 mM MgCl
2
, 1 mM CaCl
2
Gel filtration bu↵er 20 mM HEPES pH 8.0
161
6.7 Appendix B - Supplementary Figures
Figure S1: Uncropped SDS-PAGE images of MicD fusion, OscD fusion and PatD fusion
following purification. Supplementary to Figure 2.4.
162
Figure S2: Original SDS-PAGE of MicD fusion expression test described in Figure 2.7A.
163
Figure S3: MSMS Spectra corresponding to peaks 1, 2 and 3 from Figure 3.14A.
164
Figure S4: MSMS Spectra corresponding to peaks 1, 2, 4 and 4 from Figure 3.17A.
Figure S5: MALDI-MS Spectra of Leaderless peptides ITACITACAYDGE and
ITACITFCAYDG reacted with native LynD (5 µM) for 16 h.
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